Functionalized biodegradable electrospun scaffolds and nanoengineered particles as innovative tools for vascular medicine by Ferrari, PIER FRANCESCO
  
Ph.D. Program in Civil, Chemical and Environmental Engineering 
Curriculum in Chemical, Materials and Process Engineering 
 Department of Civil, Chemical and Environmental Engineering 
 Polytechnic School, University of Genoa, Italy. 
 
 
 
 
 
Functionalized biodegradable electrospun scaffolds and 
nanoengineered particles as innovative tools for vascular 
medicine 
Pier Francesco Ferrari 
Nanoliposome loaded  
with bioactive compounds 
Engineered CaCO
3
 nanoparticle with 
targeting activity encapsulating bioactive 
compounds  
PCL:PGS solution containing 
bioactive molecules 
Functionalized biodegradable 
electrospun scaffold 
  
FUNCTIONALIZED BIODEGRADABLE ELECTROSPUN SCAFFOLDS 
AND NANOENGINEERED PARTICLES AS INNOVATIVE TOOLS 
FOR VASCULAR MEDICINE 
 
BY 
PIER FRANCESCO FERRARI 
 
 
Dissertation discussed in partial fulfillment of 
the requirements for the Degree of 
 
DOCTOR OF PHILOSOPHY 
 
Civil, Chemical and Environmental Engineering 
curriculum in Chemical, Materials and Process Engineering,  
Department of Civil, Chemical and Environmental Engineering, University of Genoa, Italy 
 
 
 
 
 
May, 2018 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Adviser: 
Prof. Patrizia Perego – Department of Civil, Chemical and Environmental Engineering, 
University of Genoa 
 
 
 
External Reviewers: 
Prof. Huabing Yin – College of Science and Engineering, Division of Biomedical Engineering, 
University of Glasgow 
Prof. Nabil Chakfé – Department of Vascular Surgery and Kidney Transplantation, University Hospital of 
Strasbourg, University of Strasbourg 
 
 
 
 
 
 
 
 
 
Ph.D. program in Civil, Chemical and Environmental Engineering  
Curriculum in Chemical, Materials and Process Engineering 
Cycle XXX 
 
 
 
 
 
 
INDEX i 
  
 
INDEX 
 
AIM OF THE THESIS……………………………………………………………………….…..5 
CHAPTER I…………………………………………………………….………………………..7 
1. Background………………………………………………………………………….7 
1.1. Biomaterials……………………………………………………………………..9 
1.1.1. Synthetic polymers……………………………………………………………..9 
1.1.2. Natural polymers……………………………………………………………....11 
1.2. Vascular tissue engineering………………………..………………………………13 
1.2.1. Vessel structure………………………………………………………………..13 
1.2.2. Pathologies related to vessel obstruction………………………………………14 
1.2.3. Treatment of small-caliber blood vessel occlusion……………………………15 
1.2.4. Vascular substitutes……………………………………………………………17 
1.2.5. Electrospun scaffolds…………………………………………………………..19 
 1.2.5.1Electrospinning technique………………………………………………19 
1.3. Drug delivery……………………………………………………………………23 
1.3.1. Calcium carbonate nanoparticles……………………………………………….24 
1.3.2. Layer-by-Layer self-assembling technique…………………………………….25 
1.3.3. Encapsulation in liposomes…………………………………………………….27 
1.4. Polyphenols……………………………………………………………………...27 
1.4.1. Classification of phenolic compounds………………………………………….28 
1.4.1.1. Quercetin……………………………………………………………………28 
CHAPTER II……………………………………………………………………………………..30 
2. FUNCTIONALIZATION WITH BIOACTIVE COMPOUNDS OF 
BIODEGRADABLE ELECTROSPUN VASCULAR SCAFFOLDS……………30 
2.1. INTRODUCTION………………………………………………………………30 
2.2. MATERIALS AND METHODS……………………………………………….32 
2.2.1. Chemicals……………………………………………………………………….32 
2.2.2. Cell mediums and reagents……………………………………………………...33 
2.2.3. Fabrication of vascular prostheses……………………………………………... 33 
2.2.3.1. Preparation of spinning solution…………………………………………….33 
2.2.3.2. Density and viscosity of the spinning solution………………………….…..34 
2.2.3.3. Fabrication of small diameter tubular scaffolds via electrospinning………..35 
2.2.3.4. Surface coating of the scaffolds with gelatin………………………………..40 
2.2.4. Characterization methods for the scaffolds……………………………………..41 
2.2.4.1. Scanning Electron Microscopy (SEM) analysis…………………………….41 
2.2.4.2. Atomic Force Microscopy (AFM)…………………………………………..41 
2.2.4.3. Fourier Transform Infrared spectroscopy (FTIR)…………………………...41 
INDEX ii 
  
2.2.4.4. Contact angle measurements of the scaffolds……………………………….42 
2.2.4.5. Mercury porosimetry…………………………………………………………....42 
2.2.4.6. Water permeability test………………………………………………………….42 
2.2.4.7. In vitro degradation and fluid up-take…………………………………………..43 
2.2.4.8. Influence of gelatin coating on degradation rate………………………………..43 
2.2.4.9. Gelatin release from GCS……………………………………………………….44 
2.2.4.10. Quercetin release from QS and QGCS………………………………………...46 
2.2.4.11. BSA release from NS…………………………………………………………..47 
2.2.4.12. Mechanical characterization and suture retention strength…………………….48 
2.2.4.13. Cytotoxicity evaluation using endothelial cells………………………………...49 
2.2.4.14. Hemocompatibility……………………………………………………………..50 
2.2.4.15. In vivo suturability test…………………………………………………………51 
2.2.4.16. Anti-inflammatory activity of QS……………………………………………...51 
2.2.4.17. Statistical analysis……………………………………………………………...51 
2.3. RESULTS AND DISCUSSION…………………………………………………………53 
2.3.1. Pure polymeric scaffolds (PPS)……………………………………………………..53 
2.3.1.1. Density and viscosity of the spinning solutions…………………………………53 
2.3.1.2. Scanning Electron Microscopy (SEM) analysis of PPS………………………....54 
2.3.1.3. Contact angle measurements………………………………………………….....56 
2.3.1.4. Thickness and porosity of PPS…………………………………………………..56 
2.3.1.5. Water permeability………………………………………………………………57 
2.3.1.6. In vitro degradation and fluid uptake of PPS……………………………………57 
2.3.1.7. Mechanical characterization of PPS………………………………………….....59 
2.3.1.8. Biocompatibility of PPS………………………………………………………...61 
2.3.1.9. Hemocompatibility of PPS……………………………………………………...63 
2.3.1.10. Conclusion……………………………………………………………………..65 
2.3.2. Gelatin coated polymeric scaffold (GCS)…………………………………………..65 
2.3.2.1. Scanning Electron Microscopy (SEM) analysis of GCS………………………..66 
2.3.2.2. Thickness and porosity of GCS…………………………………………………68 
2.3.2.3. Water permeability of GCS……………………………………………………..68 
2.3.2.4. In vitro degradation, fluid uptake and release of gelatin from GCS…………….68 
2.3.2.5. Mechanical properties of GCS……………………………………………….....71 
2.3.2.6. Biocompatibility of GCS………………………………………………………..72 
2.3.2.7. Hemocompatibility of GCS……………………………………………………..73 
2.3.2.8. In vivo suturability test with GCS………………………………………………74 
2.3.2.9. Conclusions……………………………………………………………………..75 
2.3.3. Quercetin-fuctionalized scaffolds (QS) and Quercetin-functionalized and gelatin coated 
scaffolds (QGCS)……………………………………………………………………..76 
2.3.3.1. Scanning Electron Microscopy (SEM) analysis of QS and QGCS……………..76 
2.3.3.2. Atomic Force Microscopy (AFM) analysis of QS……………………………...78 
2.3.3.3. FTIR spectroscopy of QS……………………………………………………….83 
INDEX iii 
  
2.3.3.4. In vitro degradation and fluid uptake of QS and QGCS………………………..84 
2.3.3.5. Quercetin release from QS and QGCS……………………………………..85 
2.3.3.6. Water permeability of QS and QGCS……………………………………....87 
2.3.3.7. Mechanical characterization of QS and QGCS……………………….…….87 
2.3.3.8. Biocompatibility of QS and QGCS………………………………………....91 
2.3.3.9. In vitro anti-inflammatory activity of QS…………………………………...93 
2.3.3.10. Conclusions………………………………………………………….……..94 
2.3.4. Nanoparticles-functionalized Scaffolds (NS)……………………………….…..94 
2.3.4.1. Scanning Electron Microscopy (SEM) analysis of NS………………….…..95 
2.3.4.2. Thickness and porosity of NS…………………………………………….…96 
2.3.4.3. In vitro degradation and fluid uptake of NS…………………………….…..96 
2.3.4.4. Release of BSA from the scaffold………………………………………..….98 
2.3.4.5. Mechanical characterization of NS………………………………….……...99 
2.3.4.6. Biocompatibility of NS…………………………………………………….100 
2.3.4.7. Hemocompatibility of NS…………………………………………………101 
2.3.4.8. Conclusions………………………………………………………………..103 
2.3.5. Lecithin-functionalized polymeric scaffolds (RLS and SLS)………………....104 
2.3.5.1. Scanning Electron Microscopy (SEM) analysis of RLS and SLS………...104 
2.3.5.2. FTIR spectroscopy of RLS and SLS………………………………………107 
2.3.5.3. Biocompatibility of RLS and SLS…………………………………………109 
   2.3.5.4 Conclusions…………………………………………………………………….110 
CHAPTER III……………………………………………………………………………………111 
3. DEVELOPMENT OF NANODELIVERY SYSTEMS: CALCIUM CARBONATE 
NANOPARTICLES………………………………………………………………...111 
3.1. INTRODUCTION…………………………………………………………………..111 
3.2. MATERIALS AND METHODS…………………………………………………...113 
3.2.1. Chemicals………………………………………………………………………113 
3.2.2. Cell mediums and reagents……………………………………………………..113 
3.2.3. Synthesis of calcium carbonate nanoparticles incorporating bovine serum albumin
 …………………………………………………………………………………..114 
3.2.4. Scanning Electron Microscopy (SEM) analysis………………………………...115 
3.2.5. Transmission Electron Microscopy (TEM) analysis……………………………115 
3.2.6. Entrapment efficiency of bovine serum albumin in CaCO3 nanoparticles…………..115 
3.2.7. Synthesis of multilayered CaCO3 nanoparticles, immobilization and detection of anti-
rabbit IgG………………………………………………………………………….116 
3.2.8. BSA release from nanoparticles…………………………………………………117 
3.2.9. Mathematical models for BSA release from particles…………………………...117 
3.2.10. In vitro cytotoxicity assay…………………………………………………….119 
3.2.11. Cell treatment, zimography for MMP-9 and ELISA for IL-6………………...120 
3.2.12. Hemocompatibility of CaCO3 nanoparticles………………………………….120 
INDEX iv 
  
3.2.13. Confocal microscopy analysis………………………………………………...121 
3.2.14. Preparation and engineering of calcium carbonate particles by Layer-by-Layer self-
assembling technique and release of polyphenols……………………………...………121 
3.2.15. Quartz crystals microbalance (QCM) with dissipation monitoring……………..123 
3.2.16. Statistical analysis……………………………………………………………….124 
3.3. RESULTS AND DISCUSSION…………………………………………………….125 
3.3.1. Influence of PAANa concentration on CaCO3 particle size……………………......125 
3.3.2. TEM observations of CaCO3 nanoparticles with layers of chitosan/dextran………128 
3.3.3. BSA entrapment efficiency and BSA loading……………………………………...129 
3.3.4. Detection of chemiluminescent signal from anti-rabbit IgG attached to the particles
 ………………………………………………………………………………………129 
3.3.5. Release profile of BSA from particles………………………………………………130 
3.3.6. Cell toxicity using CaCO3 nanoparticles with layers of chitosan/dextran…………..132 
3.3.7. SEM analysis of CaCO3 nanoparticles with layers of poly-L-arginine/dextran…….134 
3.3.8. Cell viability using CaCO3 nanoparticles with layers of poly-L-arginine/dextran
 ………………………………………………………………………………………135 
3.3.9. Expression of MMP-9 and IL-6 after nanoparticles treatment……………………...135 
3.3.10. Hemocompatibility of nanoparticles……………………………………………..137 
3.3.11. Confocal microscopy analysis……………………………………………………138 
3.3.12. Conclusion………………………………………………………………………..139 
3.3.13. Entrapment efficiency…………………………………………………………….142 
3.3.14. Release of polyphenols from CaCO3 particles……………………………………143 
3.3.15. Quartz crystal microbalance with dissipation monitoring………………………...143 
3.3.16. Conclusions……………………………………………………………………….145 
CHAPTER IV………………………………………………………………………………………….146 
4. DEVELOPMENT OF NANODELIVERY SYSTEMS: RAPESEED LECITHIN 
NANOLIPOSOMES……………………………………………………………………...146 
4.1. INTRODUCTION……………………………………………………………………146 
4.2. MATERIALS AND METHODS…………………………………………………….147 
4.2.1. Chemicals…………………………………………………………………………….147 
4.2.2. Cell mediums and reagents…………………………………………………………..147 
4.2.3. Synthesis of BSA-loaded liposomes…………………………………………………147 
4.2.4. Measurement of liposome size, ζ-potential, and electrophoretic mobility…………..148 
4.2.5. Entrapment efficiency of BSA in liposomes………………………………………...148 
4.2.6. Synthesis of quercetin-loaded liposomes……………………………………………148 
4.2.7. Nanoparticle tracking analysis………………………………………………………149 
4.2.8. Stability of quercetin-loaded liposomes……………………………………………..150 
4.2.9. Entrapment efficiency of quercetin in liposomes……………………………………150 
4.2.10. Release of quercetin from nanoliposomes………………………………………..151 
4.2.11. Rheological characterization of nanoliposome suspensions……………………..153 
4.2.12. In vitro cytotoxicity assay………………………………………………………..153 
INDEX v 
  
4.2.13. Statistical analysis………………………………………………………………..153 
4.3. RESULTS AND DISCUSSION…………………………………………………….154 
4.3.1. Measurement of size, ζ-potential and electrophoretic mobility of BSA-loaded 
nanoliposomes…………………………………………………………………….154 
4.3.2. Entrapment efficiency…………………………………………………………...155 
4.3.3. Measurement of liposome size, ζ-potential and electrophoretic mobility of quercetin-
loaded nanoliposomes……………………………………………………………..155 
4.3.4. Nanoparticle tracking analysis…………………………………………………..157 
4.3.5. Stability of size and ζ-potential………………………………………………….159 
4.3.6. Entrapment efficiency…………………………………………………………...162 
4.3.7. In vitro release of quercetin from nanoliposomes……………………………….162 
4.3.8. Rheological studies……………………………………………………………...164 
4.3.9. In vitro cytotoxicity assay……………………………………………………….168 
4.3.10. Conclusions…………………………………………………………………..170 
5. OVERALL CONCLUSIONS……………………………………………………....171 
 
 
 
 
  
 
 
 
 
 
 
  
ABBREVIATIONS vi 
  
ABBREVIATIONS 
 
∙ O2  superoxide radical  
∙ OH  hydroxyl radical  
1O2  singlet oxygen  
3D   Three Dimensional 
AAMI Association for the Advancement of Medical Instruments 
AFM Atomic Force Microscopy 
ANOVA  ANalysis Of Variance 
ANSI  American National Standard Institute 
ATR Attenuated Total Reflectance 
BCA Bicinchoninic Acid Assay 
BSA  Bovine Serum Albumin 
CaCl2 Calcium Chloride 
CaCO3 Calcium Carbonate 
CAE Caffeic Acid Equivalent 
CHI  CHItosan 
CM  Conditioned Media 
CO2  Carbon Dioxide 
CTL  Control 
DEX DEXtran sulfate 
DLS  Dynamic Light Scattering 
DMEM Dulbecco’s Modified Eagle Medium 
DNA DeossiriboNucleic Acid 
DPBS Dulbecco’s Phosphate-Buffered Saline 
DTGS  Deuterated TriGlycine Sulfate 
E  Ethanol 
e.g.  exemplum given 
ECM  ExtraCellular Matrix 
EDTA EthyleneDiamineTetraacetic Acid 
EL  Empty Liposomes 
ELISA Enzyme-Linked ImmunoSorbent Assay 
ePTFE  expanded PolyTetraFluoroEthylene  
ABBREVIATIONS vii 
  
FTIR  Fourier Transform Infrared spectroscopy  
GCS  Gelatin Coated Scaffolds 
GIMP GNU Image Manipulation Program 
GPC Gel Permeation Chromatography 
H2O2 hydrogen peroxide  
hMSC human Mesenchymal Stem Cell 
HPLC High Pressure Liquid Chromatography 
HRP Horse Radish Peroxidase 
IgG  ImmunoGlobulin G 
IL-6  InterLeukin-6 
LbL  Layer-by-Layer 
LDH Lactate DeHydrogenase 
LDL  Low-Density Lipoprotein 
MMP-9 Matrix MetalloProteinase-9 
Mn  Mean molecular weight 
Mw   Molecular weight 
Na2CO3 Sodium Carbonate 
NaCl Sodium Chloride 
NaOH Sodium Hydroxide 
NPS  NanoParticles 
NS  Nanoparticles-functionalized Scaffolds 
NT  Not-Treated 
NTA Nanoparticles Tracking Analysis 
PAANa Poly (Acrylic Acid) sodium salt 
PBS  Phospate-Buffered Saline 
PCL  Poly (ε-CaproLactone) 
PDI   PolyDispersity Index 
PET  PolyEthylene Terephthalate  
PGA  Poly (Glycolic Acid)  
PGS  Poly (Glycerol Sebacate) 
PLA  Poly (Lactic Acid) 
PPS  Pure Polymeric Scaffolds 
PUFA  Poly-Unsaturated Fatty Acids 
Q   Quercetin  
ABBREVIATIONS viii 
  
QCM-D  Quartz Crystal Microbalance with Dissipation monitoring 
QGCS  Quercetin-functionalized and Gelatin Coated Scaffolds 
QL  Quercetin-loaded Liposomes 
QS  Quercetin-functionalized Scaffolds 
RL  Rapeseed Lecithin 
RLS   Rapeseed Lecithin-functionalized Scaffolds 
RNS   Reactive Nitrogen Species  
RO2 ∙  peroxyl radicals  
ROS   Reactive Oxygen Species  
rpm  revolutions per minute 
SD   Standard Deviation 
SEM   Scanning Electron Microscopy  
SL  Salmon Lecithin 
SLE  Solid-Liquid Extraction 
SLS  Salmon Lecithin-functionalized Scaffolds 
sp.  species 
TE   Tissue Engineering 
TEM  Transmission Electron Miscroscopy 
THF  Tetrahydrofuran 
TNF-α  Tumor Necrosis Factor-α 
TPC  Total Phenolic Concentration 
UV  UltraViolet 
v/v  volume/volume 
w/v  weight/volume 
WJ   Wharton’s Jelly 
 
 
 
 
 
 
 
 
INDEX OF FIGURES ix 
  
 
INDEX OF FIGURES 
Figure 1.1: an example of TE concept involving cell seeding on porous scaffolds. (a) Cells are isolated from the 
patient, (b) cells are in vitro cultivated and expanded, (c) cells are seeded within the porous scaffold together with 
growth factors and free or encapsulated bioactive molecules, (d) the construct is cultivated in bioreactors, (e) the 
construct is implanted in the patient to restore the lost function (adapted from Dvir et al., 2011).   8 
Figure 1.2: synthesis of PCL (adapted from Osathanon et al., 2017).                  10 
Figure 1.3: synthesis of PGS (adapted from Wang et al., 2002).                  11 
Figure 1.4 chemical structure of poly-L-arginine (adapted from Sigma-Aldrich website).               11 
Figure 1.5: chemical structure of gelatin (adapted from Ge et al., 2012).                 12 
Figure 1.6: deacetylation of chitin and formation of chitosan (adapted from Nilsen-Nygaard et al., 2015).              12 
Figure 1.7: chemical structure of dextran sulfate (adapted from De Clercq, 2013).                13 
Figure 1.8: anatomic structure of (a) arteries, veins, and (b) capillaries (adapted from Anatomy and Physiology, a 
learning initiative).                       14 
Figure 1.9: molecular and cellular mechanism involved in the atherosclerotic plaque formation (adapted from 
Moore & Tabas, 2011).                       15 
Figure 1.10: angioplasty (adapted from John Hopkins Medicine website).                 16 
Figure 1.11: atherectomy with rotary cutter (adapted from Keck School of Medicine of USC).               16 
Figure 1.12: bypass procedure (adapted from Medtronic website).                  17 
Figure 1.13: synthetic vascular prosthesis made of poly (ethylene terephthalate) (left) and expanded poly 
(tetrafluoroethylene) (right).                      18 
Figure 1.14: (A) picture and (B) schematic representation of a common electrospinning apparatus set-up: (a) 
syringe, (b) peristaltic pump, (c) high-voltage DC supply, (d) rotating and translating grounded collector.              21 
Figure 1.15: different carriers commonly studied in drug delivery (adapted from Cho et al., 2008). 
NPs: nanoparticles.                       24 
Figure 1.16: complex coacervation and mineralization for CaCO3 particles synthesis (adapted from Lauth et al., 
2014).                         25 
Figure 1.17: schematic protocol for LbL self-assembling technique (adapted from Xiang et al., 2012).              25 
Figure 1.18: encapsulation of different bioactive molecules in liposomes and functionalization of their surface 
(adapted from Liu & Boyd, 2013).                      27 
INDEX OF FIGURES x 
  
Figure 1.19: chemical structure of the flavonoid quercetin (adapted from McKay et al., 2015).               29 
Figure 2.1: representative scaffold made of PCL:PGS (1:1).                   36 
Figure 2.2: representative scaffold made of PCL:PGS (1:1) (left) and one functionalized with Q (right).              37 
Figure 2.3: representative scaffold made of PCL:PGS (1:1) and functionalized with CaCO3 nanoparticles.             38 
Figure 2.4: representative scaffold made of PCL:PGS (1:1) and functionalized with RL.               39 
Figure 2.5: coating process with gelatin.                     40 
Figure 2.6: set-up of the equipment used during the water permeability test.                 43 
Figure 2.7: calibration curve for the quantification of gelatin released from GCS.                45 
Figure 2.8: spectrum of quercetin in ethanol:PBS (50:50, v/v).                  46 
Figure 2.9: calibration curve for the quantification of quercetin.                  47 
Figure 2.10: calibration curve for the quantification of BSA released from NS.                 48 
Figure 2.11: representative SEM micrographs of (A) internal and (B) external surfaces of electrospun scaffolds 
made of PCL 20 % and of (C) internal and (D) external surfaces of electrospun scaffolds made of PCL:PGS        
(1:1, v/v).                        55 
Figure 2.12: (A) mass loss and (B) fluid uptake of electrospun scaffolds with different percentage of PCL and 
different blend ratio of PCL:PGS. Mass loss:  PCL (10 %),  PCL (15 %),  PCL (20 %),  PCL:PGS (1:1),  
PCL:PGS (2:1),  PCL:PGS (3:1). Fluid uptake: PCL ( ): ♦ PCL (10 %),  PCL (15 %), ▲ PCL (20 %), 
PCL:PGS ( ): ● PCL:PGS (1:1), * PCL:PGS (2:1); ○ PCL:PGS (3:1).                 59 
Figure 2.13: cell viability of all the electrospun (A) PPS and (B) PCL:PGS (1:1) scaffold by MTS assay.  control, 
 PCL:PGS (1:1).                       63 
Figure 2.14: hemocompatibility of electrospun scaffolds with different percentage of PCL and different blend ratio 
of PCL:PGS. (A) Kinetics of clotting time and (B) hemolysis percentage. Clotting time: PCL ( ): ♦ PCL (10 %), 
 PCL (15 %), ▲ PCL (20 %), PCL:PGS ( ): ● PCL:PGS (1:1), * PCL:PGS (2:1); ○ PCL:PGS (3:1), ( ) + 
glass.                         64 
Figure 2.15: representative SEM micrographs of gelatin coated (A) internal and (B) external scaffold surfaces and 
of (C) internal and (D) external surfaces of PCL:PGS (1:1) without coating.                 67 
Figure 2.16: (A) mass loss (B) and fluid uptake of PCL:PGS (1:1) and GCS. Mass loss:  PCL:PGS (1:1).  GCS. 
Fluid uptake: (♦) GCS, (●) PCL:PGS (1:1).                     70 
Figure 2.17: cumulative release of gelatin from GCS.                   71 
Figure 2.18: cell viability of PCL:PGS (1:1) and GCS by MTS assay.  control,  PCL:PGS (1:1), and  GCS.  73 
INDEX OF FIGURES xi 
  
Figure 2.19: hemolysis of PCL:PGS (1:1), GCS, poly (ethylene terephthalate) and expanded poly 
(tetrafluoroethylene).  PCL:PGS (1:1),  GCS,  poly (ethylene terephthalate), and  expanded poly 
(tetrafluoroethylene).                       74 
Figure 2.20: implantation of GCS in White Star rat.                    75 
Figure 2.21: representative SEM micrographs of (A) internal and (B) external surfaces of QS, of (C) internal and 
(D) external surfaces of QGCS, and of (E) internal and (F) external surfaces of PCL:PGS (1:1).               77 
Figure 2.22: AFM height (left) and deflection (right) images of (A) QS and (B) PCL:PGS (1:1) external surfaces.80 
Figure 2.23: AFM 3D images of (A) QS and (B) PCL:PGS (1:1). Figures on the left and on the right are from a 
different area,                        82 
Figure 2.24: FTIR spectra of QS ( ) and PCL:PGS (1:1) ( ).                  83 
Figure 2.25: (A) mass loss (B) and fluid uptake of PCL:PGS (1:1), QS, and QGCS. Mass loss:  PCL:PGS (1:1),  
QS,  QGCS. Fluid uptake: PCL:PGS (1:1) ● ( ), QS ♦ ( ), QGCS ▲ ( ).                85 
Figure 2.26: cumulative release of quercetin from QS ♦ ( ) and QGCS ▲ ( ).                86 
Figure 2.27: representative stress-strain curves for (A) dry samples of PCL:PGS (1:1), dry samples of QS, and dry 
samples of QGCS and (B) dry samples of PCL:PGS (1:1), dry samples of QS, and wet samples of QGCS. PCL:PGS 
(1:1) ( ), QS ( ) and QGCS ( ).                     89 
Figure 2.28: representative stress-strain curves for native QS ( ) and after one month ( ) of soaking in PBS.
                         90 
Figure 2.29: Cell viability quantified by MTS assay. Cells were treated with: 5 μM Q ( ), 10 μM Q ( ), 50 
μM Q ( ), the volume of ethanol present in 5 μM Q ( ), the volume of ethanol present in 10 μM Q ( ), 
the volume of ethanol present in 50 μM Q ( ), and no treatment ( ).                 91 
Figure 2.30: cell viability of PCL:PGS (1:1), QS, and QGCS on (A) endothelial cells  and on (B) hMSC.  control, 
 PCL:PGS (1:1),  QS, and   QGCS.                     92 
Figure 2.31: relative expression of MMP-9. Data are normalized on the expression obtained with the treatment with 
TNF-α. Results are mean of three measurements ± SD. Among all the reported data there are statistically significant 
differences (p < 0.05).                       93 
Figure 2.32: representative SEM micrographs of (A) internal and (B) external surfaces of NS and of (C) internal 
and (D) external surfaces of PCL:PGS (1:1) (images at different magnification).                95 
Figure 2.33: (A) mass loss and (B) fluid uptake of PCL:PGS (1:1) and NS. Mass loss:  PCL:PGS (1:1) and  NS. 
Fluid uptake: PCL:PGS (1:1) ● ( ), NS ▲ ( ). Results are mean of three measurements ± SD.              99 
Figure 2.34: cumulative release of BSA from NS.                    99 
Figure 2.35: representative stress-strain curves for PCL:PGS (1:1) ( ) and NS ( ).             100 
INDEX OF FIGURES xii 
  
Figure 2.36: cell viability of PCL:PGS (1:1) and NS.   control,   PCL:PGS (1:1), and  NS.             101 
Figure 2.37: hemocompatibility of PCL:PGS (1:1) and NS. (A) Kinetics of clotting time and (B) hemolysis 
percentage. Clotting time: PCL:PGS (1:1) ● ( ), NS ▲ ( ), poly (ethylene terephthalate) ♦ ( ),expanded 
poly (tetrafluoroethylene)  ( ), and glass + ( ).                 103 
Figure 2.38: representative SEM micrographs of internal (left) and external (right) surface of RLS made with (A 
and B) 0.5, (C and D) 1.0, and (E and F) 5.0 mg/mL of rapeseed lecithin.               105 
Figure 2.39: representative SEM micrographs of internal (left) and external (right) surface of SLS made with (A 
and B) 0.5, (C and D) 1.0, and (E and F) 5.0 mg/mL of salmon lecithin.               106 
Figure 2.40: FTIR spectra of (A) PCL:PGS (1:1) ( ) and of RLS with: 0.5 ( ), 1.0 ( ), and 5.0 mg/mL     
( ) of rapeseed lecithin; (B) FTIR spectra of PCL:PGS (1:1) ( ) and of SLS with: 0.5 ( ), 1.0 ( ), and 
5.0 mg/mL ( ) of salmon lecithin.                   108 
Figure 2.41: cell viability of (A) RLS and (B) SLS at different concentration of lecithin. RLS:  control,  
PCL:PGS (1:1),   0.5,  1.0, and  5.0 mg/mL. SLS:  control,  PCL:PGS (1:1),  0.5,  1.0, and  5.0 
mg/mL.                       110 
Figure 3.1: schematic representation of CaCO3 nanoparticles synthesis.               114 
Figure 3.2: schematic representation of LbL deposition on CaCO3 nanoparticles.              117 
Figure 3.3: calibration curve for the quantification of total polyphenol concentration.              123 
Figure 3.4: representative SEM images of the nanoparticles obtained with different concentrations of PAANa: (A) 
native nanoparticles with 700 mg/mL, (B) native nanoparticles with 1900 mg/mL, (C) BSA-loaded nanoparticles 
with 700 mg/mL, and (D) BSA-loaded nanoparticles with 1900 mg/mL.               126 
Figure 3.5: representative SEM images of the nanoparticles: (A) native nanoparticles loaded with BSA (B) 
mutilayered nanoparticles with shell architecture (chitosan/ dextran)2/chitosan. White arrows indicate the fusion 
between the nanoparticles.                    127 
Figure 3.6: representative TEM images of (A and B) native nanoparticles and of (C and D) BSA-loaded 
nanoparticles obtained with different magnification.                  128 
Figure 3.7: chemiluminescent signal from (a) nanoparticles functionalized with HRP-linked IgG and (b) 
nanoparticles without HRP-linked IgG (control).                  129 
Figure 3.8: release profile of BSA from non-multilayered (♦) and multilayered (▲) nanoparticles. Dashed lines refer 
to second order model applied to experimental data. ( ) non-multilayered nanoparticles, ( ) multilayered 
nanoparticles.                      131 
Figure 3.9: cell viability of CaCO3 (A) non-multilayered and (B) multilayered with chitosan/dextran nanoparticles 
by MTS assay.  control,  40 μg/mL,  80 μg/mL,  160 μg/mL,  320 μg/mL.              133 
INDEX OF FIGURES xiii 
  
Figure 3.10: representative SEM micrographs of the nanoparticles: (A) native nanoparticles, (B) nanoparticles with 
shell architecture (poly-L-arginine /dextran)2/ poly-L-arginine.                134 
Figure 3.11: cell viability of CaCO3 nanoparticles with layers of poly-L-arginine/dextran by MTS assay.  control, 
 40 μg/mL,  80 μg/mL,  160 μg/mL.                   135 
Figure 3.12: gel zymography of MMP-2 and MMP-9 of endothelial cells treated with different concentrations of 
immunonanoparticles (20, 40, 80 and 160 μg/mL). NT: not-treated; TNF-α: treated with tumor necrosis factor-α.136 
Figure 3.13: relative expression of IL-6 in endothelial cells treated with different concentrations of 
immunonanoparticles (20, 40, 80 and 160 μg/mL). NT: not-treated; TNF-α: treated with tumor necrosis factor-α. 
Results are mean of three measurements ± SD.                  136 
Figure 3.14: (A) hemolysis percentage and (B) clotting time of fresh blood after incubation with different 
concentration of nanoparticles. Results are mean of three measurements ± SD. PBS: phosphate-buffered saline.   138 
Figure 3.15: fluorescence photographs of phagocytized CaCO3 nanoparticles (A) before and (B) after washing. 
White arrows indicate phagocytized nanoparticles.                  139 
Figure 3.16: representative SEM micrographs of a (dextran/chitosan)4 particle loaded with a polyphenolic solution 
made of ethanol:water (35:65, v/v).                   142 
Figure 3.17: release profile of polyphenols from CaCO3 particles prepared with ethanol:water (35:65) (♦) and water 
(▲) loading solution.                     143 
Figure 3.18: (a) plot of surface coverage as a function of layers during the alternated adsorption of chitosan and 
dextran; (b) dissipation changes measured by QCM-D during the build-up of a (chitosan/dextran)4 multilayer. The 
data for the 3rd, 5th and 7th overtones are presented.                  144 
Figure 4.1: schematic representation of the synthesis of quercetin-loaded nanoliposomes.             149 
Figure 4.2: gradient for solvent B (0.1 % of formic acid in acetonitrile) during HPLC-DAD analysis of quercetin.  
                       150 
Figure 4.3: calibration curve for the quantification of quercetin by HPLC.               151 
Figure 4.4: calibration curve for the quantification of quercetin by spectrophotometric analysis.             152 
Figure 4.5: video frame for (A) empty and (B) quercetin-loaded nanoliposomes obtained with nanoparticles 
tracking analysis.                      157 
Figure 4.6: size distribution of (A) empty and (B) quercetin-loaded nanoliposomes obtained with nanoparticles 
tracking analysis.                      158 
Figure 4.7: size stability of control (●) and quercetin-loaded (▲) nanoliposomes at (A) 4, (B) 20, and (C) 37°C. 160 
Figure 4.8: zeta potential stability of control (●) and quercetin-loaded (▲) nanoliposomes at (A) 4, (B) 20, and (C) 
37°C.                       162 
INDEX OF FIGURES xiv 
  
Figure 4.9: cumulative release of quercetin from nanoliposomes at 4 ( ), 20 ( ), and 37°C ( ).            164 
Figure 4.10: flow curves of empty ( ) and quercetin-loaded liposomes ( ).              165 
Figure 4.11: Casson plots of the square root of the shear stress versus the square root of the shear rate for empty      
( ) and quercetin-loaded liposomes ( ).                  166 
Figure 4.12: curves obtained with quercetin-loaded nanoliposomes increasing and decreasing in the shear stress in 
the same shear stress range.                    167 
Figure 4.13: frequency sweep test of empty ( ) and quercetin-loaded liposomes ( ).             168 
Figure 4.14: cell viability of free quercetin, empty and quercetin-loaded nanoliposomes at different concentrations 
on (A) hMSC and (B) human fibroblast. CTL: control, EL: empty liposomes, QL: quercetin-loaded liposomes, Q: 
quercetin, E: ethanol   day 1,  day 2,  day 3. EL1: 6.87 μg/mL, EL2: 13.8 μg/mL, EL3: 0.33 mg/mL, EL4: 0.67 
mg/mL, QL1: 6.87 μg/mL, QL2: 13.8 μg/mL, QL3: 0.33 mg/mL, QL4: 0.67 mg/mL, Q1: 1 μM, Q2: 10 μM, Q3: 25 
μM, Q4: 50 μM, E1, E2, E3, E4: same volume of ethanol of Q1, Q2, Q3, and Q4.              169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDEX OF TABLES xv 
  
 
INDEX OF TABLES 
Table 2.1: process parameters and operating conditions during electrospinning of PPS.                36 
Table 2.2: process parameters and operating conditions during electrospinning of QS.                37 
Table 2.3: process parameters and operating conditions during electrospinning of NS.                38 
Table 2.4: process parameters and operating conditions during electrospinning of RLS and SLS.               39 
Table 2.5: viscosity and density values of PCL and PCL:PGS blend solutions with different concentrations and 
ratios between the two polymers.                       54 
Table 2.6: fiber diameter for internal and external surfaces of PCL 20 % and PCL:PGS (1:1).               56 
Table 2.7: thickness and porosity of PCL and PCL:PGS blend scaffolds.                 57 
Table 2.8: mechanical properties of PCL and PCL:PGS blend scaffold.                 61 
Table 2.9: fiber diameters of GCS and PCL:PGS (1:1).                   67 
Table 2.10: thickness and porosity of GCS and PCL:PGS (1:1).                  68 
Table 2.11: degradation of the polymer in presence of gelatin or not after 24 hours.                70 
Table 2.12: mechanical properties of GCS and PCL:PGS (1:1).                  72 
Table 2.13: fiber diameter of QS, QGCS, and PCL:PGS (1:1).                  78 
Table 2.14: water permeability of QS, QGCS, and PCL:PGS (1:1) at 0.2 bar.                 87 
Table 2.15: mechanical properties of QS, QGCS, and PCL:PGS (1:1).                  90 
Table 2.16: fiber diameter of NS and PCL:PGS (1:1).                   96 
Table 2.17: thickness and porosity of NS and PCL:PGS (1:1).                  96 
Table 2.18: Young’s modulus, tensile strength, and elongation percentage of NS and PCL:PGS (1:1).            100 
Table 2.19: fiber diameter of RLS and SLS.                  107 
Table 3.1: average diameters of native and BSA-loaded nanoparticles obtained with 700 and 1900 μg/mL of 
PAANa.                       127 
Table 3.2: average diameters of native and nanoparticles with layers of chitosan/dextran.             128 
 
INDEX OF TABLES xvi 
  
Table 3.3: kinetic parameters of first, second order, and power law model for BSA release from native and 
multilayered nanoparticles. 𝑘𝐼 refers to first order model, 𝑘𝐼𝐼 to the second order model, and 𝑘 to power law.                131 
Table 3.4: average diameters of native and nanoparticles with layers of poly-L-arginine/dextran.             134 
Table 3.5: total polyphenol concentrations (TPCs, expressed as mgCAE/mL) and amount of polyphenols (in mgCAE) 
released from nanocapsules (11.3 µL) prepared in solutions with different ethanol:water ratio after 120 min of 
incubation in water.                     141 
Table 4.1: mean particle size, polydispersity index, zeta potential and electrophoretic mobility of empty and BSA-
loaded nanoliposomes.                     154 
Table 4.2: entrapment efficiency of BSA-loaded nanoliposomes.                155 
Table 4.3: mean particle size, polydispersity index, zeta potential and electrophoretic mobility of empty and 
quercetin-loaded nanoliposomes.                    156 
Table 4.4: rheological properties according to the power law model for empty and quercetin-loaded liposomes.  166 
Table 4.5: rheological properties according to the Casson model for empty and quercetin-loaded liposomes.        167 
Table 5.1: main results of the studied coated/functionalized scaffolds.                172 
Table 5.2: main results and future perspectives of the studied encapsulation techniques.              173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 1 
  
ABSTRACT 
In the Western World, atherosclerosis-related diseases, including coronary and peripheral arterial 
pathologies, are one of the most common cause of morbidity and mortality. In some cases, in order to 
restore the blood flow, preserving all the functions of the downstream tissue, is necessary to introduce 
an arterial bypass or substitute in the patient. If autologous veins or artery are not available for different 
reasons (previous harvest, anatomical defects and anomalies, disease progression, other vascular 
problems etc.), artificial vascular constructs are required. During the last decade, different type of 
vascular grafts have been used to bypass or replace stenosed blood vessels. Non-degradable synthetic 
grafts (e.g. poly (ethylene terephthalate fibers and expanded poly (tetrafluoroethylene), commercially 
known as Dacron® and Teflon®, respectively) have been successfully used as vascular grafts for aortic 
and iliac reconstruction. These materials are poorly used as substitutes for small-caliber vessels (inner 
diameter < 6 mm) in the clinical practice for many reasons: high frequency of infection, absence of 
endothelialization after the implantation, a possible short-term thrombosis and myointimal hyperplasia, 
presence of dystrophic calcification and aneurysm, compliance mismatch between the native tissue and 
the artificial material, and related inflammatory response to the foreign materials. Until today, different 
approaches have been studied to fabricate high-performing small-caliber blood vessel grafts, including 
cell-seeded collagen gels, cell seeded or not, biodegradable polymers through 3D printing, 
electrospinning, film casting, self-assembling methodologies, and decellularized matrices from 
animals. The ideal vascular prosthesis could be biodegradable, acting as a structural framework in 
order to reproduce a native artery. It should hopefully exhibit resistance to thrombosis, infections, 
aneurysmal dilatation and ectopic calcification showing good suture retention, ease of handling, 
flexibility with kink resistance, bio- and hemocompatibility and predictable degradation kinetic. 
Considering this background, the aim of this Ph.D. thesis was at first to fabricate small-caliber vascular 
prostheses made of biodegradable and bioadsorbable polymers through electrospinning and then to 
functionalize them with bioactive compounds. Electrospinning has been considered in the last decade 
one of the most promising technique in the field of vascular tissue engineering since a microstructure 
very similar to extracellular matrix is formed during the whole process. During electrospinning the 
solvents evaporate quickly and a high electrical field charges the polymeric solution that is deposed 
onto a roto-translating collector. The two studied polymers were poly (ε-caprolactone) (PCL) and poly 
(glycerol sebacate) (PGS), alone or in a mixture with different ratios. In details, it was possible to 
obtain electrospun vascular grafts working with PCL:PGS (both 20 %, w/v) at ratios of 1:0, 1:1, 2:1, 
and 3:1. As a result, the first part was addressed to elect, after an adequate physico-chemical and 
mechanical characterization and biological validation, the best performing PCL:PGS blend. PCL:PGS 
(1:1, v/v) was considered the construct showing the best properties but its water permeability was too 
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high even at low pressure. For this reason, it was coated with gelatin. The presence of gelatin 
significantly reduced the permeability of water make the scaffold potentially implantable in animal 
models. 
  
Nowadays the classical concept of tissue engineering, according to which the scaffold is described 
as a simple extracellular matrix-inspired framework, is overcome. The new concept is to fabricate 
constructs able to actively interact with cells during the regeneration process, releasing growth factors 
and chemoattractant proteins. Despite the majority of tissue engineering research is focused on the 
fabrication of the perfect vascular scaffold mimicking biochemical, physiological, biomechanical and 
architectural characteristics of the native tissues, the counteracting of the surgical-related inflammation 
represents today a new challenge. In fact, the post-surgical inflammation is able to affect negatively 
the cellular attachment and cellular growth on the bioprostheses, inducing many damages to the 
microstructure of the biomaterials, compromising its physico-chemical and mechanical properties, 
leading, in the worst case, to the rejection of the graft. For this reason, PCL:PGS (1:1, v/v), the best 
performing scaffold, was functionalized with the direct addition of an antioxidant in the spinning 
solution. Among antioxidants, there is a class of compounds, known as polyphenols, that show anti-
inflammatory activity both in vitro and in vivo.  
 
Quercetin (3, 3’, 4’, 5, 7-pentahydroxyflavone) is one of the most prominent dietary antioxidant 
present in different kinds of fruit (apples, grapes, berries), vegetables (red onions, celery, broccoli) and 
beverages (tea, wine). It plays various beneficial health effect, not only acting as scavenger towards 
peroxynitrites and hydroxyl radicals, but even protecting against osteoporosis, cancer, cardiovascular 
diseases and inflammation. The presence of free quercetin in the polymeric scaffold did not induce 
negative changes in morphology, physicochemical, mechanical properties and it was bio- and 
hemocompatible. In addition, the presence of quercetin counteracted the activity of TNF-α inducing a 
decrease in MMP-9 expression level, showing a general anti-inflammatory activity. 
 
To have protein in the scaffolds, PCL:PGS (1:1, v/v), was functionalized with the addition of 
calcium carbonate (CaCO3) nanoparticles encapsulating bovine serum albumin (BSA), as a model 
protein. The addition of CaCO3 nanoparticles directly inside the biomaterial architecture did not 
modify its properties and, as a consequence, a more sustained release of the protein during time was 
obtained.  
 
To develop a biocompatible surface, one approach is that of mimicking the erythrocyte and 
endothelial cellular membranes. Lecithin is made of phospholipids that are one of the main component 
of the plasmatic membrane. Phospholipids are amphiphilic molecules, with a hydrophilic head and a 
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hydrophobic tail. Because of their chemical structure, they organize into a bilayer matrix and serve as 
a good building block of cell membranes. For all these reasons, PCL:PGS (1:1, v/v) was functionalized 
employing three different concentrations of rapeseed and salmon lecithin. 
The novelty of this part of the work was to fabricate a general model of biodegradable small diameter 
vascular scaffold that was prone to be easily functionalized with bioactive compounds with different 
chemical properties, without negatively influencing all the characteristics of the material itself. 
 
The second part of this Ph.D. research thesis is focused on the synthesis and biological validation 
of two different nanosystems for drug delivery. These nanodelivery systems were thought to be 
potentially applied as innovative therapy for vascular pathologies. In particular, for atherosclerotic pre-
lesions, when the blood flow is not compromised, the use of vascular scaffolds is not required. It is 
preferable to have a particles-based system able to inhibit with specific drugs the progression of the 
atherosclerotic lesion. Despite of different positive effects on the human health, the majority of 
polyphenols show only a limited application in the pharmaceutical sector, due to their low solubility 
in water and, similarly to the proteins, a low stability when they are exposed to environmental 
conditions (temperature, light, presence of oxygen etc.). With the aim of overcoming all these 
drawbacks, two different synthesis protocol were established to synthetize CaCO3 nanoparticles and 
nanoliposomes. 
In this work, CaCO3 nanoparticles were synthetized through a two-step protocol which consisting 
in complex coacervation and mineralization. They were loaded with different antioxidants and with 
BSA, as a model protein. The second step was to engineered the nanoparticles in order to prevent a 
burst release of the embedded compounds, deposing onto their surface different polysaccharidic layers. 
This multi-shell architecture allowed the immobilization at the level of the last layer of an antibody. 
When this functionalized nanoparticles were put in contact with human endothelial cells EA. hy 926, 
their phagocytosis occurred. 
The second nanoencapsulation system was studied at the Laboratoire d’Ingénierie des 
Biomoleculès (LIBio), at the University of Nancy, under the supervision of Professor Elmira Arab-
Tehrany. Here, it was optimized the encapsulation of quercetin, one of the most common and promising 
polyphenolic compound, and BSA, a model protein, in rapeseed lecithin nanoliposomes. Liposomes 
were prepared mixing quercetin and rapeseed lecithin in water and nanoparticles were obtained after 
the sonication process. Morphology, size, ζ-potential, stability at three different temperatures, 
entrapment efficiency, release studies in different environmental conditions, FTIR, rheological 
properties of the water-based nano-formulation and biocompatibility with human stem cells and 
fibroblasts were assessed. 
This part of the work represents a promising therapeutic approach for the treatment of the early stages of 
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one of the most widespread cardiovascular disease, atherosclerosis. The main advantage of this research 
was to take into account the possibility of developing two drug delivery systems to counteract 
atherosclerosis with a targeted therapy. 
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Cardiovascular diseases that result in the occlusion of vessels are one of the leading cause of death in the 
Western world. They are provoked as a consequence of an unhealthy lifestyle, genetic susceptibility, and 
other concomitant disorders. Nowadays, with the aim of counteracting such pathologies different strategies 
are commonly used. First of all, it has to be cited the use of different drugs that are able to interfere with 
the metabolism of cholesterol (e.g. statin). Another possibility to avoid the complete occlusion of vessel, 
with dramatic consequences depending on the site it will occur, is vascular surgery. The use of synthetic 
prostheses is a widespread surgery practice in all over the world. The occurrence of thrombosis in the case 
of implanting synthetic small dimeter vascular grafts has stimulated the vascular research in the developing 
of small diameter biodegradable prostheses. They are good candidate in vascular tissue engineering to 
substitute occluded vessel or to be implanted as bypass. Their play a pivotal role in patients in which the 
diameter of the lumen is already compromised. On the other hand, vascular medicine is forcing to the 
prevention of the complete occlusion of vessel and different protocol of therapy will be approved to 
counteract the early stages of the occlusion. This Ph.D. thesis present two different innovative tools to 
counteract the occlusion of vessel during in early (nanodelivery systems) or late (biodegradable scaffolds) 
stages.  
The first part is addressed to the synthesis of small diameter vascular prostheses made of biodegradable 
polymers and their coating/functionalization with different bioactive molecules: gelatin, quercetin, proteins, 
and lecithin from rapeseed and salmon. Gelatin was used to reduce the permeability of the scaffolds, 
quercetin was used because of its anti-inflammatory activity that will be useful in the early period after the 
implantation to prevent the rejection of the graft, proteins encapsulated in nanoparticles because of their 
prolonged release will be able to recruit cells, induce their growth, and in some cases, their differentiation, 
and lecithin will prevent oxidative stress and will serve as a building block for cellular membranes. The 
choice to synthetize specifically small diameter substitutes (2 and 5 mm in diameter) derived from the lack 
of synthetic materials showing good performances when implanted in upper and lower limbs. 
The second part of the thesis was dedicated to the synthesis of two different nanodelivery systems for 
the treatment of the early stages pre-lesions of occluding pathologies, when the prostheses are not yet 
required because of the vessel is not completely occluded. Their role is the encapsulation and the delivery 
in site of bioactive compounds (polyphenols and proteins) with the aim of decreasing their potentially side 
effects and to reduce the concentration used in the common therapy. The proposed nanosystems are 
nanoparticles made of calcium carbonate and poly (acrylic acid) and rapeseed lecithin nanoliposomes. The 
first nanosystem was engineered through Layer-by-Layer self-assembling technique to allow the 
attachment of a specific antibody on the nanoparticle surface. The antibody acted as a driving molecule, 
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allowing the nanoparticles to reach exclusively the pathologic tissue, where they are able to release a 
specific drug. 
The thesis consists of: 
- chapter I: it is a brief introduction to the main topics of the thesis, focusing on vascular tissue 
engineering and nanotechnologies for drug delivery systems; 
- chapter II: this chapter concerns the synthesis, the functionalization, and the characterization of 
electrospun small diameter scaffolds; 
- chapter III: this chapter describes the synthesis, the engineering and the biological validation of 
calcium carbonate nanoparticles encapsulating proteins and polyphenols, 
- chapter IV: this chapter is focused on the development and characterization of rapeseed 
nanoliposomes entrapping proteins and quercetin 
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         CHAPTER I 
1. BACKGROUND 
The lost or irreversible damages to a tissue or to a whole organ is one of the most common, disabling and 
costly problem in the modern medicine. The replacement of failed organs represents today the only 
solution to this problem (Langer and Vacanti, 1993). The problems regarding an autogenic 
transplantation derive from the difficulties we have nowadays to generate a new organ starting from 
cells isolated from patients. A possibility to overcome this kind of problem is taking into consideration 
an allogenic transplantation instead of the autogenic ones. Here, the insufficient number of donors, the 
risk of pathogen (viral and bacterial) transmission and the possibility of a rejection by immune system 
have limited the allogenic transplantation of donor organs (Lanza et al., 2000; Fuchs et al., 2001). As 
a consequence, patients have to wait for an organ for many years and if they will receive one in time, 
they have to get immunosuppressive drugs for a long period. In the worst cases, their situation do not 
change because of the transplanted organ is completely rejected by their immune system. 
Tissue engineering (TE) is defined as an interdisciplinary and multidisciplinary field that applies the 
principles of engineering, material, life, and clinical science to study and develop substitutes to restore, 
maintain or improve tissue functions (Langer and Vacanti, 1993). One of the aim of TE is to obtain a 
valid substitute that could temporarily replace the damaged organ, better known as scaffold, that could 
potentially generate a new well-functioning organ. A good knowledge of the involved tissues is 
required before starting to develop new substitutes for them. Under a biological point of view, tissues 
consist of cells, signaling pathways and extracellular matrix (ECM) (Lanza et al., 2000). Cells secrete 
the ECM in which they are completely immersed and in which they communicate through signaling 
molecules. The ECM could be considered as a framework responsible of supporting cells during their 
growth and for their entire life (Badylak, 2007). 
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Figure 1.1: an example of TE concept involving cell seeding on porous scaffolds. (a) Cells are isolated from the 
patient, (b) cells are in vitro cultivated and expanded, (c) cells are seeded within the porous scaffold together with 
growth factors and free or encapsulated bioactive molecules, (d) the construct is cultivated in bioreactors, (e) the 
construct is implanted in the patient to restore the lost function (adapted from Dvir et al., 2011). 
 
Figure 1.1 depicts the classical principles of TE. The first step is represented by isolating cells from the 
patient. Then, they are expanded in vitro and introduced into a biodegradable scaffold. Finally, the scaffold 
is implanted in vivo. The modern concept of TE consists of the development of biodegradable scaffolds that 
could be functionalized with free or micro- and nanoencapsulated bioactive compounds (proteins, drugs, 
natural molecules etc.) and then they are directly implanted, bypassing the cell seeding step, in vivo. Once 
it is in the patient, the presence of biomolecules within the scaffold induces a cell recruitment and their 
attachment and proliferation on the implanted scaffold. Furthermore, the presence of synthetic or natural 
compounds with anti-inflammatory activity could counteract the post-surgical inflammation process. The 
design of a good substitute need optimization of several aspects. Each tissue requires different materials 
and porosity of the scaffold. In general, the scaffold should allow three dimensional tissue regeneration, 
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providing a good support for cells, enabling nutrient and waste exchange (Takezawa, 2003; Hollister, 2005).  
The term regenerative medicine is often used as synonym of TE but it has to be considered as a broader 
field which includes tissue engineering. The basic principle of regenerative medicine is that the body, with 
the help of biomaterial, uses its own system to recreate and rebuild tissues and organs. Regenerative 
medicine is based on the use of stem cells.  
1.1. Biomaterials  
Biomaterials are materials able to interact with cells in living tissues/organs. Biomaterials are generally 
polymers and they can be synthetic or natural. Poly (ε-caprolactone) (PCL), poly (glycerol sebacate) (PGS), 
poly (lactic acid) (PLA), and poly (glycolic acid) (PGA) are well-known examples of synthetic biomaterials 
while gelatin, chitosan, hyaluronic acid, and dextran are examples of natural ones. Synthetic materials show 
good mechanical properties while the natural ones are less toxic and induce a limited inflammatory reaction. 
All these materials find application as tissue engineering scaffolds. Biocompatibility is the most important 
and desirable property they have to show. The first definition of “biocompatibility” was provided by the 
European Society for Biomaterials in 1986 as: “the ability of a material to perform with an appropriate host 
response in a specific application” (Williams, 1986). Therefore, the biomaterials have to induce an adequate 
biological response without causing negative effects in the surrounding tissues and in the whole body. 
Another peculiarity of scaffolds is that they have to be biodegradable at the same time as the tissue 
regeneration. 3D scaffolds have to provide mechanical and adhesive support for cells, allowing 
vascularization and shape maintenance during the regeneration process. Initially enough mechanical 
strength and stiffness is required to counteract wound contraction forces and later to ensure a perfect 
rebuilding of the tissue, physically supporting the growing cells (Hutmacher, 2000). Scaffolds should 
present high porosity, high surface area, fully interconnected geometry and a well-defined 3D shape. 
Finally, scaffolds should be manufactured in a reproducible, controlled and, if it is possible, cost-effective 
process. During their synthesis is desirable to include bioactive compounds inside their matrices to make 
them “active scaffolds”, able to participate actively to the regeneration of the damaged tissue.  
Biomaterials are often divided into two groups: synthetic or natural, depending from their origin. 
 
1.1.1. Synthetic polymers 
 
Different polymers are used in TE because of their good versatility, stable properties and high workability. 
Working with synthetic polymers, presents the advantage of obtaining scaffolds with predictable properties. 
As examples, it is reported that the degradation and fluid uptake rate can be adapted to specific applications 
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by changing the composition of the scaffolds in terms of polymers, copolymers or blends. However, a 
disadvantage of synthetic polymers is their low biocompatibility. This property could be overcome working 
with blends of polymers with natural materials or reducing their hydrophobicity. In this section, a brief 
description of the polymers used during the Ph.D. research activity are presented. 
 
Poly (ε-caprolactone) 
Poly (ε-caprolactone) (PCL) is an aliphatic biodegradable polyester. It is well-known for its good 
biocompatibility and bioresorbability. It is synthetized by a ring-opening polymerization of ε-caprolactone, 
employing stannous octanoate as catalyst (Figure 1.2). It has been reported that it is degraded by hydrolytic 
mechanism (Sun et al.,  2006; . It is suitable for long-term implantable substitutes because its hydrolytic 
degradation is slower in comparison with hydrophilic biomaterials. 
 
  
 
 
 
 
 
 
Figure 1.2: synthesis of PCL (adapted from Osathanon et al., 2017). 
 
Poly (glycerol sebacate)  
Poly (glycerol sebacate) (PGS) is a transparent, almost colorless biodegradable polymer. Chemically, it is 
a polyester prepared by the polycondensation of glycerol and sebacic acid (Figure 1.3). Since its high 
hydrophilicity, it shows a good biocompatibility with different kind of cells and a good biodegradability. 
Controlling curing time, curing temperature and the reagents concentration, is possible to modulate the 
degradation kinetic and mechanical properties of the resulting polymer. Due its mechanical properties, it is 
generally used for soft tissues as cardiac muscle, vessels, nerve, cartilage and retina (Rai et al., 2012). 
ε-caprolactone poly (ε-caprolactone) 
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Figure 1.3: synthesis of PGS (adapted from Wang et al., 2002). 
 
Poly-L-arginine 
Poly-L-arginine is a positively charged synthetic polyamino acid (Figure 1.4). It appears as a crystalline 
solid soluble in water. It is widely used for the layer-by-layer deposition technique in combination with 
dextran sulfate (De Geest et al., 2006; De Koker et al., 2009). 
 
Figure 1.4 chemical structure of poly-L-arginine (adapted from Sigma-Aldrich website). 
 
1.1.2. Natural polymers 
 
Natural polymers are generally extracted form plants, animals or human tissues. Usually, chemical 
modifications are useful to enhance their properties, like mechanical and surface properties. The chemical 
modifications are able to modulate both the degradation and fluid uptake rate of the polymer. In this section, 
the natural polymers used during the Ph.D. research activity are briefly described. 
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Gelatin 
Gelatin derives from the hydrolysis of collagen, the most abundant protein in the connective tissue (K. Y. 
Lee & Mooney, 2001) (Figure 1.5). Gelatin solubilizes in water at 60°C and it forms gels at room 
temperature (Young et al., 2005). Gelatin is widely used for pharmaceutical and medical applications. In 
fact, it is easy to be manipulated, extremely biodegradable and cheap (Zandi et al., 2007). 
 
Figure 1.5: chemical structure of gelatin (adapted from Ge et al., 2012). 
 
Chitosan 
Chitosan is an amino polysaccharide synthetized by partial N-deacetylation of chitin (Figure 1.6). In nature 
it is the structural element of the exoskeleton of crustaceans (shrimp, crabs etc.) and cell walls of fungi. 
 
Figure 1.6: deacetylation of chitin and formation of chitosan (adapted from Nilsen-Nygaard et al., 2015). 
Chitosan shows many applications in the biomedical sector because of its low cytotoxicity, structural 
similarity to natural glycosaminoglycans, and good biodegradability (Singh & Ray, 2000). It is widely 
employed as polycation in layer-by-layer self- assembling protocols (Zhou et al., 2010). 
 
Dextran  
Dextran is a complex branched homopolysaccharide made of many glucose molecules (Figure 1.7). The 
straight chain consists of α-1,6 glycosidic linkages between glucose molecules. Branches start from α-1,3 
linkages. Some acid bacteria, like Leuconostoc sp. are able to produce dextran starting from sucrose. It is 
                                                                                                                                                                        BACKGROUND 13 
 
  
used as an antithrombotic to reduce blood viscosity and as polyanion in drug delivery applications 
(Serizawa et al., 2002). 
 
Figure 1.7: chemical structure of dextran sulfate (adapted from De Clercq, 2013). 
 
1.2. Vascular tissue engineering 
Vascular diseases are the leading cause of morbidity and mortality in the Western World (Ravi & Chaikof, 
2010). The fabrication of prosthetic vascular conduits began necessary in the last decades because of a 
limited availability of healthy autologous vessels. To overcome this problem, different strategies were 
proposed over the time and to date in vascular surgery only artificial non-degradable prostheses are used. 
Nevertheless, the current synthetic polymers used (e.g. polyethylene terephthalate and expanded 
polytetrafluoroethylene) show many important drawbacks. 
1.2.1. Vessel structure 
 
Vessels are conduits of the cardiovascular system able to transport blood from heart to tissues and from the 
tissues to the heart again. There are three different kind of vessels: arteries, veins and capillaries (Figure 
1.8). Arteries are responsible of carrying the oxygenated blood from the hearth. They consist of three 
different layers: the tunica intima, made up of endothelial cells, tunica media, made up of smooth muscle 
cells and elastic tissue, and tunica externa, made up of connective tissue. Veins are responsible of 
transporting the deoxygenated blood from the periphery to the heart. Structurally, they are similar to arteries 
but they present thinner walls and valves. Each layer that contributes to the formation of a vessel has a 
defined role and contributes to its function. In particular, endothelial cells constitute the inner surface of 
the vessel and they, being aligned, show anti-thrombotic properties. Smooth muscle cells and elastin are 
responsible of the elasticity of the vessel. Collagen makes viscoelastic the vessel, inducing a higher 
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elasticity at low pressure and a higher rigidity at high pressure (Baguneid et al., 2006; (Isenberg, Williams, 
& Tranquillo, 2006). 
 
Figure 1.8: anatomic structure of (a) arteries, veins, and (b) capillaries (adapted from Anatomy and Physiology, 
a learning initiative). 
 
1.2.2. Pathologies related to vessel obstruction 
 
In general, a vessel has to be considered occluded when there is a significant reduction of its lumen. This 
phenomenon can happen because of many reasons. The widest pathology related to vessel obstruction is 
atherosclerosis. The typical lesion of this pathology is the atherosclerotic plaque characterized by the 
thickening of tunica intima due to the accumulation of lipids and a consequent recruitment of leukocyres 
from blood, fibroblasts proliferation, and macrophages proliferation. Generally, this pathology is 
characterized by two steps: first, endothelial damages and oxidation of low-density-lipoprotein (LDL) in 
the tunica intima, and second, the inflammation-related process. At this time, macrophages try to 
phagocytize oxidized LDL, becoming foam cells. These cells secrete molecular factors that play a pivotal 
role in recruiting blood leukocytes and in inducing the synthesis of ECM by smooth muscle cells (Figure 
1.9). In the worst cases, the atherosclerotic plaque can evolve to a thrombus with a full occlusion of the 
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blood vessel. 
 
 
Figure 1.9: molecular and cellular mechanism involved in the atherosclerotic plaque formation (adapted from 
Moore & Tabas, 2011). 
1.2.3. Treatment of small-caliber blood vessel occlusion 
 
Angioplasty, atheroectomy and use of bypass are current surgery strategies performed to remove the 
occlusion of small-diameter blood vessel 
 
Angioplasty 
Balloon angioplasty or percutaneous transluminal angioplasty, is a low invasive endovascular procedure to 
widen narrowed or occluded blood vessels and typically is used to treat arterial atherosclerosis. It is usually 
performed when the occlusion of the blood vessel is less than 70 %. A deflated balloon attached to a catheter 
is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces an 
expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow (Figure 
1.10). A stent may be inserted at the time of using the balloon to ensure the complete reopening of the 
vessel (Tatterton et al., 2012). 
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Figure 1.10: angioplasty (adapted from John Hopkins Medicine website). 
 
Atherectomy 
Atherectomy is a minimally invasive endovascular surgery technique addressed to remove atherosclerotic 
plaque from blood vessel (Figure 1.11). It is suitable for the treatment of peripheral and coronary artery 
diseases (Ambler et al., 2014). 
 
Figure 1.11: atherectomy with rotary cutter (adapted from Keck School of Medicine of USC). 
 
Use of bypass 
Bypass technique consists of overcoming a partially or completely obstructed blood vessel. Briefly, an 
autologous blood vessel is removed from another region of the body and it is used to do a bypass closed to 
the occluded vessel. Unfortunately, not always is possible, for many reasons, to do a by-pass with 
autologous vessel. A valid solution to this problem is the use of synthetic grafts (Figure 1.12), that are the 
main topic of this Ph.D. thesis. 
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Figure 1.12: bypass procedure (adapted from Medtronic website). 
 
1.2.4. Vascular substitutes 
 
According to a recent statistical study of the American Health Association, cardiovascular diseases are 
responsible of 34 % of deaths in United States of America. Another report states that 36 thousands babies 
per year is affected by congenital diseases of the cardiovascular system (Nuti et al., 2010). The treatment 
to such pathologies needs vascular substitutes. The treatment of cardiovascular diseases with autologous 
substitutes still remains a valid option. To this purpose, the vena saphena magna, the internal mammary 
artery or the radial artery are employed. Although vascular bypass grafting remains the most common 
revascularization treatment for ischemic heart and peripheral vascular diseases, the majority of patients do 
not have healthy vessels suitable to be harvested. In addition, the population undergoing repeated coronary 
revascularization is augmenting. Therefore, there is an increased need for alternative, synthetic vascular 
substitutes. It has been well accepted that the formation of neointima, endothelialization at the graft walls 
and the absence of thrombogenicity are the goals of graft healing. Materials that are currently used in the 
vascular surgery are polyethylene terephthalate (PET, Dacron®) and expanded polytetrafluoroethylene 
(ePTFE, Teflon®) (Figure 1.13). 
                                                                                                                                                                        BACKGROUND 18 
 
  
 
Figure 1.13: synthetic vascular prosthesis made of poly (ethylene terephthalate) (left) and expanded poly 
(tetrafluoroethylene) (right). 
Poly (ethylene terephthalate) is a thermo-elastic polymer belonging to the polyesters family. Poly (ethylene 
terephthalate) is a resistant, biostable and stretchy polymer. It is commonly used in vascular surgery as a 
substitute only in the case of large diameter vessel. 
Expanded poly (tetrafluoroethylene) is one of the most inert polymers known, and its electronegative 
surface has been supposed to be non-thrombogenic, even in the case of small diameter grafts (Campbell et 
al., 1975). Its matrix is highly porous and permits the formation of neointima lining the lumen of the graft. 
Cellular infiltration and endothelialization of implanted expanded poly (tetrafluoroethylene) grafts was 
observed in animal models (Sauvage et al., 1974). On the contrary, several authors demonstrated that the 
endothelialization of expanded poly (tetrafluoroethylene) grafts in human was rare except the short segment 
next to the anastomosis site, even after five years. In fact, other clinical studies highlighted that the tissue 
ingrowth and the development of a well-organized neointima was extremely poor in expanded poly 
(tetrafluoroethylene) small diameter grafts implanted in human (Camilleri et al., 1985; Guidon et al., 1993; 
Formichi et al., 1998). As a consequence, the use of these two synthetic materials is limited to the dimension 
of the graft. These synthetic prostheses are good candidates when the required diameter is higher than 5-6 
mm. For the opposite, as mentioned before, the majority of small diameter vascular graft fails within 5 
years and the frequency of thrombogenic event is high. For all these reasons, the use of vascular substitutes 
fabricated with these two materials is limited to cases where there is a substantial blood flow and in 
conditions of low resistance. 
 
The properties to be improved developing a synthetic graft are: 
1. poor elasticity and compliance to the hematic flow; 
2. thrombogenicity of the surfaces; 
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3. impossibility to accept and sustain the growth of cells for a long period. 
 
Requisites of a vascular substitute 
The properties of a blood vessel are rather complex, starting from its multilayered structure. In particular, 
a small caliber blood vessel substitute have to possess: 
1. a smooth internal surface with the lowest possible friction coefficient; 
2. size and properties similar to the vessel to be substituted; 
3. avoid platelet aggregation and thrombogenic phenomena; 
4. minimize blood flow interferences, 
5. show optimal transfer of pulsatile energy. 
Moreover, a vascular substitute should resist bending, be simple to be sutured and handle, and require 
short production time and low production cost. At the moment being, the scaffold used in the new 
generation vascular tissue engineering scenario can essentially be divided into two categories: 
 polymeric scaffolds, including electrospun ones; 
 biological, like decellularized scaffolds. 
 
1.2.5. Electrospun scaffolds 
 
Among polymeric scaffolds, electrospun scaffolds are playing a primary role in the vascular surgery field. 
Fibrous structures are raising a great interest, due to the fact that they are structurally closed to the ECM 
architecture. Electrostatic spinning (electrospinning) is one of the most emerging techniques to fabricate 
fibrous scaffold. The numerous process parameters that characterize this technique offer a wide range of 
possibilities to modulate the properties of the resulting electrospun scaffolds. Different type of polymers 
can be used during the electrospinning process: synthetic, natural or mixtures of them. For TE applications, 
the most promising bioresorbable polymers, as previously reported, are PCL, PGS and PLA. 
1.2.5.1. Electrospinning technique 
 
Electrospinning has established a significant role in the field of TE over the last fifteen years. Indeed, this 
technique allows to obtain polymeric scaffolds with ultrathin micro- or nanofibers (Cui et al., 2010). 
Electrospinning can be considered a particular case of electrospraying. It is indeed a method for atomization 
of fluids with application in mass spectrometry and in the industrial field of surface coating. If the fluid 
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employed for electrospinning presents a low molecular weight, the stream becomes unstable before it 
reaches the collector and transfroms just into a spray of electrostatically charged small drops. By using fluid 
polymers instead, the viscoelastic forces stabilize the stream, allowing the formation of thin charged 
filaments that deposit into a twist of fibers. The diameter are far smaller that those of extruded or 
mechanically stretched fibers (wet, dry, and melt spinning).The electrospinning technique is able to produce 
micro- or nanofibers through an uniaxial stretching of a viscoelastic solution. Unlike dry-spinning and melt-
spinning, electrospinning uses electrostatic forces to stretch the polymeric solution as it is extruded from 
the needle. The instrumentation is composed by (Figure 1.14): 
 a syringe (usually in glass), containing the polymeric solution to be electrospun; 
 a pump, feeding the polymeric solution that is extruded from the syringe; 
 a high voltage DC generator that is connected to the needle by means of an electrical contact (the 
set-up could be either in positive or negative modality (Lingaiah et al., 2007); 
 a metallic collector, on the ground, that has the role to collect the fibers. There are many collectors 
that differ in terms of size, shape (cylinder, flat etc.), and material. 
 
 
 
 
 
 
 
 
 
 
 
 
b 
a 
c 
d 
A) 
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Figure 1.14: (A) picture and (B) schematic representation of a common electrospinning apparatus set-up: (a) 
syringe, (b) peristaltic pump, (c) high-voltage DC supply, (d) rotating and translating grounded collector. 
 
The advantage of electrospinning system can be summarized in: 
 the fiber structure, with tunable fiber diameter, that mimics that of ECM (ECM presents protein 
fibers ranging between 50 and 500 nm); 
 high surface/volume ratio of the ultrathin fibers, which allows a significant cell attachment. In 
particular, it seems that micrometric structures are better accepted by cells than sub-micrometer 
structures (Del Gaudio et al., 2009); 
 control over fiber orientation (aligned or random distribution); 
 wide range of electrospun materials. 
The electrospinning process and the fiber morphology could be influenced by many parameters. These 
parameters can be divided into three categories: properties of the polymeric solution, electrospinning 
set-up, and environmental conditions. The type of collector employed influenced the properties of the 
final constructs, especially the shape and consequently the application. Solution properties depend on 
its viscosity, electrical conductivity, and surface tension. They are clearly tied to both the 
characteristics of the polymer and of the solvent or mixture of solvents used. 
 Viscosity: it is one of the parameters with a greater influence over the diameter and morphology of 
the fibers. Viscoelastic forces are deeply correlated to the polymer structure (linear or reticulated) 
and to its molecular weight. Hence, for any considered system there is a range of concentration. 
Below a prefixed concentration, the chain entanglements are too limited to support the spinning 
process and drops are formed; above it the drop of solution dries before the stream starts to carry 
a 
b 
c 
d 
B) 
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the fibers accelerated by electric field towards the collector. To increase the viscosity of the 
solution, one can increase the molecular weight or the concentration of the polymer. However, 
increasing viscosity also increases the fiber diameter because the solution becomes more resistant 
to be stretched because of the electric field, and consequently the stream stabilizes and runs over a 
shorter path. 
 Electrical conductivity: the increase of a solution conductivity causes a greater repulsion of the 
flow’s jet, and therefore a greater stretch of the fibers, which decrease in diameter (Bosworth and 
Downes, 2009). Possible approaches to increase conductivity are the addition of salts (Deitzel et 
al., 2001), and the use of more conductive solvent (Beachley & Wen, 2009). 
 Surface tension: with the aim of fabricating nanofibers, the electric charge should overcome the 
solution surface tension. During the electrospinning process, the surface tension opposes the jet 
stretch, causing the formation of drops or fibers with drops. To avoid this phenomenon, a solution 
with low surface tension is preferable. 
Set-up parameters are related to the fibers production and they comprise the voltage, the flow rate, 
the distance between the collector and the needle and roto-translating movement of the collector. 
 Voltage: an increase in voltage induces a higher electrostatic repulsion of the flow. Therefore, 
thinner fibers will be obtained. With large potential differences, fiber diameters become larger due 
to the difficulty of the solvent to evaporate (Venugopal et al., 2007). 
 Pumping flow rate: high flow rate cause an increase in fiber mean size. Indeed, these do not have 
sufficient time to permit the solvent evaporation (Bosworth and Downes, 2009). However, this 
parameter is less influent than the others. 
 Distance between the needle and the collector: this distance influences the time that the fiber has 
to reach the collector. Reducing the distance, the flow has a minimal time to dry before be deposed 
on the collector. 
 Diameter of the needle: a needle with smaller internal diameter reduces the number of drops and 
consequently the fiber diameter. A drop at the end of the needle will have smaller size and greater 
surface tension. For the same voltage, a greater Coulomb friction is therefore needed to form the 
flow, with a consequent decrease in flow acceleration (Buruaga et al., 2009). 
Even environmental parameters influence the morphology of the fibers and the external electrical 
field. 
 Humidity: an increase in humidity increases the size, number and distribution of pores on the fiber 
surface (Bosworth and Downes, 2009). At the same time, depending on the polymer, the increase 
in humidity causes an increase or a decrease in fiber diameter. 
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 Temperature: the increase in the temperature of the solution has two opposed effects on the 
electrospinning process. Indeed, it increases solvent evaporation, increasing fiber size as a 
consequence. However, it could also decreases the viscosity with an opposite effect (Mo et al., 
2004). 
 
1.3. Drug delivery 
Bioactive compounds often show undesired pharmacological properties (Langer, 1998). In the field of 
nanotechnology, pivotal challenges are represented by overcoming the insufficient drug doses reaching the 
pathological site, by increasing the short half-life and/or by prolonging the shelf-life of drugs. In order to 
achieve these objectives, scientists have been developing innovative drug delivery systems. Another aim 
of drug delivery is to have the release of drugs in a control and localized way. In drug delivery different 
materials are used. They derive from natural or synthetic sources and, in any case, they have to be extremely 
biocompatible. As shown in Figure 1.15, all these materials can be rearranged in such a manner that they 
are considered as micro- or nanosized particles (polymeric, nanoparticles, liposomes, polymeric micelles 
etc.) (Rampino et al., 2013). Controlled and localized delivery of drugs is related to the concept of 
concentrating the therapeutic treatment only at a level of the pathological tissue (Bhatt & Addepalli, 2010). 
As a consequence of that, an improved bioavailability of the drug occurs. The control of the release of a 
determined drug at a specific site could be very difficult and it is obtain modifying the surface of the carriers 
(e.g. layer-by-layer technology). Often when the drug delivery system enter in our body, an inflammatory 
reaction is provoked (Farra et al., 2012). For that reason, it is fundamental to assess if the studied drug 
delivery system is able to evoke inflammation. The list of advantages that derives from drug delivery is 
quite extensive (Wu & Grainger, 2006; Zilberman et al., 2010). First, by concentrating the drug only to the 
target tissue, it reduces the quantity of drug, often expensive, that is necessary to have a therapeutic effect 
(Uhrich et al., 1999). Second, by carrying the drugs to site where they are necessary, the side effects are 
drastically reduced. Third, by delivering the drugs to the site where they are needed, it allows to increase 
the bioavailability of the drug (Ndesendo et al., 2011; Wong et al., 2010). 
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Figure 1.15: different carriers commonly studied in drug delivery (adapted from Cho et al., 2008). 
NPs: nanoparticles. 
 
1.3.1. Calcium carbonate nanoparticles 
 
Calcium carbonate (CaCO3) is one of the most abundant inorganic biominerals. The worldwide availability 
of CaCO3 (as limestone), and its non-toxicity towards the human body makes the synthesis of this material  
an interesting and attractive topic for scientists and researchers to delve into. Therefore, countless studies  
dealt with the task of using CaCO3 particles in drug delivery procols. Its biocompatibility, its 
biodegradability, its low toxicity and its low cost make it a perfect candidate as a micro/nanocarrier of a 
wide range of biomolecules. 
Thanks to these properties, CaCO3 is becoming an usual material for the encapsulation and  
delivery of biomolecules. CaCO3 exists as three anhydrous crystalline polymorphs (calcite, vaterite,  
aragonite); two hydrated metastable forms (monohydrocalcite and CaCO3 hexahydrate), and an unstable  
amorphous phase. Calcite, vaterite and aragonite have typical morphologies (shapes) which are 
rhombohedral, spherical and needle-like, respectively (Boyjoo et al., 2014). Calcite is the most  
thermodynamically stable phase among the six forms of CaCO3. Vaterite has better water solubility, higher  
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porosity, and is more easily dissolved than calcite or aragonite. The thermodynamic instability of vaterite, 
however, makes its natural occurrence rare, requiring kinetic stabilization even for laboratory production  
(Nagaraja et al., 2014). Aragonite has needle-like crystals that are used as fillers for the improvement of  
mechanical properties of paper and polymeric materials, and is also a good biomedical material, because it 
is denser than calcite and can be easily replaced by bone (Wang et al., 1999). Amorphous calcium carbonate 
is the least stable phase and transforms rapidly into one of the crystalline polymorphs unless it is stabilized  
by specific additives. Thus, it has the highest solubility in water and is the only form that has isotropic 
property and does not diffract X-rays (Huang et al., 2007). There are three main techniques 
to encapsulate biomolecules in CaCO3 particles: direct crystallization, co-precipitation, and complex 
coacervation followed by mineralization (Lauth et al., 2014).  
Briefly: 
 direct crystallization: the encapsualtion of drugs is a consequence of the physical adsorption onto 
synthetized crystals (Sukhorukov et al., 2004). The main characteristic of the produced carriers 
regards their large size (1-5 μm), crystalline polymorphism and highly porous structure. Some 
disadvantages come from this technique, such as the crystalline structure that is subject to 
recrystallization in water, which could induce changes in the shape (Petrov et al., 2005). 
 Co-precipitation method: the precipitation of CaCO3 is initiated in a solution that contains the drug 
to be encapsulated. The morphology of products obtained via co-precipitation is extremely 
heterogeneous, ranging from macrosized to nanosized particles. Working with a co-precipitation 
method ensure to obtain high encapsulation efficiency values (Wang et al., 2014). 
 Complex coacervation followed by mineralization: the coacervation is considered the separation 
into two liquid phases (Eghbal & Choudhary, 2018). During complex coacervation two molecules 
with oppositely charge are mixed together in a single solvent (e.g. water) (Figure 1.16). The 
dispersed core material is suspended in an aqueous phase containing the active agent (Onder et al., 
2007). The resulting product of this process are coacervates that are miscible in the solvent. After 
the formation of these coacervates, it is possible to increase their stability using inorganic salts, like 
sodium carbonate, obtaining fully mineralized amorphous CaCO3 particles. 
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Figure 1.16: complex coacervation and mineralization for CaCO3 particles synthesis (adapted from Lauth et al., 
2014). 
1.3.2. Layer-by-Layer self-assembling technique  
 
Layer-by-Layer (LbL) is a quite simple technique based on the alternated deposition of polycations and 
polyanions onto the surfaces of inorganic or organic substrates (De Cock et al., 2010) (Figure 1.17). For its 
good versatility, low cost, and possibility to control the thickness of each single layer, it is a wide technique 
to functionalize particles having a diameter ranging from 50 nm up to 10 μm (Pastorino et al., 2011). The 
presence of different layers surrounding particles is aimed to: first, to obtain a fully controlled release of 
the entrapped molecules, changing the number and the thickness of the layers, second, to attach at the level 
of the last layer guidance molecules, such as antibodies.  
 
Figure 1.17: schematic protocol for LbL self-assembling technique (adapted from Xiang et al., 2012).  
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1.3.3. Encapsulation in liposomes 
 
Liposomes were described for the first time by Bangham et al., (1965) as colloidal particles formed by one 
or more phospholipids bilayers separated by water compartments (Figure 1.18). In the last decades, they 
were used for the entrapment, delivery and release of a wide spectrum of molecules, both hydrophilic and 
hydrophobic (Fang & Bhandari, 2010). Important advantages of the encapsulation of bioactive compounds 
in liposomes are the possibility to carry them exactly to the tissue where they are needed, in complete 
agreement with the definition of drug delivery system, and to protect the entrapped substances during the 
transport from the injection site to the pathological tissue. In literature several technique to synthetize 
liposomes were reported, such as lipid film hydration, reverse phase evaporation, solvent injection or freeze 
thawing, sonication, French press and extrusion (Mozafari et al., 2008; Fathi et al., 2012; Patil & Jadhav, 
2014). 
 
 
Figure 1.18: encapsulation of different bioactive molecules in liposomes and functionalization of their surface 
(adapted from Liu & Boyd, 2013). 
 
1.4. Polyphenols 
Polyphenols are a large family of secondary metabolites produced by plants via shikimate pathway (Tsao, 
2010). They are characterized by the presence of one or more aromatic rings, with one or more hydroxyl 
group as substitutes. They are well-known for their antioxidant activity. This property consists in 
counteracting the activity of reactive oxygen species (ROS), such as such as superoxide radical (∙ O2), 
hydrogen peroxide (H2O2), hydroxyl radical (∙ OH), singlet oxygen (1O2) or peroxyl radicals (RO2 ∙) and 
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reactive nitrogen species (RNS). These reactive species are produced both by exogenous chemicals or by 
endogenous metabolic activity (Georgetti et al., 2008). Their antioxidant activity is due to two different 
activities: the radical scavenging activity and the interactions with proteins and ions (Munin & Edwards-
Lévy, 2011). They exhibit antioxidant activity trought two different mechanisms: donation of a hydrogen 
atom or donation of an electron (Leopoldini et al., 2011; Rice-Evans et al., 1996). They can prevent the 
formation of free radical even sequestering metal ions by chelating the inorganic reaction catalyst 
(Leopoldini et al., 2011). 
1.4.1. Classification of phenolic compounds 
 
Polyphenols can be classified on the basis of different criteria. The most widely used is on the chemical 
structure. According to this consideration, polyphenols are divided in non-flavonoid phenols and flavonoid 
phenols. The non-flavonoid phenols include phenolic acids (benzoic acid and cinnamic acids) and stilbens. 
All the benzoic acids derive from p-hydroxybenzoic acid. Gallic, vanillic and syringic acid are examples 
of this kind of compounds. Chemically, cinnamic acid share the structure of the hydroxycinnamic acid. The 
most famous member of this class is caffeic acid. Stilbens are characterized by the presence of two benzene 
rings joined by an ethylene bridge, and multiple hydroxyl substitutes on the aromatic rings. 
Flavonoids represent a large family of compounds which share the structure formed by a backbone of  
carbon atoms arranged into two benzene rings joined by a heterocycle.  Quercetin is a well-known example 
of flavonoids. 
 
1.4.1.1. Quercetin 
 
Quercetin (3, 3’, 4’, 5, 7-pentahydroxyflavone) is a plant-derived flavonoid and it is widely distributed in 
fruits, vegetables, leaves and grains such as capers, green tea, apples, berries, celery, broccoli, and onions. 
Quercetin shows antioxidant, anti-inflammatory, anti-atherogenic and anti-carcinogenic activities. The U.S. 
Food and Drug Administration has not approved any health claims for this flavonoid. In comparison with 
other polyphenols, its purification process is easier, thus lead to a competitive market price. It has been 
estimated that the daily dietary intake of flavonoids is approximately 20 mg and quercetin is the major 
fraction of such intake (Figure 1.19). 
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Figure 1.19: chemical structure of the flavonoid quercetin (adapted from McKay et al., 2015). 
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         CHAPTER II 
 
2. FUNCTIONALIZATION WITH BIOACTIVE COMPOUNDS OF 
BIODEGRADABLE ELECTROSPUN VASCULAR SCAFFOLDS  
 
2.1. INTRODUCTION 
In the Western World, atherosclerosis-related diseases, including coronary and peripheral arterial 
pathologies, are one of the most common cause of morbidity and mortality. In some cases, in order to 
restore the blood flow, preserving all the functions of the downstream tissue, is necessary to introduce 
an arterial bypass in the patient (Hu et al., 2012) or to replace a diseased blood vessel (Wippermann et 
al., 2009). If autologous veins or artery are not available for different reasons (previous harvest, 
anatomical defects and anomalies, disease progression, other vascular problems etc.), artificial vascular 
substitutes are required (Nerem & Seliktar, 2001). Current treatment strategies include the use of auto- 
or allografts or the use of stents which are not yet a definitive solution. The limited availability of 
suitable autogenous and allograft veins for complete coronary revascularization and the frequency of 
post-surgery occlusion of small-diameter synthetic prostheses has attracted several investigators to 
focus their attention on the fabrication of alternative biocompatible small caliber grafts. During the last 
decade, different type of vascular grafts have been used to bypass or replace stenosed vessels. Non-
degradable synthetic grafts (e.g. poly (ethylene terephthalate) fibers, and expanded 
polytetrafluoroethylene) have been successfully implanted as vascular substitutes for aortic and iliac 
reconstruction (Konig et al., 2009). When they are used as analogues for small-caliber vessels (inner 
diameter < 6 mm), many drawbacks have been reported: increased frequency of infection, absence of 
endothelialization after the implantation, possible short-term thrombosis and myointimal hyperplasia, 
presence of dystrophicic calcification and aneurysm (Wilson et al., 1990), compliance mismatch 
between the native tissue and the artificial material, and the related inflammatory response to the 
foreign materials (Lee et al., 2012). Thus, there is a need for the development of scaffolds that can 
collectively overcome these above-mentioned drawbacks. Blends of biodegradable and biocompatible 
poly (ε-caprolactone) (PCL) and poly (glycerol sebacate) (PGS) are among the materials that have been 
successfully used in vascular tissue engineering. The composition is biodegradable and biocompatible 
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and offers mechanical properties comparable to the native vessel. In addition, it has been shown that 
PCL:PGS scaffolds support the growth of human umbilical vein endothelial cells (Sant et al., 2011) 
and human mesenchymal stem cells (Tong et al., 2011). Thus, this chemical composition is promising 
for small-caliber engineering vascular grafts. Until today, different approaches have been studied to 
fabricate high-performing small-caliber blood vessel grafts, including collagen porous materials (Shen 
et al., 2008), cell seeded or not biodegradable polymers through 3D printing, electrospinning, film 
casting, self-assembling methodologies, and decellularized matrices from animals (Teebken et al., 
2000) and humans (Gui et al., 2009). In the last years, electrospinning has considered one of the most 
promising technique in the field of vascular tissue engineering since a microstructure very similar to 
extracellular matrix is formed during the whole process. During electrospinning the solvents evaporates 
quickly and a high electrical field charges the solidified polymers that are deposed onto a roto-
translating collector.  
Gelatin is a hydrophilic protein obtained by the partial hydrolysis of collagen. Collagen is the main 
constituent of bones, cartilages, skin, and , in general, of extracellular matrix in animals (Gomez-
Guillen et al., 2011). In this work, it was used to make impermeable to water the polymeric scaffold.  
Among antioxidants, there is a class of compounds, known as polyphenols, that show antinflammatory 
activity both in vitro and in vivo. Quercetin (3, 3’, 4’, 5, 7-pentahydroxyflavone) is one of the most 
prominent dietary antioxidant present in different kinds of fruit (apple, grapes, berries), vegetables (red 
onions, celery, broccoli, and beverages) (Kobuchi et al., 1999; Singh Baghel et al., 2012). It plays 
various beneficial health effect, not only acting as scavenger towards peroxynitrites and hydroxyl 
radicals (Boots et al., 2008), but even protecting against osteoporosis (Wattel et al., 2004), cancer 
(Ranelletti et al., 2000), cardiovascular diseases (Russo et al., 2012), and inflammation (Crespo et al., 
2008). Despite the majority of tissue engineering research is focused on the finding of a perfect 
candidate scaffold mimicking biochemical, physiological, mechanical and architectural characteristics 
of the native tissues. However, polymeric scaffolds could provoke inflammation after the implantation 
of the material and in the worst cases its rejection. The counteracting of the implanted-related 
inflammation by functionalized biomaterials, represents today a new challenge. In fact, the post-
surgical inflammation is able to affect negatively the cellular attachment and their growth on the 
bioprosthesis, inducing many damages to the microstructure of the biomaterials, compromising its 
physico-chemical and mechanical properties, leading, in the worst case, to the rejection of the graft. 
The functionalization of polymeric scaffold with CaCO3 nanoparticles aimed to create a good model of 
scaffold being able to attract cells during the release of the protein encapsulated in the nanoparticles 
themselves. 
Finally, polymeric scaffolds were functionalized with rapeseed and salmon lecithin. Rapeseed lecithin is 
formed by esterified mono- and poly-unsaturated fatty acids (PUFA), like oleic, linoleic, and linolenic 
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acids while salmon lecithin is characterized by a high content of eicosapentaenoic and docosahexaenoic 
acids (Bouarab et al., 2014). These PUFAs act both directly (e.g. by replacing arachidonic acid as an 
eicosanoid substrate, inhibiting arachidonic acid metabolism, and inhibiting the production of 
inflammatory mediators) and indirectly (e.g. by altering the expression of inflammatory genes through 
effects on transcription factor activation) (Khalfoun et al., 1997; Calder, 2006). 
 
2.2. MATERIALS AND METHODS 
In this section, materials and methods used during the research activity concerning the fabrication of pure 
polymeric and functionalized vascular grafts are presented. In details, after a short section on 
chemicals, a part regarding the materials and the methods to fabricate and to functionalize with 
bioactive compounds the polymeric vascular scaffold is described.  
 
2.2.1. Chemicals 
 
Poly (ε-caprolactone) (PCL) (Mn = 80.000 g/mol), glycerol, sebacic acid, gelatin from bovine and porcine 
bones, quercetin, bovine serum albumin (BSA), tetrahydrofuran (THF), anhydrous chloroform, absolute 
ethanol, and Dulbecco’s phosphate-buffered saline (DPBS, pH = 7.4) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).  
Poly (glycerol sebacate) (PGS) was synthetized as described by  Wang et al. (2002). Briefly, glycerol and 
sebacic acid were added in a 2:3 molar ratio and melted at 120°C under argon gas flow for 24 hours before 
the pressure was reduced below the atmospheric pressure over 5 hours. The reaction mixture was kept at 
120°C and under vacuum for 48 hours after which it was obtained a highly viscous pre-polymer. 
Molecular weight of PGS was determined using gel permeation chromatography (GPC, Agilent 1100 series, 
USA). PGS was dissolved in THF and 20 μL of the solution was injected to a column (Agilent PLgel 5 µm 
MIXED-D, 7.5 × 300 mm) at 25 °C and at flow rate of 1 mL/min. 
Water used for the preparation of solutions and washing operations was purified by Milli-Q® system 
(Millipore, Molsheim, France). 
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2.2.2. Cell mediums and reagents 
 
Two different types of cells were used for the experimentation, human endothelial cell line EA. hy 926 and 
human mesenchymal stem cells (hMSC). EA. hy 926 were cultivated in Dulbecco’s Modified Eagle 
Medium (DMEM) high glucose with L-glutamine (Euroclone, Milan, Italy) with the addition of 10 % of 
fetal bovine serum (v/v) (Carlo Erba, Milan, Italy) and penicillin/streptomicin 1 % (v/v) (Ge Healthcare, 
Pasching, Austria). hMSC were collected from Wharton’s jelly (WJ) from connective tissue of human 
umbilical cord. In this case, umbilical cords were used after mother information and agreement, applying 
the guidelines ratified by the University Hospital Center of Nancy (agreement TCG/11/R11). Cells were 
collected after enzymatic digestion of the WJ using a collagenase solution at 1 mg/mL (Sigma-Aldrich, 
France) during 18 hours at 37°C. hMSC were cultivated using DMEM (Gibco, France) after the addition 
of 10 % of fetal bovine serum (v/v), 2 mM of L-glutamine, 2.5 g/L of fungizone®, 100 IU/mL of penicillin 
and 100 μg/mL of streptomycin. Cells were collected and grown in an incubator at 37°C and 5 % CO2 and 
culture medium was changed every 3 days of cultivation. Trypsin-EDTA was purchased from Carlo Erba 
(Milan, Italy), 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenil)-2H-
tetrazolium) (MTS) from Promega (Madison, WI, USA) and TNFα from Biovision Inc. (Milpitas, CA, 
USA). 
 
2.2.3. Fabrication of vascular prostheses 
2.2.3.1. Preparation of spinning solution 
 
PCL (10, 15 and 20 %, w/v) and PGS solutions (20 %, w/v) were prepared dissolving the polymers in a 
mixture of chloroform:ethanol (9:1, v/v) under magnetic stirring (Heidolph Mr 2002, Kelheim, Germany) 
for at least 12 hours at room temperature (25 ± 1°C). Three different type of spinning solution were prepared 
during the research, pure polymeric solutions (PPS) consisting of PCL, PGS or a combination of them, 
polymeric solution with calcium carbonate nanoparticles (CaCO3), polymeric solution with free quercetin 
(Q), and polymeric solution with rapeseed and salmon lecithin (RL an SL, respectively). In order to prepare 
PCL:PGS solutions at different volume ratios (0:1, 1:0, 1:1, 2:1, 3:1, respectively), the stock solutions at 
20 % (w/v) were mixed for at least 2 hours at room temperature. In the case of quercetin-functionalized 
scaffold (QS), both the polymeric solutions were prepared using a constant percentage of polymers (20 %, 
w/v) in chloroform and an ethanolic solution of quercetin (5.5 mg/mL), instead of pure ethanol, with the 
same solvent ratio reported above (9:1, v/v). Even in this case, the two polymers solutions were mixed 
keeping always constant at 1:1 (v/v) the ratio between them and they were mixed at the same conditions 
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reported before in glass amber bottles under magnetic stirring for at least two hours before being 
electrospun. In order to obtain nanoparticles-functionalized scaffold (NS), the two polymer solutions (20 
%, w/v each) were then combined only in a ratio 1:1 and it was added an equivalent of 0.1 % (w/v) of 
CaCO3 nanoparticles and stirred again for 45 minutes. To fabricate rapeseed and salmon lecithin-
functionalized scaffold (RLS and SLS, respectively), lecithins were weighted and the two polymers 
solutions (20 %, w/v each) were added to them in a ratio 1:1. Three different concentration for both the 
lecithins were studied (0.5, 1.0 and 5.0 mg/mL). RLS and SLS were characterized only in terms of 
morphology studies (SEM) and they were analysed using FTIR. This research is still ongoing as 
collaboration between University of Genova and University of Nancy. 
2.2.3.2. Density and viscosity of the spinning solution 
 
At first, to understand if the pure polymeric solutions were suitable for the electrospinning process, both 
their density and their viscosity were calculated.  
Density of each pure polymeric solution was measured by weighing the same volume of each sample (5 
mL) at room temperature. Each solution was placed in a 5-mL Pyrex single metric scale graduated cylinder, 
it was kept at 25°C for 15 min, and the mass of the sample (after taring the cylinder) was determined by a 
four-digit analytical balance (model AE240, Mettler-Toledo, Milan, Italy). Density was mathematically 
calculated by dividing mass of the sample by volume. The density results are the mean of at least four 
independent measurements. 
The solution viscosity measurements were performed by using Cannon Fenske glass capillary kinematic 
viscometers (Fisher Scientific, Pittsburgh, PA, USA) at room temperature. Kinematic viscosity (ν) 
expressed in centistokes, was calculated measuring the flow time (𝑡) and instrument constant (𝑐) provided 
by the viscometer manufacturer, using the following equation: 
𝑣 = 𝑐𝑡           (Equation 2.1) 
Dynamic viscosity (𝜇𝐿), expressed in centipoise, was calculated from the kinematic viscosity (𝑣) and the 
density of the solution (𝜌) using the equation: 
𝜇𝐿 = 𝜌𝑣          (Equation 2.2) 
 
 
 
 
FUNCTIONALIZATION OF ELECTROSPUN SCAFFOLDS                                                  MATERIALS AND METHODS 35 
 
  
2.2.3.3. Fabrication of small diameter tubular scaffolds via electrospinning 
 
The electrospinning apparatus (Spinbow, Bologna, Italy) used to fabricate small diameter tubular scaffolds 
consisted of a high voltage power supply (PCM series, Spellman, NY, USA) to negatively charge the 
polymeric solution, a grounded roto-translating aluminium cylindrical drum (2 or 5 mm outer diameter and 
13 cm in length) to collect fibers, and a syringe pump (KDS-100, KD Scientific, Holliston, MA, USA) to 
control the feed flow rate. In the preliminary experiments, operative parameters of the electrospinning 
process were varied. In detail, voltage (from 14 to 20 kV), distance from needle to collector (from 15 to 18 
cm), and flow rate (from 0.60 to 2.20 mL/h) were used. Among all these experiments, electrospun 
homogeneous grafts could be obtained only working with a flow rate between 1.10 and 2.20 mL/h and with 
the maximum distance (18 cm) between the needle and the collector. Low voltage, low distance, and low 
flow rate were not suitable for our electrospinning. At short distance of needle to collector and under a low 
voltage, the formation of beads and fibrous non-homogenous fragile constructs were noticed. High voltage 
of 20 kV resulted to instability of the jet and fusion of fibers. Rotation and translating speed were kept at 
minimum to minimize their effect on the graft microarchitecture. Once determined the optimal working 
conditions, 1.50 mL polymeric solutions were loaded into a 5 mL glass syringe (FORTUNA® OPTIMA®, 
Poulten & Graf GmbH, Wertheim, Germany) and extruded from a 16G flat needle tip at a vertically distance 
of 18 cm onto a cylindrical collector. The potential was set at 17 kV, the flow rate was 1.10 (working with 
2 mm collector) or 2.20 mL/h (working with 5 mm collector) and, in any case, the rotation and the 
translation speed were 500 rpm and 600 mm/min, respectively. Fibers were collected at room temperature 
and in dark conditions. All electrospun constructs were then placed in a desiccator overnight to allow the 
completely evaporation of the solvents. In Table 2.1, 2.2, 2.3, and 2.4 are reported all the different 
conditions used during the synthesis of PPS, QS, NS, RLS, and SLS, respectively. The following figures 
are representative pictures of the final electrospun construct made of PCL:PGS (1:1, v/v) (Figure 2.1) and 
functionalized with Q (Figure 2.2), or with nanoparticles (Figure 2.3), or with RL (Figure 2.4). 
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Table 2.1: process parameters and operating conditions during electrospinning of PPS. 
Process parameters Operating conditions 
needle diameter (G) 16 
orientation of the needle vertical 
collector outer diameter (mm) 2 
distance between needle and 
collector (cm) 
18 
rotational speed (rpm) 500 
translation speed (mm/min) 600 
right limit (mm) 115 
left limit (mm) 15 
flow rate (mL/h) 2.20 
voltage (kV) 17.0 
electrospun volume (mL) 1.50 
 
 
 
 
 
Figure 2.1: representative scaffold made of PCL:PGS (1:1). 
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Table 2.2: process parameters and operating conditions during electrospinning of QS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: representative scaffold made of PCL:PGS (1:1) (left) and one functionalized with Q (right). 
 
 
Process parameters Operating conditions 
needle diameter (G) 16 
orientation of the needle vertical 
collector outer diameter (mm) 5 
distance between needle and 
collector (cm) 
18 
rotational speed (rpm) 500 
translation speed (mm/min) 600 
right limit (mm) 115 
left limit (mm) 15 
flow rate (mL/h) 1.10 
voltage (kV) 17.0 
electrospun volume (mL) 2.00 
FUNCTIONALIZATION OF ELECTROSPUN SCAFFOLDS                                                  MATERIALS AND METHODS 38 
 
  
Table 2.3: process parameters and operating conditions during electrospinning of NS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: representative scaffold made of PCL:PGS (1:1) and functionalized with CaCO3 nanoparticles. 
 
 
 
Process parameters Operating conditions 
needle diameter (G) 16 
orientation of the needle vertical 
collector outer diameter (mm) 2 
distance between needle and 
collector (cm) 
18 
rotational speed (rpm) 500 
translation speed (mm/min) 600 
right limit (mm) 115 
left limit (mm) 15 
flow rate (mL/h) 2.20 
voltage (kV) 17 
electrospun volume (mL) 1.50 
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Table 2.4: process parameters and operating conditions during electrospinning of RLS and SLS. 
Process parameters Operating conditions 
needle diameter (G) 16 
orientation of the needle vertical 
collector outer diameter (mm) 5 
distance between needle and 
collector (cm) 
18 
rotational speed (rpm) 500 
translation speed (mm/min) 600 
right limit (mm) 115 
left limit (mm) 15 
flow rate (mL/h) 1.10 
voltage (kV) 17 
electrospun volume (mL) 2.00 
 
Figure 2.4: representative scaffold made of PCL:PGS (1:1) and functionalized with RL. 
 
As reported in Table 2.1, 2.2, 2.3 and 2.4, needle diameter, orientation of the needle, distance between 
needle and collector, voltage, rotational and translation speed, right and left limit were kept constant for 
each type of samples. Adding free Q, RL, and SL to the polymeric solution, it was not possible to fabricate 
a homogeneous scaffold, applying the same operating conditions used for PPS and NS. Furthermore, two 
collectors with a different outer diameters were used during the research. A 2 mm collector was employed 
to have polymeric constructs to be potentially implanted in rats (Rattus norvegicus) and a 5 mm collector 
was utilized to have polymeric constructs to be potentially implanted in rabbit (Oryctolagus cuniculus). 
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Working with the thicker collector, it was necessary to halve the flow rate and to increase from 1.50 to 2.00 
mL the electropsun volume in order to obtain comparable scaffolds. 
 
2.2.3.4. Surface coating of the scaffolds with gelatin 
 
With the aim of reducing the porosity and the excessive water permeability of PCL:PGS (1:1, v/v) scaffolds, 
a coating with gelatin of the external surface of the scaffolds was performed. To obtain surface coated 
scaffolds, they were completely immersed in a gelatin solution (67 mg/mL, w/v) and maintained under 
mechanical agitation (agitator model Kirk 510, Bicasa, Monza Brianza, Italy) for 1 hour at 37 ± 2°C at a 
constant rotational speed of 135 rpm (Figure 2.5). After that, gelatin-coated scaffolds were placed under an 
UV lamp for 1 hour to allow gelatin cross-linking on the surface (Pulieri et al., 2007). At the end of these 
total two hours, the gelatin-coated scaffolds were put again into a desiccator overnight. The coating with 
gelatin was performed for both PPS (1:1, v/v) and QS. Hereinafter, PCL:PGS (1:1, v/v) coated with gelatin 
will be called Gelatin Coated Scaffold (GCS) and QS coated with gelatin will be reported as Quercetin-
functionalized and Gelatin Coated Scaffold (QGCS).  
 
 
Figure 2.5: coating process with gelatin. 
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2.2.4. Characterization methods for the scaffolds 
2.2.4.1. Scanning Electron Microscopy (SEM) analysis 
 
Scaffold morphology was studied using LEO scanning electron microscope Model Stereoscan 440 for PPS, 
a SEM Hitachi 2500 (Tokyo, Japan) for NS and GCS, and the Quanta FEG 650 SEM (ThermoFisher 
Scientific, USA) for QS, QGCS, RLS and SLS. Fibers mean diameters were measured using image 
processing software (Image J, USA) in at least three different images. For each sample, the diameters of 
about 60 fibers were taken into account to have a meaningful statistical value. 
2.2.4.2. Atomic Force Microscopy (AFM) 
 
AFM images of PCL:PGS (1:1, v/v) and QS were recorded using a AFM (Bruker, Karlsruhe, Germany). 
Non conductive silicon nitride cantilevers of conical shape were purchased from Bruker (NPG-10 Bruker, 
Camarillo, USA).Experiments were performed at room temperature, using small pieces of each scaffold. 
 
2.2.4.3. Fourier Transform Infrared spectroscopy (FTIR) 
 
FTIR spectra for PPS (PCL:PGS, 1:1) QS, RLS and SLS were obtained using a Tensor 27 mid-FTIR 
spectrometer (Burker, Karlsruhe, Germany), equipped with a diamond ATR (attenuated total reflectance) 
module and a DTGS (deuterated triglycine sulfate) detector. Scanning rate was fixed to 10 kHz and 100 
scans were performed for both reference (air) and samples between 400 and 4000 cm-1 at a resolution of 4 
cm-1 at room temperature. At first, an initial reference spectrum was recorded. Next, a small piece of the 
different samples was directly put on the diamond crystal of the optical cell and a minimum of four 
independent analysis were done for each sample. All the data were treated using OPUS software (Bruker, 
Karlsruhe, Germany). Crude absorbance spectra were smoothened, centred and normalized using OPUS 
software. 
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2.2.4.4. Contact angle measurements of the scaffolds 
 
The hydrophilicity of the PCL:PGS (1:1, v/v) and QS scaffolds was done by a goniometer (Digidrop, GBX 
instruments, France) equipped with three different syringes. They were used to drop 0.48 μL of three 
different liquids with different polarity (deionized water, glycerol and diiodomethane) on the flat surfaces 
of the different studied materials. The contact angle was measured by a video contact angle system. 
2.2.4.5. Mercury porosimetry 
 
Mercury porosimetry has been widely used to analyze the pore characteristics of various scaffold types 
(Loh & Choong, 2013; Skotak et al., 2011). Pore size distribution, bulk and apparent density, and porosity 
were measured using two porosimeter devices (Pascal 140 and 240, ThermoQuest, Rodano, Italy). A 
fragment of tubular scaffold (3 cm in length) was weighted and placed into the dilatometer, and the void 
space in the chamber was filled with mercury. Operative pressure range were 0.1–400 kPa and 0.1–200 
MPa for Pascal 140 and 240, respectively. Test was performed in triplicate and all data were analyzed with 
the software SOL.I.D. (SOLver of Intrusion Data), Ver. 1.5.0. Mercury porosimetry was performed to 
understand the different behaviour in terms of water permeability of GCS in comparison to PCL:PGS, (1:1, 
v/v).  
2.2.4.6. Water permeability test 
 
It was evaluated the value of pressure that made permeable the studied scaffolds. For this test, scaffolds 
were cut in small pieces and cannulated by the connection of one end of the scaffold to a water reservoir 
after closing the other end by a flow valve (Figure 2.6). The pressure of the water was increased since it 
achieved diastolic and systolic values (80-120 mmHg in healthy conditions). Therefore, water passed 
through the scaffold and pressure was monitored during time since the graft started to be leaky. Once 
reached the pressure at which the water leakage occurred, the flux was maintained constant for one minute 
more and permeated water was collected in a beaker. After that, the volume of collected water was measured 
and permeability of the scaffold (𝜏) was calculated, as reported by Madhavan et al. (2013), using the 
following equation: 
𝜏 =
𝑉
𝐴
           (Equation 2.3) 
where: 
- 𝜏 is the permeability of the graft (mL/cm2/min); 
- 𝑉 is the volume of the fluid passing through the graft (mL/min); 
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- 𝐴 is the cross-sectional area of the aperture in the sample holder (cm2).  
Tests were performed with PPS (only with PCL:PGS, 1:1), GCS, and QGCS. 
 
 
Figure 2.6: set-up of the equipment used during the water permeability test. 
2.2.4.7. In vitro degradation and fluid up-take 
 
An essential characteristic of biomaterials is their degradability during time. To test the mass loss in 
function of time, samples were first cut into small cylindrical pieces (5 x 2 mm2), lyophilized (freeze-dryer 
Christ model Alpha1-2 LDplus, Osterode am Harz, Germany), and then incubated at 37°C after immersion 
in 1.5 mL of DPBS for a total period of 28 days or 8 weeks. At each time point (1, 7, 14, and 28 days for 
PPS, GCS and NS and 2, 3, 4, 5, 6, 7, 8 weeks for QS and QGCS) triplicate sample pieces were taken out, 
washed three times with deionized water, and lyophilized with the same freeze-dryer reported above for 24 
hours after which they were reweighted. The percentage of degradation of each sample was calculated by 
dividing the mass loss by the initial dry mass. 
To study the fluid-uptake, tubular scaffolds were cut as described above, weighted, and then immersed in 
DPBS. After 2, 4, 7, and 24 hours for PPS, GCS, and NS and after 2, 4, 8, and 24 hours for QS and QGCS, 
the excess DPBS on their surface was removed and the scaffolds were weighted again. The fluid uptake 
percentage was calculated by the following equation: 
𝐹𝑙𝑢𝑖𝑑 𝑢𝑝𝑡𝑎𝑘𝑒 (%) =  
𝑚𝑤−𝑚0
𝑚0
 × 100       (Equation 2.4) 
where m0 and mw are the mass of the sample before and after immersion, respectively.  
Different samples (n = 3) of each scaffold type were tested. 
2.2.4.8. Influence of gelatin coating on degradation rate 
 
To understand if the coating with gelatin influenced, positively or negatively, the degradation rate of the 
PCL:PGS blends, degradation of coated scaffold (GCS) was study under a mathematical point of view, 
following these equations: 
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     fgfsts mmm   
     rgigfg mmm   and substituting the term  fgm  in the equation  
        rgigfsts mmmm   
        rgigtsfs mmmm         (Equation 2.5) 
The mass loss percentage was calculated following this formula: 
𝑀𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 (%) =  
𝑚𝑠(𝑖)−𝑚𝑠(𝑓)
𝑚𝑠(𝑖)
       (Equation 2.6) 
where: 
 ism : mass of the scaffold before the coating process; 
 tsm : total mass of the scaffold (mass of the polymer and of the gelatin); 
 fsm : mass of the polymer after the degradation and release study; 
 fgm : mass of the residual gelatin on the scaffold after degradation and release study; 
 igm : mass of the initial gelatin deposed on the scaffold; 
 rgm : mass of the released gelatin during the study. 
2.2.4.9. Gelatin release from GCS 
 
In order to quantify the released gelatin from coated scaffolds during time, entire GCS were cut into small 
pieces and put into a 50 mL test tube with 5 mL of PBS. Then, they were incubated at 37 ± 2°C, in order to 
mimic the physiological conditions of human body, in the same incubator described before, used for 
degradation and fluid up-take assays. At regular intervals (after 1, 2, 3, 4, 8, 24, 48, and 72 h), 10 % of the 
solution was collected and it was replaced by the same volume of fresh PBS. After freeze drying of the 
samples, the bicinchoninic acid assay (BCA) (Euroclone, Milan, Italy) allowed to calculate the 
concentration of the released gelatin through UV-Visible spectroscopy at 562 nm. 
The BCA assay is a convenient tool, as it permits to work with small volumes of sample: in fact, only 5 μL 
of the sample were mixed with 125 μL of the BCA reagent in an centrifuge tube and placed into the 
incubator at 37 ± 2°C for 30 minutes. After that, it was possible to record the absorbance values of the 
sample with a plate reader (Microplate Reader Tecan, Männendorf, Switzerland). The BCA reagent is 
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composed of 50 part of reagent A (bicinchoninic acid, sodium carbonate, sodium tartrate, and sodium 
bicarbonate in 0.1 M NaOH, pH 11.25) and 1 part of reagent B (4 % cupric sulfate). 
The assay is based on a reaction of reduction in which Cu2+ becomes Cu+ in presence of proteins in an 
alkaline conditions. The Cu+ ions thus formed are detected by conversion into a violet-coloured substance 
by reaction with bicinchoninate. The absorbance at 562 nm of the Cu(Ⅰ)-(bicinchoninate)2 complex is 
directly proportional to protein concentration over a broad working range (20-2000 μg/mL). The 
absorbance of the samples was related to the concentration of the protein using an opportune calibration 
curve obtained with standard bovine serum albumin (Figure 2.7). 
 
The relation between the absorbance of albumin at 562 nm and its concentration was given by the following 
linear equation (R2= 0.9894) (Eq. 2.7): 
𝐴𝑏𝑠562 = 0.1887 × 𝐶        (Equation 2.7) 
where: 
• 𝐴𝑏𝑠562is the absorbance of bovine serum albumin at 562 nm; 
• 𝐶 is bovine serum albumin concentration expressed in mg/mL. 
 
 
Figure 2.7: calibration curve for the quantification of gelatin released from GCS. 
 
Results are presented in terms of percentage of the total amount of gelatin that originally covered the 
scaffold. The total amount of gelatin layer was evaluated by subtracting the mass of the scaffold after the 
gelatin coating process and the original mass. This procedure was repeated six times and the average value 
was taken into account for calculations. 
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2.2.4.10. Quercetin release from QS and QGCS 
 
To evaluate the release of quercetin, QS and QGCS were cut in small pieces, immersed in 5 mL of PBS at 
pH = 7.4 and maintained at 37 ± 2°C in the same incubator described above. Daily, for 54 days, 10 % of 
the solution was collected and it was replaced by a same volume of fresh PBS. Samples were frozen at -
20°C and before spectrophotometric analysis, they were lyophilized with the same freeze-dryer described 
above. Then, samples were resuspended in a solution of water:ethanol 50:50 (v/v) and they were analysed 
using a SPECTROStar Nano plate reader (BMG LABTECH, Ortenberg, Germany). At first, it was done a 
spectrum analysis (from 300 to 500 nm) of the collected samples to identify the absorbance with the highest 
absorption (Figure 2.8). 
 
Figure 2.8: spectrum of quercetin in ethanol:PBS (50:50, v/v). 
 
Once verified that the maximum peak of absorbance corresponded to 380 nm, a calibration curve was made 
with standard solutions of quercetin in a mixture of PBS:ethanol 50:50 (v/v) obtaining the following 
equation 2.8: 
𝐴𝑏𝑠380 = 13.755 × 𝐶   (R
2 = 0.9939)    (Equation. 2.8) 
where: 
• 𝐴𝑏𝑠380is the absorbance of quercetin at 380 nm; 
• 𝐶 is quercetin concentration expressed in mg/mL. 
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Figure 2.9: calibration curve for the quantification of quercetin. 
 
The total amount of quercetin in electrospun scaffold was evaluated through solid/liquid extraction (SLE) 
using ethanol as unique solvent. Briefly, an entire scaffold was cut into small pieces and it was put in 2 mL 
of absolute ethanol and agitated under magnetic stirring for 2 days at room temperature. This extraction 
was made in triplicate. After this procedure, 150 μL of the extracting solvent was collected, its absorbance 
analysed at 380 nm and quercetin concentration calculated using an opportune calibration curve (Figure 
2.9).  
Results are presented in terms of percentage of the total amount of quercetin that originally was present in 
the scaffold. 
2.2.4.11. BSA release from NS 
 
For BSA release analysis, scaffold were cut, weighted, immersed in 5 mL of PBS and mildly shaken at 220 
rpm in the same incubator previously reported at 37°C. At each measurement time-point (1, 2, 3, 4, 8 h and 
from day 1 to 28), an aliquot of 0.5 mL was removed and replaced with an equal volume of the same buffer. 
The protein concentration was determined by UV-visible spectrophotomer (BioPhotometer Eppendorf, 
Hamburg, Germany) at 562 nm through the bicinchoninic acid (BCA) assay. The relation between the 
absorbance of albumin at 562 nm and its concentration was given by the following linear equation (R2= 
0.9957) (Equation 2.9):  
𝐴𝑏𝑠562 = 0.5859 × 𝐶 + 0.0348       (Equation 2.9) 
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where: 
• 𝐴𝑏𝑠562is the absorbance of bovine serum albumin at 562 nm; 
• 𝐶is bovine serum albumin concentration expressed in mg/mL.  
This equation describes the curve reported in Figure 2.10. 
 
 
Figure 2.10: calibration curve for the quantification of BSA released from NS. 
 
All the measures were done in triplicate. 
 
2.2.4.12. Mechanical characterization and suture retention strength 
 
Mechanical loading tests were performed on the electrospun grafts in the axial direction using uniaxial Z0.5 
test machine (Zwick Roell, Ulm, Germany). Each tubular scaffold was cut to obtain rectangular specimen 
(n = 3, length = 30 mm, width = 2 mm) with the short edge of each sample originally oriented 
circumferentially on the original tube. The thickness of each sample was measured using a digital caliper 
(Series 209, Mitutoyo, USA). Every segment was clamped at its cut ends and the crosshead speed was set 
at 20 mm/min with a preload of 0.1 N. Young’s modulus was calculated taking into account stress and 
strain values between 0.5-2 % of strain (about 25 data points) through a MATLAB algorithm. For each type 
of scaffold, the measurements were done at least four times. In the case of GCS and QGCS, mechanical 
tests were performed using both dry and wet samples, after their immersion in a solution of NaCl (0.9 %, 
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w/v) for 5 minutes. Mechanical loading tests were also performed on QS after one month of degradation in 
PBS, in order to analyse their behaviour even during degradation. Suture retention test was performed in 
accordance to American National Standard Institute/Association for the Advancement of Medical 
Instruments (ANSI/AAMI). The samples were prepared as described above and a single loop of 5-0 
VascufilTM suture (CovidienTM) was created at approximately 2 mm from one free end. The suture loop and 
the opposite end of the graft were secured to the grips of the same tensile machine described above. In this 
case, to pull the suture, an extension rate of 1 mm/s was used and suture retention strength was taken as the 
maximum force recorded. The preload was set at 0.05 N. 
 
2.2.4.13. Cytotoxicity evaluation using endothelial cells 
 
Recent studies, in line with this, reported that electrospun PCL:PGS constructs promote cell adhesion and 
proliferation compared to PCL scaffolds (Sant et al., 2011), because of their enhanced hydrophilicity in 
comparison to hydrophobic PCL. Two different test were performed in order to assess the biocompatibility 
of PPS. One was done seeding endothelial cells directly on the surface of PPS, after having cut them to 
have a suitable dimension for a 96-well plate with an autopsy punch. The second was done using Trans-
well system but only in the case of PCL:PGS (1:1, v/v) scaffolds. Scaffolds were sterilized under UV light 
for 1 h, and washed with 1 % penicillin–streptomycin. To study the potential cytotoxicity of grafts and by-
products generated during their degradation rather than studying the interaction between cells and grafts, 
scaffolds were placed in the Transwell-clear multiwell inserts (Corning Costar Corporation, MA, USA) 
without any direct contact with endothelial cells. The graft was introduced in the cell culture system for 24 
h after cell seeding to do not interfere with a proper cell attachment. The adopted protocol is described in 
different publications (Burdick et al., 2002; Trudel & Massia, 2002; Wang et al., 2013). Before interactions 
with the scaffold, the human vascular endothelial cell line EA. hy 926 was plated at a seeding density of 2 
x 105/well in a 24-well plate in complete medium. Cell viability was evaluated using the colorimetric 
CellTiter96® AQueous One Solution Cell Proliferation Assay (Promega, WI, USA) according to the 
manufacturer’s instructions. Briefly, at any time point (1, 2, 3, and 7 days), 20 % 3-(4, 5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenil)-2H-tetrazolium) reagent was added directly to the 
culture wells, and tetrazolium was bioreduced by cells into a colored formazan product soluble in the culture 
medium. Thereafter, aliquots were transferred into a 96-well plate and the quantity of formazan was 
measured by a spectrophotometric plate reader (Microplate Reader Tecan, Männendorf, Swiss) at 492 nm. 
The first protocol was adopted for all PPS scaffolds, QS, GCQS, RLS, and SLS while the use of the Trans-
well system was adopted in the case of PCL:PGS (1:1, v/v) GCS, and NS. 
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2.2.4.14. Hemocompatibility 
 
Hemocompatibility is a fundamental factor to determine the application of implantable biomaterials, 
especially vascular prosthesis. For hemocompatibility tests, blood was collected from healthy volunteers 
by venipuncture into ethylenediaminetetraacetic acid (EDTA) anticoagulant vacutainer tubes. For 
hemolysis test, each scaffold was cut (50 mm2 in area) and rinsed three times with distilled water. Then 
hemolysis test was performed by placing the scaffold in a solution of 0.9 % NaCl or deionized water. Then, 
0.1 mL of human fresh blood was added to the solution. After 30 min, erythrocytes membranes were broken 
and hemoglobin was released in the solution. At the end of the incubation time (30 min), the supernatants 
of all the samples were collected and transferred into cuvettes to measure their absorbance at 540 nm, which 
is the wavelength were there is a maximum of absorbance in haemoglobin spectrum. Hemoglobin was 
chosen since it is one of the most abundant proteins expressed by erythrocytes. Similarly, 0.1 mL of fresh 
blood was added to 5 mL of distilled water and 0.9 % NaCl using, respectively, as positive and negative 
controls. Positive and negative controls are necessary to exclude erythrocyte disruption not directly caused 
by the samples. At the end of the incubation, all the samples were centrifuged at 3.000 rpm for 5 min. The 
supernatants were carefully collected and transferred into cuvettes to determine the absorbance at 540 nm 
(spectrophometer Lambda 25, PerkinElmer, Milan Italy). The hemolysis percentage (HR) was calculated 
by the following equation: 
𝐻𝑅 (%) =
𝐴𝑠−𝐴𝑛
𝐴𝑝−𝐴𝑛
× 100        (Equation 2.10) 
where𝐴𝑠, 𝐴𝑝, and 𝐴𝑛 are the absorbance values of haemoglobin in the sample, in the positive and negative 
controls, respectively. 
The anticoagulant properties of electrospun scaffold were registered by the kinetic clotting time method 
(Imai & Nose, 1972). The coagulation is an extremely complicated process where different cells and 
molecules play a fundamental role. After a detailed research in the literature, free hemoglobin appeared as 
one of the most common parameters analyzed to study the anticoagulant properties of materials (Meng et 
al., 2010; Zhang et al., 2013; Elahi et al., 2014; Shen et al., 2015). A total of 64 μL of EDTA blood was 
dropped on the inner surface of the samples (32 mm2), followed by the addition of 16 μL of CaCl2 (0.2 
mol/L) solution, and mixed uniformly. After predetermined intervals of time (5, 30, and 60 min), the 
specimens were put into 16 mL of distilled water and incubated at 37°C for 5 min. The concentration of the 
free hemoglobin in water was measured by monitoring the absorbance at 540 nm using the same 
spectrophotometer described above. Glass was used as reference thrombogenic material (Motlagh et al., 
2006). All the hemocompatibility analysis were performed using as reference poly (ethylene terephthalate) 
and expanded poly (tetrafluoroethylene). 
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2.2.4.15. In vivo suturability test 
 
All animal treatments were approved by the S.S.D. Animal Facility, IRCCS AOU San Martino - IST. Wistar 
rats (Charles River Laboratories International Inc., MA, USA) were anesthetized feeding isoflurane with a 
starting flow of 3-4 mL/h. Then the flow was kept constant at 1.5 mL/h with addition of O2 at 30 mL/min 
during the surgical procedure. Under general anesthesia and after subrenal aortic clamping, aorta was 
resected and the vascular graft was implanted. Electrospun PCL:PGS (1:1, v/v) blend coated with gelatin 
(GCS) graft of 3 cm in length was sutured to the aorta in an end-to-side fashion using monofilament 10-0 
VascufilTM sutures (CovidienTM). The implantation of GCS was done in two animals. This test has to be 
considered a preliminary test and it was only done to assess the practical suturability of the electropsun 
vascular prosthesis with native vessels. 
 
2.2.4.16. Anti-inflammatory activity of QS 
 
PCL:PGS (1:1, v/v) constructs (control) and GCQ scaffolds were cut in cylindrical pieces (0.5 cm in 
diameter × 0.5 cm in length) and they were sterilized using a solution of penicillin/streptomycin (1 %) for 
at least three hours, in order to avoid possible contamination once in contact with human cells. 5 × 104 EA 
hy 926 were seeded in each well using Transwell-clear multiwell (Corning Costar Corporation, MA, USA). 
The material was put into each insert and as a result there was no a direct contact between the cells and the 
scaffold. After 24 hours, the medium was replaced with serum free medium and cells were treated with 
TNF-α (1 ng/ml, Biovision). After 24 hours, the conditioned media (CM) were collected and centrifuged 
to remove cellular debris and stored at -20°C before analysis. Matrix Metalloprotease 9 (MMP-9) 
expression was observed using optical densitometry of gelatinolytic bands (gel analysis system, 
GeneGenius, Syngene, Cambridge, UK). The same quantity of proteins, estimated by BCA assay, from CM 
were loaded on SDS-acrylamide gel cast with 0.28 % (w/v) gelatin (type A), rinsed two times  in 2.5 % 
Triton-X-100 for 30 minutes. After that, the samples were incubated for 18 hours in 40 mM Tris–HCl, 0.2 
M NaCl, 10 mM CaCl2 at 37°C for 18 hours and then stained with 0.2% Coomassie blue and destained in 
ethanol:water:acetic acid (50:40:10, v/v). 
 
2.2.4.17. Statistical analysis 
 
All the experiments were performed at least in triplicate and the results were expressed as mean values and 
standard deviations. The analysis of variance (ANOVA) and the Tukey’s post hoc test were used to 
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highlight statistically significant differences among the different studied samples. Multiple comparison of 
the mean values was performed by the least significant difference test at p < 0.05. For data analysis, the 
Statistica v 8.0 software (StatSoft, Tulsa, OK, USA) was used. 
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2.3. RESULTS AND DISCUSSION 
In this section of the thesis, tables and figures concerning all the data obtained investigating electrospun 
vascular scaffolds are presented and critically discussed. In the order, the attention will be focused on 
Pure Polymeric Scaffolds (PPS), Gelatin-Coated polymeric Scaffolds (GCS), Quercetin-functionalized 
polymeric Scaffolds (QS), Quercetin-functionalized and Gelatin-Coated polymeric Scaffolds (QGCS), 
Nanoparticles-functionalized polymeric Scaffolds (NS), and Rapeseed and Salmon Lecithin-
functionalized polymeric Scaffolds (RLS and SLS, respectively). In every section regarding GCS, QS, 
QGCS, NS, RLS, and SLS, the PPS made of poly (ε-caprolactone) and poly (glycerol sebacate) 
(PCL:PGS, 1:1) has to be considered as the control. In fact, it was fabricated using the same polymeric 
mixture of the others scaffolds but without the bioactive compounds present in the functionalized 
counterpart. 
 
2.3.1. Pure polymeric scaffolds (PPS) 
2.3.1.1. Density and viscosity of the spinning solutions 
 
In general, the concentration of the polymers in the spinning solution plays a pivotal role at first on the 
electrospinning process and after on the physicochemical and biomechanical properties of electrospun 
products. The synthetized PGS resulted to have a molecular weight of 2673 Da with a polydispersity index 
(PDI) equal to 1.98. The effects on the properties of the grafts due to PCL concentration as well as those 
due to the addition of PGS to the spinning solution, were studied. During the preliminary tests, three 
different concentrations of PGS (10, 15, and 20 %, w/v) were taken into account (data not showed). 
However, because of their low viscosity, it was not possible to fabricate scaffold with a well-defined 
architecture working with PGS alone at 10 and 15 % (w/v) via electrospinning. As a result, concentration 
of PGS was limited to 20 % (w/v) to facilitate the electrospinning process itself. The properties of the 
different spinning solutions, such as density and viscosity, were measured and they are reported in Table 
2.5. The density of the different polymeric solutions resulted to be in the range from 1.25 ± 0.09 to 1.38 ± 
0.6 g/mL. An increase in PCL concentration did not significantly influence the density of the solutions (p 
< 0.05). A glass capillary kinematic viscometers was used to measure the viscosity of solutions. As 
expected, the viscosity of the PCL solution significantly increased (p < 0.05) by increasing the 
concentration of the polymer from 10 to 20 %. The addition of PGS (20 %, w/v) to the PCL solution resulted 
to a reduction in the viscosity of solution from 4.54 ± 0.02 to 1.10 ± 0.13 Pa⸱s for PCL:PGS (1:1, v/v) and 
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2.45 ± 0.12 for PCL:PGS (3:1, v/v). PGS solution is known to have a low viscosity, thus, the mixture of 
PCL and PGS solutions  showed a lower viscosity in comparison to those made of PCL alone. Even the 
viscosity of solutions plays an important role during the electrospinning process and it influences the 
generated construct. Low-viscosity solutions cannot generate fibrous structures, while too viscous solutions 
require a higher voltage to form fibrous scaffold (Tamayol et al., 2013).  
Table 2.5: viscosity and density values of PCL and PCL:PGS blend solutions with different concentrations and ratios 
between the two polymers.  
Sample Density (g/mL) Viscosity (Pa·s) 
PCL (10 %) 1.30 ± 0.13a 0.32 ± 0.02b 
PCL (15 %) 1.32 ± 0.04a 1.69 ± 0.02a 
PCL (20 %) 1.35 ± 0.09a 4.54 ± 0.02e 
PCL:PGS (1:1) 1.25 ± 0.02a 1.10 ± 0.13c 
PCL:PGS (2:1) 1.32 ± 0.09a 1.47 ± 0.03a 
PCL:PGS (3:1) 1.38 ± 0.06a 2.45 ± 0.12d 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
2.3.1.2. Scanning Electron Microscopy (SEM) analysis of PPS 
 
Representative SEM images of internal (Figure 2.11, top) and external (Figure 2.11, bottom) surfaces of 
electrospun scaffolds, made of PCL 20 % and PCL:PGS (1:1, v/v) showed randomly oriented bead free 
fibers. The fabricated scaffolds were porous with uniform morphology. In the inner surfaces of scaffolds 
(Figure 2.11 A and 2.11 C), some fiber fusion was observed. It could be caused by the presence of mineral 
oil used for covering the drum collector to allow an easy extrusion of the scaffold at the end of the 
electrospinning process. Fiber diameters are reported in Table 2.6 for internal and external surfaces of the 
scaffolds. The microfibers had diameters between 3.94 ± 1.39 and 5.57 ± 1.55 μm. These results 
demonstrated that the average of fiber diameter was not statistically different (p < 0.05) for internal and 
external surfaces of the studied polymers. However, the scaffold containing PGS resulted to have fibers 
with greater diameter when compared to only PCL fibers. The same trend was also noticed by Sant et al. 
(2011). They found that at the same electrospinning condition, an increase in PGS content in the PCL:PGS 
blend resulted to increase fiber diameter. As described by Ghasemi-Mobarakeh et al., (2008), thickness of 
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electrospun nanofibers influences cell proliferation by providing better substrate with more dimensional 
stability. The microfiber scaffolds can be potentially advantageous with respect to the nanofibers scaffolds 
by their larger pores between the fibers which can facilitate cellular infiltration and/or nutrient diffusion 
during cell culturing (Pham et al., 2006; Balguid et al., 2009). It is chosen to present only PCL 20 % and 
only PCL:PGS (1:1, v/v) because of they represented the scaffold with the highest amount of PCL and PGS, 
respectively. 
 
 
Figure 2.11: representative SEM micrographs of (A) internal and (B) external surfaces of electrospun scaffolds 
made of PCL 20 % and of (C) internal and (D) external surfaces of electrospun scaffolds made of PCL:PGS   
(1:1, v/v). 
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Table 2.6: fiber diameter for internal and external surfaces of PCL 20 % and PCL:PGS (1:1). 
 
Sample 
Internal diameter 
(μm)  
External diameter 
(μm) 
PCL (20 %) 3.94 ± 1.40a 4.80 ± 0.80a,c 
PCL:PGS (1:1) 5.11 ± 1.11b,c 5.57 ± 1.55b 
Results are mean of at least one hundred measurements ± SD. Different letters do refer to statistically significant differences among results 
for each column (p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
2.3.1.3. Contact angle measurements 
 
Contact angle measurements were carried out to study the wettability of PCL:PGS (1:1, v/v) scaffold. Once 
a solvent drop was put on the scaffold, it was completely unstable and adsorbed in few seconds, with all 
the solvents employed during the analysis. Since the instability of the drop on the surface of the material, 
it was not possible to measure the contact angle. These observations demonstrated that the PCL:PGS (1:1, 
v/v) scaffold was hydrophilic. However, the high porosity of PCL:PGS (1:1, v/v) played an important role 
allowing the drop of the solvent to disappear among the numerous pores. This observation was in 
completely accordance with the work published by Sant et al. (2011). 
 
2.3.1.4. Thickness and porosity of PPS 
 
The thickness of scaffolds is a fundamental parameter to take under consideration before the implant of the 
prostheses. The thickness of electrospun scaffolds were measured using a digital caliper and resulted to be 
from 0.32 to 0.73 mm (Table 2.7). The increase in PCL in the solution resulted to increase the thickness of 
scaffold (p < 0.05). The sample containing PCL:PGS (1:1, v/v) resulted to have an intermediate thickness 
(0.46 ± 0.11 mm), thus providing a good substrate for cell proliferation. The porosity of scaffolds in tissue 
engineering plays a crucial factor affecting biocompatibility properties of the samples. Data reported in 
Table 2.7 show that the porosity of samples ranged from 68.19 ± 0.02 % for PCL:PGS (1:1, v/v) to 78.97 
± 2.96 % (PCL 15 %). These values are in agreement with the values reported in the literature for PCL 
electrospun sheets (Wang et al., 2009; Liu et al., 2012; Salehi et al., 2014). Pertinent literature suggests that 
a porosity range from 60 to 90 % can facilitate cell spreading, penetration, and proliferation. 
 
 
 
FUNCTIONALIZATION OF ELECTROSPUN SCAFFOLDS                                                  RESULTS AND DISCUSSION 57 
 
  
Table 2.7: thickness and porosity of PCL and PCL:PGS blend scaffolds. 
 
 
 
 
 
 
 
 
 
 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
2.3.1.5. Water permeability 
 
Showing highly porosity and highly hydrophilic properties, all the scaffold made of PGS were leaky even 
applying low pressure of water. This test confirmed that their porosity and their wettability were too much 
high to be employ like vascular graft. Working with these samples, it was not possible to calculate the 
permeability of the grafts. 
 
2.3.1.6. In vitro degradation and fluid uptake of PPS 
 
The biomaterial degradation is a key factor which can influence cell adhesion, proliferation, and the 
neoforming tissue architecture, reorganization, and integration. Degradability of biomaterials is a possible 
drawback in tissue engineering. It is associated to the polymer creep and weakening and should be kept in 
consideration. When a scaffold is used as prosthesis, slow degradation and integrity of the sample enable 
host body to gradually replace the implanted scaffold with native tissue over an extended period of time 
(Salehi et al., 2014). As can be seen from Figure 2.12 (A), weight loss was more evident in the samples of 
PCL:PGS blends during 28 days of incubation when compared to the only PCL samples. A notable weight 
loss (approximately 11 %) was noticed after the first day of soaking for PCL:PGS samples, whereas PCL 
samples were resulted to be more stable and very slowly degradable after the same soaking period. The 
addition of relatively hydrophilic PGS into the blends enhanced the water adsorption and thus faster 
Sample Thickness (mm) Porosity (%) 
PCL (10 %) 0.32 ± 0.11c 71.90 ± 5.29a,b 
PCL (15 %) 0.49 ± 0.16a 78.97 ± 2.96,b 
PCL (20 %) 0.68 ± 0.09b 76.26 ± 0.77a,b 
PCL:PGS (1:1) 0.46 ± 0.11a 68.19 ± 0.02a 
PCL:PGS (2:1) 0.51 ± 0.12a 73.96 ± 0.01a,b 
PCL:PGS (3:1) 0.73 ± 0.12b 73.10 ± 0.90a,b 
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biodegradation. The maximum degradation was observed for the sample composed of PCL:PGS (1:1, v/v) 
which resulted to lost 20 % of the initial weight after 28 days of soaking. This behaviour was in agreement 
with those reported by other research groups working with PGS (Sant et al., 2011; Salehi et al., 2014). 
Kharaziha et al. (2013) explained that the degradation of PGS scaffolds at 37°C in DPBS was caused by 
the decomposition of ester bonds into its sebacic and glycerol monomers. In one of their experiments, Sant 
et al. (2011) showed only a 6 % mass loss of PCL scaffolds under accelerated degradation conditions (0.1 
mM NaOH solution, at 37°C) in 7 days, compared with a 16 % of mass loss for the PCL:PGS (1:2, v/v) 
electrospun scaffolds. Salehi et al. (2014) attributed the fast degradation of the PCL:PGS scaffolds (15 %) 
after 24 h of incubation at 37°C in DPBS to the hydrolytic mechanism of materials which involves surface 
and bulk degradation. 
The fluid uptake of biomaterials is an important factor that can influence cellular adhesion, proliferation, 
and growth and consequently affects their specific applications in the biological and biomedical field. The 
water uptake of electrospun scaffolds was assessed. The samples were kept at physiological conditions 
(37°C and DPBS) and water uptake was calculated after 2, 4, 7, and 24 hours. As can be seen from the 
Figure 2.12 B, for all samples, the percentage of fluid uptake resulted to be almost constant after 2 h of 
soaking up to 24 h. After 24 h of soaking, the maximum percentage of uptake was noticed for PCL 20 % 
(296 %) and the lowest value was observed for PCL:PGS (1:1, v/v) (166 %). PCL is known to be a 
hydrophobic polymer and it was expected that the addition of hydrophilic PGS could increase the water 
uptake of sample; however, the microstructure is another factor affecting the water uptake property of the 
electrospun samples. In this regard, the lowest fluid uptake of PCL:PGS samples with respect to PCL 
scaffolds could be attributed to their lower porosity already described in Section 2.3.1.4. 
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Figure 2.12: (A) mass loss and (B) fluid uptake of electrospun scaffolds with different percentage of PCL and 
different blend ratio of PCL:PGS. Mass loss:  PCL (10 %),  PCL (15 %),  PCL (20 %),  PCL:PGS (1:1), 
 PCL:PGS (2:1),  PCL:PGS (3:1). Fluid uptake: PCL ( ): ♦ PCL (10 %),  PCL (15 %), ▲ PCL (20 
%), PCL:PGS ( ): ● PCL:PGS (1:1), * PCL:PGS (2:1); ○ PCL:PGS (3:1). 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each day (p 
< 0.05), ANOVA with Tukey’s multiple comparison test. 
 
2.3.1.7. Mechanical characterization of PPS 
 
In vascular surgery, prostheses are tightly fixed by pins, are treated with medical glue and sutured and, once 
implanted, they are physiologically subject to a relative constant high pressure. Hence, it is necessary to 
fabricate mechanically stable bioprostheses to avoid their rupture during surgery and for all the post-surgery 
period. To do that, mechanical properties of the electrospun scaffolds were studied in terms of Young’s 
modulus, tensile strength, and elongation.  
Tensile strength of PCL samples increased with the percentage of PCL in the pre-polymer dispersion from 
1.16 to 2.37 MPascal (Table 2.8). The corresponding increase in elongation at rupture, that for the PCL 20 
%, displayed a value about seven times higher than PCL (10 %), was strictly linked with a growth of the 
specimen plasticity and can be explained with a change in the internal microstructure of the polymer as 
well as of the scaffold. Young’s modulus instead seemed to reach a maximum value in the PCL (15 %) 
with a minimum for PCL (10 %). This trend, that surprisingly was opposite to the change of the specimen 
porosity (maximum in PCL 15 %) (Table 2.8) might be due to a more interconnected network of the 
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randomly polymer wires produced during the electrospinning, as a consequence of different values of the 
pre-polymer viscosity. A progressive increase in Young’s modulus with the amount of PGS dispersed, from 
4.25 to 7.61 MPascal, and consequently a reduction of elongation at rupture, from 453 % to 218 %, can be 
observed (Table 2.8). This increase in scaffolds’ rigidity toward values of Young’s modulus about three 
times higher than the one of native human artery might be considered inopportune. However, this fact is 
make up for an ultimate tensile strength and an elongation at rupture elevated in comparison with the human 
vascular tissue and therefore with higher values of their toughness. Among all samples, PCL (10 %) resulted 
to have Young’s modulus (2.48 ± 0.19 MPascal) and tensile strength (1.16 ± 0.24 MPascal) comparable 
with native human artery (2.58 ± 0.34 and 1.13 ± 0.06 MPascal, respectively). However, elongation at 
rupture was higher when compared to native human artery. As reported by Sant et al. (2011), photocured 
acrylated PGS films have shown elastic modulus from 0.15 to 30 MPa with ultimate elongation up to 200 
%. In other works, thermally cured PGS films resulted to have ultimate tensile strength less than 1 MPa and 
ultimate elongation about 200–400 % (Wang et al., 2002). The fabricated PCL:PGS (1:1, v/v) scaffolds in 
this study resulted to have similar elasticity but higher ultimate strength without any thermal or photo-
crosslinking process. Biomimetic Young’s modulus, suture retention, and tensile strength combined with 
high elongation at rupture make the fabricated PCL:PGS (1:1, v/v) graft promising for engineering human 
arteries.  
The anastomotic strength is one of the physical factors concerning the conventional grafts. A method to 
assess this property is the measurement of suture retention strength, a parameter depending on the wire 
diameter, on the needle size, and on the thickness of tissue (Mine et al., 2010). In this work, for each specific 
type of PPS, the retention strength is to be evaluated, independently from the thickness of scaffold. For this 
reason, the force was normalized, by dividing the thickness of sample by the value obtained from the test, 
performed according the protocol ANSI/AAMI. The normalized values of suture retention strength (Table 
2.8) displayed a maximum for the PCL (15 %) but with a high standard deviation. Also for the copolymer 
PCL:PGS, the specific strength, ranging between 5.98 and 3.84 N/mm, is comparable with the one obtained 
in the case of natural artery (4.09 N/mm). The value abnormally low in PCL (10 %) can be due to the 
excessive thinness of the sample and to its different microstructures. 
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Table 2.8: mechanical properties of PCL and PCL:PGS blend scaffold. 
Sample 
Young’s modulus 
(MPa) 
Tensile strength 
(MPa) 
Elongation 
(%) 
Normalized suture 
retention 
(grams-force/mm) 
PCL (10 %) 2.48 ± 0.19b 1.16 ± 0.24a 84.16 ± 7.95b 0.42 ± 0.18a 
PCL (15 %) 4.25 ± 0.22a 1.84 ± 0.75a 282.76 ± 127.72a 6.80 ± 4.17a 
PCL (20 %) 3.87 ± 0.36a,c 2.37 ± 0.60a,b 643.30 ± 30.68d 5.75 ± 2.31a 
PCL:PGS (3:1) 4.25 ± 0.21a 1.78 ± 0.31a 453.11 ± 19.38c 4.94 ± 1.20a 
PCL:PGS (2:1) 5.39 ± 0.84d 1.89 ± 0.45ª,b 242.83 ± 39.38a 5.98 ± 2.45a 
PCL:PGS (1:1) 7.61 ± 0.92e 3.14 ± 1.47b 218.48 ± 27.72a 3.84 ± 2.72a 
Native human 
artery 
2.58 ± 0.34b,c 1.13 ± 0.06a 46.54 ± 11.32b 4.09 ± 2.12a 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
2.3.1.8. Biocompatibility of PPS 
 
To demonstrate the absence of cytotoxicity effects on human endothelial cells EA. hy 926, they were put 
in contact for 24, 72, and 96 hours with PPS. Cell proliferation in presence of the scaffold was evaluated 
trough the MTS assay. Working with pure PCL, it was noticeable that the proliferation during the first 24 
hours was higher in comparison with those scaffold containing both PCL and PGS. Among PCL:PGS 
scaffolds, by increasing the amount of PCL in the scaffold, there was an increase in cellular growth after 
24 hours, in a ratio dependent manner. After 72 and 96 hours of contact with PCL scaffold (15 and 20 %), 
endothelial cells significantly reduced their metabolic activity (Figure 2.13 A). This cellular behaviour 
found an explanation in the fact that PCL is a hydrophobic material and probably it made difficult the 
diffusion of nutrients and metabolites between the attached cells and the medium. On the contrary, the 
presence of the hydrophilic PGS allow cells to grow even after 3 and 4 days after their seeding. These data 
are completely consistent with those presented by Sant et al. (2013). To confirm once more the 
biocompatibility of PGS in the scaffold, the electropsun grafts with the highest percentage of PGS 
(PCL:PGS, 1:1) were tested alone using the same cells reported above but performing the experiments with 
a Trans-well system over a longer period (7 days) (Figure 2.13 B). In fact, recent studies have reported that 
electrospun PCL:PGS constructs promote cell adhesion and proliferation compared to PCL scaffolds (Sant 
et al., 2011), because of their enhanced hydrophilicity in comparison to hydrophobic PCL. For this reason, 
biological test with only PCL:PGS scaffolds was decided to perform. The viability of EA. hy 926 on days 
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1, 2, 3, and 7 is shown in Figure 2.13 (B). Cell proliferation, evaluated through the mitochondrial metabolic 
activity, indicated that cells grown in the presence of electrospun scaffolds with no significant differences 
when compared with cells grown on a tissue culture plate as a negative control. The increasing absorbance 
values during the culture period demonstrated that proliferation can occur in the presence of the studied 
scaffolds without any cytotoxic event. The results suggest that PCL:PGS (1:1, v/v) blends can promote cell 
growth and thus may be used for bioengineering vascular prosthesis. 
 
 
 
 
 
A) 
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Figure 2.13: cell viability of all the electrospun (A) PPS and (B) PCL:PGS (1:1) scaffold by MTS assay. 
 control,  PCL:PGS (1:1). 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results  (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
2.3.1.9. Hemocompatibility of PPS 
 
When blood contacts solid material surface, many physiological reactions such as thrombus formation and 
red blood cells disruption can occur. Therefore, hemocompatibility represents one of the most important 
parameters to take into account working with vascular prostheses (Elahi et al., 2014). In this work, the 
hemocompatibility of electrospun scaffolds was evaluated by hemolysis and kinetic clotting time method. 
The blood clotting behavior in the presence of scaffolds is shown in Figure 2.14 (A). The aim of in vitro 
dynamic clotting time test is to measure the clotting time influenced by the presence of materials. The 
absorbance of free hemoglobin in the solution varies with time; the higher the absorbance, the better the 
antithrombotic properties. Figure 2.14 A shows that blood incubated with PCL and PCL:PGS blends had a 
significantly higher absorbance than glass almost at each fixed time point. Glass ws used as a reference 
thrombogenic material (Motlagh et al., 2006). PCL:PGS (1:1, v/v) samples showed the best anticoagulant 
properties with an absorbance of 0.533 after 30 minutes. Furthermore, it may be seen that, after 5 minutes, 
scaffolds made only by PCL are less efficient in comparison to those made by PCL and PGS together. 
Hemolysis percentage is a parameter to express quantitatively the breakage of erythrocytes after the contact 
with materials. Figure 2.14 (B) shows that with the increasing PCL content in PCL:PGS blend, the 
hemolysis percentage decreased, probably because the surface roughness depends on the presence of PGS. 
Nevertheless, the data suggest that PCL at different percentages and PCL:PGS blend scaffold were highly 
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compatible with human blood. In fact, for each kind of sample, the hemolysis percentage resulted < 5, with 
no significant differences between them. 
 
 
 
 
Figure 2.14: hemocompatibility of electrospun scaffolds with different percentage of PCL and different blend 
ratio of PCL:PGS. (A) Kinetics of clotting time and (B) hemolysis percentage. Clotting time: PCL ( ): ♦ PCL 
(10 %),  PCL (15 %), ▲ PCL (20 %), PCL:PGS ( ): ● PCL:PGS (1:1), * PCL:PGS (2:1); ○ PCL:PGS 
(3:1), ( ) + glass. 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
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2.3.1.10. Conclusion 
 
In this study regarding PPS, electrospun small-diameter (2 mm) tubular grafts were successfully fabricated 
as a suitable replacement for small diameter vessels. Degradable and porous grafts generated from 20 % 
(w/v) of PCL and PGS solution, mixed together in the ratio 1:1(v/v), offered good biomimetic mechanical 
properties and comparable suture retention with the native human artery. Fabricated tubular scaffolds of 
PCL:PGS 1:1 (v/v) were nontoxic to human vascular endothelial cell line EA. hy 926 and they showed 
good anticoagulation property with a low hemolysis percentage. Taking together all these data, we were 
able to select among all PCL and PGS-based material, PCL:PGS (1:1, v/v) as a good candidate for vascular 
tissue engineering. For this reason, only PCL:PGS (1:1) blend was functionalized with bioactive 
compounds. 
 
This work was partially published as: “Tailored electropsun small diameter graft for vascular prosthesis”, 
International Journal of Polymeric Biomaterials 66, (2017) 635-643, by Ferrari P.F., Aliakbarian B., 
Lagazzo A., Tamayol A., Palombo D., Perego P.”, partially presented as “Effect of electrospinning 
parameters on mechanical properties of engineered small diameter vascular grafts” at the 64th international 
Congress of the European Society of Cardiovascular and Endovascular Surgery (ESCVS) 2015, Istanbul, 
Turkey, by Aliakbarian B., Ferrari P.F., Perego P., Palombo D, and published in The Journal of 
Cardiovascular Surgery, abstract book, Vol. 56 – Suppl. 1 to n° 2, 94. 
2.3.2. Gelatin coated polymeric scaffold (GCS) 
 
The vessel prosthesis show often a suitable porosity to allow the metabolic exchanges of the cells during 
the building of the regenerated tissue. However, after the implantation of porous prosthesis, these pores 
commonly could generate high blood loss. As a result, it is mandatory to seal the pores with a biocompatible 
and adsorbable filling agent (Fleckenstein & Werner, 1988). In this thesis, in order to reduce the porosity, 
the water permeability, and to increase the biocompatibility, PCL:PGS (1:1, v/v) scaffolds were coated with 
gelatin. We chose gelatin as coating agent because of its extremely well-known physicochemical properties, 
its commercial availability at low cost, its high biocompatibility and its low antigenicity (Zhang et al., 2005; 
Pulieri et al., 2007).  
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2.3.2.1. Scanning Electron Microscopy (SEM) analysis of GCS 
 
In PCL:PGS (1:1, v/v) and GCS scaffolds, fibers appeared randomly distributed and they were bead-free 
(Figure 2.15). The presence of gelatin (Figure 2.15, A and B) did not affect the structure of the electrospun 
scaffolds in comparison with uncoated PCL:PGS (1:1, v/v) (Figure 2.15, C and D). Both the inner and the 
outer surfaces of GCS exhibited microfibers, without any differences between GCS and control. The 
coating with gelatin did not interfere with the diameter of fibers (p < 0.05) (Table 2.9). 
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Figure 2.15: representative SEM micrographs of gelatin coated (A) internal and (B) external scaffold surfaces 
and of (C) internal and (D) external surfaces of PCL:PGS (1:1) without coating. 
 
Table 2.9: fiber diameters of GCS and PCL:PGS (1:1). 
Sample 
Fiber diameter 
(μm)  
GCS 5.50 ± 1.34a 
PCL:PGS (1:1) 5.29 ± 1.31a 
 
Results are mean of at least one hundred measurements ± SD. Different letters do refer to statistically significant differences among results 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
C D 
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2.3.2.2. Thickness and porosity of GCS 
 
The thickness of GCS and PCL:PGS (1:1, v/v) was measured and resulted to be 0.46 ± 0.11 and 0.43 ± 0.11 
mm, respectively (Table 2.10). Data suggested that surface modification did not increase scaffold thickness 
and therefore the gelatin layer can be considered at a sub-millimeter level. In general, porosity of 
biomaterials plays a pivotal role due to its influence to favour cellular colonization and growth on the 
prosthesis. Porosity is defined as the measure of the open pore volume, known as the void fraction 
(Lawrence & Madihally, 2008). In the case of GCS, porosity was significantly lower (43.49 ± 10.85 %) in 
respect of PCL:PGS (1:1, v/v) (68.19 ± 0.02 %) (Table 2.10). This fact can be attributed to the formation 
of a uniform layer during gelatin coating that is able to occlude the pores of the scaffolds. 
 
Table 2.10: thickness and porosity of GCS and PCL:PGS (1:1). 
 
Sample Thickness (mm)  Porosity (%) 
GCS 0.43 ± 0.11a 43.49 ± 10.85b 
PCL:PGS (1:1) 0.46 ± 0.11a 68.19 ± 0.02a 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
2.3.2.3. Water permeability of GCS 
 
Water permeability was greatly decreased by gelatin surface modification. In fact, in the case of PCL:PGS 
(1:1, v/v), first water drops were already registered at 0.2 atm, while working with GCS there was not water 
leakage until 0.7 atm was reached. 
 
2.3.2.4. In vitro degradation, fluid uptake and release of gelatin from GCS 
 
Degradation rate of biomaterials is a key factor that has to be considered once studying tissue architecture 
reorganization and integration. In fact, during a fast degradation, scaffolds do not represent a good substrate 
for cell attachment and growth while, during a slow degradation, biomaterials go under a process of 
calcification and hardening, losing their mechanical properties. As can be seen from Figure 2.16 (A), mass 
loss was more evident with GCS. In fact, during the first period of degradation, also gelatin is released from 
the scaffolds, lowering their weights. Mass loss, in this case, is the sum of two different processes, 
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degradation of the polymers and release of gelatin. However, the degradation profile was very similar 
between GCS and the PCL:PGS (1:1, v/v). 
In addition, it was studied if the degradation of the polymeric scaffold was accelerated in presence of gelatin 
or not using equation 2.5, presented in Section 2.2.4.8. In particular, we focused our attention only on the 
24 hours of releasing of gelatin and degradation of the polymers. Our aim was to understand if the releasing 
of gelatin had an effect on the degradation rate of the polymeric scaffolds. To do that, we performed 
releasing and degradation experiments starting from the same samples. After 24 hours, it was noticed that 
the degradation rate of the coated polymer was remarkably higher in the case of GCS (Table 2.11). 
Probably, the release of gelatin, that was physically deposed onto the surface of the scaffold, caused an 
instability of the polymers with a subsequent co-release of the components of the scaffold. 
Figure 2.16 (B) shows the fluid uptake profile of the studied materials during 24 hours. The presence of 
gelatin induced an increase of fluid uptake during the first hours. GCS presented a peak of fluid uptake after 
2 hours (248 %) and after 24 hours this parameter decreased (144 %) as a consequence of a concomitant 
gelatin release. As shown in Figure 2.17, the majority of gelatin (58.96 %) was released within the 8 hours 
and the total amount of released gelatin was 70.64 % after 72 hours. In conclusion, the release of gelatin 
from the scaffolds is responsible of the different behaviour between GCS and PCL:PGS (1:1, v/v) in 
degradation rate and fluid uptake profiles. 
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Figure 2.16: (A) mass loss (B) and fluid uptake of PCL:PGS (1:1) and GCS. Mass loss:  PCL:PGS (1:1).  
GCS. Fluid uptake: (♦) GCS, (●) PCL:PGS (1:1). 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each day (p 
< 0.05), ANOVA with Tukey’s multiple comparison test. 
 
Table 2.11: degradation of the polymer in presence of gelatin or not after 24 hours. 
 
Sample Degradation (%)  
GCS 26.13 ± 4.12a 
PCL:PGS (1:1) 10.82 ± 0.37b 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
 
0
50
100
150
200
250
300
0 5 10 15 20 25
F
lu
id
 u
p
ta
k
e 
(%
)
Soaking time (hours)
B) 
FUNCTIONALIZATION OF ELECTROSPUN SCAFFOLDS                                                  RESULTS AND DISCUSSION 71 
 
  
Figure 2.17: cumulative release of gelatin from GCS. 
2.3.2.5. Mechanical properties of GCS 
 
With the aim of comparing mechanical properties between PCL:PGS (1:1, v/v) and GCS, Young’s 
modulus, tensile strength and elongation were calculated (Table 2.12). Dry GCS showed a very different 
behaviour under a mechanical point of view in comparison with all the other samples. Considering Young’s 
modulus, statistically significant differences (p < 0.05) were reported only in the case of dry GCS that 
presented a modulus approximately nine times higher in respect with PCL:PGS (1:1, v/v). In complete 
accordance with Meng et al., (2010), the presence of gelatin decreased the mechanical properties of 
PCL:PGS (1:1,v/v) scaffold. This hardening property was overcome by immersing GCS in a NaCl solution 
(0.9 %, w/v) for 5 minutes. After that, surprisingly, all the tested samples showed a comparable tensile 
strength without any relevant differences (p < 0.05). The hardening of the polymeric samples caused by the 
surface modification with gelatin was responsible of low values in elongation. Following vascular surgery 
procedures, even in this case, GCS and PCL:PGS (1:1) scaffolds were immersed in a NaCl solution (0.9 
%) and their mechanical responses were investigated. Wet samples were considered nearer than dry samples 
to the final application of the prostheses, and therefore, taken together, all these data suggested that the 
coating of PCL:PGS scaffolds with gelatin did not modify the mechanical properties of control (uncoated 
samples). 
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Table 2.12: mechanical properties of GCS and PCL:PGS (1:1). 
 
Sample 
Young’s modulus 
(MPa) 
Tensile strength 
(MPa) 
Elongation 
(%) 
GCS (dry) 62.02 ± 8.81b 4.00 ± 1.21a 12.79 ± 4.44b 
PCL: PGS (1:1) 
(dry) 
6.21 ± 2.13a 2.33 ± 0.75a 482.34 ± 193.44a 
GCS (wet) 8.63 ± 2.02a 3.27 ± 1.44a 327.56 ± 74.36a 
PCL:PGS (1:1) 
(wet) 
8.05 ± 0.86a 2.89 ± 0.81a 516.66 ± 63.13a 
    
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column (p < 
0.05), ANOVA with Tukey’s multiple comparison test. 
 
2.3.2.6. Biocompatibility of GCS 
 
Different studies have suggested that gelatin is able to enhance biocompatibility of biomaterials promoting 
cell adhesion and proliferation (Ghasemi-Mobarakeh et al., 2008). In our case, only the external surface of 
the scaffold was coated with gelatin with the aim of reducing water permeability. In order to study whether 
our scaffolds were responsible to release toxic molecules, they were put in Transwell-clear multiwell inserts 
and the EA. hy 926 cell viability after 1, 2, 3 and 7 days was monitored through MTS assay. The results, 
expressed as percentage values with respect to the control, are shown in Figure 2.18. After 1 and 2 days, a 
significant increase in cell viability was noticed. No statistically significant differences (p < 0.05) were 
observed between the cells grown on a tissue culture plate as control and the cells grown in presence of 
GCS and PCL:PGS (1:1) after one week. 
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Figure 2.18: cell viability of PCL:PGS (1:1) and GCS by MTS assay.  control,  PCL:PGS (1:1), and  GCS. 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
 
2.3.2.7. Hemocompatibility of GCS 
 
Hemocompatibility of electrospun scaffolds was evaluated registering the absence of material-derived 
erythrocytes disruption. Figure 2.19 shows that working with GCS it was dramatically diminished the 
hemolysis percentage, probably because of the gelatin coating, reducing the porosity of the scaffolds, 
caused a decrease of the roughness of PCL:PGS scaffolds. Considering that, for both GCS and PCL:PGS 
(1:1, v/v)  this parameter was always < 5 % and we can conclude that they were highly hemocompatible 
(Sternberg et al; 2015). Studying hemolysis, the biodegradable electrospun scaffolds were compared to the 
current commercial prostheses, poly (ethylene terephthalate) and expanded poly (tetrafluoroethylene). 
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Figure 2.19: hemolysis of PCL:PGS (1:1), GCS, poly (ethylene terephthalate) and expanded poly 
(tetrafluoroethylene).  PCL:PGS (1:1),  GCS,  poly (ethylene terephthalate), and  expanded poly 
(tetrafluoroethylene). 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
 
2.3.2.8. In vivo suturability test with GCS 
 
Once evaluated the impermeability of GCS through the water permeability test, a feasibility study to 
confirm the in vivo suturability of the scaffolds was assessed. GCS (2 mm in diameter) were implanted in 
two White Star rats with the aim of replacing the native aorta (Figure 2.20). Baseline structural integrity 
and host responses were evaluated. No evidence of trans-graft leakage of blood was demonstrated when 
the GCS were implanted in rats. No bleeding occurred throughout the entire duration of the surgery. 
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Figure 2.20: implantation of GCS in White Star rat. 
 
2.3.2.9. Conclusions 
 
During this research, small diameter tubular grafts as vascular prostheses by electrospinning were 
fabricated. Fibrous, degradable, porous, bio- and hemocompatible scaffolds of PCL:PGS (1:1, v/v) showed 
good mechanical properties. Oppositely, these scaffolds exhibited an excessive water permeability even at 
low pressure. In order to overcome this drawback, scaffolds were coated with gelatin. The coating made of 
gelatin influenced the degradation rate of the studied polymers, but it didn’t alter their fluid uptake 
properties. Furthermore, the surface modification with gelatin did not alter thickness, fiber diameters, 
mechanical properties, when they were wet, biocompatibility, and hemocompatibility of PCL:PGS 
scaffolds. The coating with gelatin was responsible of the water impermeability of the scaffolds Taking 
together all these data, GCS could be used to be surgically implanted in animal model as arterial graft. 
 
This work was partially published as: “Small diameter vascular grafts coated with gelatin”. Chemical 
Engineering Transactions 57, 2017 by Ferrari P.F., Aliakbarian B., Palombo D., Perego P., partially 
presented as: “Functionalizing small diameter vascular grafts with gelatin” at the 65th international 
Congress of the European Society of Cardiovascular and Endovascular Surgery (ESCVS) 2016, Belgrade, 
Serbia, by Aliakbarian B., Ferrari P.F., Perego P., Palombo D, and published in The Journal of 
Cardiovascular Surgery, abstract book, Vol. 57 – Suppl. 2 to n° 2, 73.  
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2.3.3. Quercetin-fuctionalized scaffolds (QS) and Quercetin-functionalized and 
gelatin coated scaffolds (QGCS) 
 
Herein the effect of incorporating free quercetin on the properties of the scaffolds is investigated. Quercetin 
(Q) is a naturally occurring polyphenolic flavonol present in several food and beverages (e.g. onions, 
broccoli, apples, tea, and red wine). It shows different beneficial activity on the body, being an antioxidant 
and a free-radical scavenger (Harborne & Baxter, 1999; Gomathi, et al., 2003). It protects against 
cardiovascular pathologies (Tribolo et al., 2008), inflammation (Boots et al., 2008), and tumorigenesis 
(Murakami et al., 2008). After implantation, scaffolds could induce immunological reactions in response 
to injury due to the presence of a foreign material in the body, leading to acute inflammation (Lee et al., 
2012). In this part of the research, PCL:PGS (1:1, v/v) scaffolds were functionalized with quercetin to 
evaluate its effects on inflammatory response. On the basis of the previous study concerning gelatin coating, 
even in this case, after functionalization with quercetin, scaffolds were coated with gelatin. 
2.3.3.1. Scanning Electron Microscopy (SEM) analysis of QS and QGCS 
 
In tissue engineering it is necessary characterized the scaffold matrix in terms of the microscale thickness 
of the single fibers. When a biomaterial is made only by of a bed of fibers, the fiber stickness is done from 
the diameter of an individual fiber (Lawrence & Madihally, 2008). As a result of this, representative SEM 
images of internal and external scaffold surface of QS, QGCS, and PCL:PGS (1:1, v/v) were collected 
(Figure 2.21). These images were useful for evaluating the microarchitecture of the functionalized scaffold. 
The presence of free quercetin in the spinning solution did not interfere with the fiber formation process 
during electrospinning. Morphologically, scaffolds consisted of fibers with a random orientation and 
disposure. In any case, fibers, both for the internal and the external surface, can be considered as 
microfibers. Their diameter ranged is for each kind of graft around 5 μm (Table 2.13). Typical 
microstructure of PCL:PGS (1:1, v/v) functionalized with quercetin matched well with the morphological 
properties for pure PCL:PGS (1:1, v/v), described in Section 2.3.1.2. The presence of few fused fibers in 
the internal surface of the scaffold (QS and PCL:PGS (1:1)) was a consequence of using mineral oil on the 
aluminium collector with the aim of easily extruding the construct after the electrospinning process. As a 
result, there was no significant differences (p < 0.05) between QS and PCL:PGS (1:1, v/v), both for the 
internal and external surface. Similarly, the gelatin coating step did not alter the fiber diameter. Considering 
QGCS, fibers appeared sticky for the presence of the gelatin and more undefined in comparison with QS 
and PCL:PGS (1:1, v/v).  
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Figure 2.21: representative SEM micrographs of (A) internal and (B) external surfaces of QS, of (C) internal 
and (D) external surfaces of QGCS, and of (E) internal and (F) external surfaces of PCL:PGS (1:1). 
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Table 2.13: fiber diameter of QS, QGCS, and PCL:PGS (1:1). 
 
Sample Diameter (μm)  
QS 4.12 ± 1.06a 
QGCS 3.96 ± 0.47a 
PCL:PGS (1:1) 4.01 ± 0.92a 
Results are mean of at least one hundred measurements ± SD. Different letters do refer to statistically significant differences among results 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
2.3.3.2. Atomic Force Microscopy (AFM) analysis of QS 
 
SEM analysis represents a good technique to characterize the microstructure of fibers but it is not useful to 
evaluate the roughness of the scaffold surface (Kim et al., 2009). Therefore, to further characterize the 
scaffold surfaces, AFM analysis were carried out using QS and PCL:PGS (1:1, v/v) as control. The 
structures of the electrospun fibers was imaged, mapping variations in surface properties. Adhesive 
interactions are shown as darker regions whereas repulsive interactions are shown as brighter regions in the 
collected images. Figure 2.22 shows representative images of the surfaces of scaffolds obtained by AFM. 
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Figure 2.22: AFM height (left) and deflection (right) images of (A) QS and (B) PCL:PGS (1:1) external surfaces. 
B 
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Figure 2.23: AFM 3D images of (A) QS and (B) PCL:PGS (1:1). Figures on the left and on the right are from 
a different area, 
 
AFM studies confirmed the micrometric dimension of fibers forming both PCL:PGS (1:1, v/v) and QS. Fibers resulted 
to be randomly distributed and bead-free. The AFM 3D images (Figure 2.23) demonstrates that fibers have cylindrical-
like geometries. Furthermore, AFM studies validated the presence of many pores among the fibers of the electrospun 
scaffolds. In general, the presence of quercetin did not make changes to the properties of the PCL:PGS (1:1, v/v) 
scaffolds. 
B 
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2.3.3.3. FTIR spectroscopy of QS 
 
Figure 2.24 shows FTIR spectra in the wavenumber ranging from 4000 to 400 cm-1 for QS and PCL:PGS 
(1:1, v/v). FTIR spectroscopy was used to study possible changes in polymeric materials during the 
fabrication process due to the addition of free quercetin. In the PCL:PGS (1:1, v/v) spectrum, it was possible 
to notice some aspects that derive from the two component alone, PCL and PGS. One of this was the 
presence of esters peaks related to PCL at 1724 and 1170 cm-1. Regarding PGS, there were different stretch 
vibration peaks for the alkyl group (-CH2) at 2929, 2851, and 1384 cm-1. An intense signal was present at 
both 1734 and 1165 cm-1; it has to be attributed to a carboxyl groups (C-O and C=O). In PCL:PGS (1:1, 
v/v) samples the most important change, in comparison with the two pure polymers, is between 3300 and 
2500 cm-1. These new shoulders were strictly related to the PGS, indicating an increase in hydroxyl group 
in the blend sample. FTIR spectra of pure PCL and PGS were not reported but they could be easily find on 
FTIR data bank. In the QS, the low concentration of quercetin and the most intense bands related to the two 
polymers prevented the detection of the free quercetin characteristics bands. FTIR spectra of QS and 
PCL:PGS (1:1, v/v) did not show any differences in their absorbance pattern. As a result, it was possible to 
notice that the chemical composition of the scaffold was not compromised adding free quercetin during the 
fabrication process. 
 
Figure 2.24: FTIR spectra of QS ( ) and PCL:PGS (1:1) ( ). 
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2.3.3.4. In vitro degradation and fluid uptake of QS and QGCS 
 
In general, biomaterial degradation plays a pivotal role in the formation of the new tissue since it can 
influence positively or negatively cell adhesion and proliferation. Biodegradability could be considered a 
possible disadvantage in tissue engineering, especially when it is associated with polymer creep and 
weakening during time. As shown in Figure 2.25, degradation tests were performed until 8 weeks. The 
mass loss percentage in the case of PCL:PGS (1:1, v/v) after 4 weeks was about 20 %, according to data 
observed by other authors (Salehi et al., 2014). Comparing these data with those collected working with 
QS, it was noticeable that the addition of quercetin in the scaffold did not interfere with the degradation 
kinetic. In fact, QS and PCL:PGS (1:1, v/v) showed the same degradation trend over 8 weeks. A complete 
different behaviour was remarkable for QGCS. After 4 weeks, its mass loss reached about 45 %, a higher 
value in comparison with both QS and PCL:PGS (1:1, v/v). This rapid kinetic of degradation was just a 
superimposed effect due to the presence of gelatin as coating agent. Samples lost more mass since they 
were releasing gelatin. Probably, the polymer that formed QGCS showed a degradation kinetic similar to 
the other samples but it was not possible to take into account the mass loss directly related to the gelatin 
release because of the co-release of quercetin from the same scaffold. 
Fluid uptake of biomaterials is an important factor that affects their specific applications for biological and 
biomedical applications. In particular, working with scaffolds for vascular tissue engineering, the swelling 
of the material due to the adsorption of liquids should be considered when a surgical implant is planned. 
The diameter of the bioprosthesis should not change after fluid uptake to have a correct anastomosis 
between the vessel and the graft. The samples were immersed in PBS and kept at 37°C for a period of 24 
hours (Figure 2.25). After 4 hours of immersion, fluid uptake percentage reached a steady-state for all the 
analyzed samples. In details, it was 111.26 ± 9.18, 101.31 ± 7.85, and 112.19 ± 3.32 for QS, QGCS, and 
PCL:PGS (1:1, v/v), respectively. Interestingly, QGCS samples exihibited a more sustained fluid up-take 
in comparison with QS and PCL:PGS (1:1, v/v), in the first hours, with a peak after 2 hours of soaking 
time. This was due to the presence of gelatin that, being hydrophilic, could capture at first more water than 
the polymer itself. However, after this initial phase, the fluid uptake percentage decreased, reaching lower 
values. The mass loss that was registered during the fluid uptake experiments was attributable to a 
contemporary release of gelatin from the scaffold during time. In fact, as preously reported (Section 
2.3.2.4), gelatin had a significant release during the first hours of immersion in PBS. 
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Figure 2.25: (A) mass loss (B) and fluid uptake of PCL:PGS (1:1), QS, and QGCS. Mass loss:  PCL:PGS 
(1:1),  QS,  QGCS. Fluid uptake: PCL:PGS (1:1) ● ( ), QS ♦ ( ), QGCS ▲ ( ). 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each day 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
2.3.3.5. Quercetin release from QS and QGCS 
 
Figure 2.26 refers to the release of quercetin in PBS at 37°C for a period of 54 days. As regards to QS, the 
amount of released quercetin during the first 10 days was very low. Then, the release accelerated reaching 
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1 % of the total quercetin in the electrospun scaffold after 19 days and a final value of 2.14 % (0.59 ± 0.13 
mg) at the end of the experiment. This pretty poor release of quercetin was probably related to the low 
solubility of this compound in aqueous solutions. Comparing the results obtained working with QGCS, it 
was found that the two curves showed the same release trend, meaning that the coating with gelatin did not 
interfere with the release kinetic. However, QGCS displayed a higher release of quercetin, taking into 
account the same intervals, in comparison with QS: after 19 days and at 54 days the amount of released 
quercetin was 2.79 and 4.51 % (1.19 ± 0.06 mg), respectively. Probably, there was more than only one 
explanation to this trend. First, when gelatin left the scaffold, it induced a co-release of superficial quercetin. 
Second, the presence of a coating with gelatin preserved quercetin from oxidation and this is reflected in 
an enhanced detection of quercetin using spectrophotometry. In fact, in this second case, the percentage of 
the released quercetin could be the same but working with QS a part of released Q was oxidized.  During 
the spectrophotometric analysis, in fact, only the active quercetin and not the oxidized form, is detected. 
This interesting aspect will need a more detailed studies to prove which is the correct hypothesis. Q was 
chosen as anti-inflammatory molecule with whom functionalize PCL:PGS (1:1, v/v) scaffold, after a 
detailed research in literature. As reported by Kobuchi et al. (1999), it shows an anti-inflammatory effect 
after 24 hours at a concentration of 1 μM. This concentration is always overcome by the released quercetin 
from the scaffolds in (QS and QGCS). Regarding these data, these samples were considered promising for 
the subsequent experiments with human endothelial cells. 
 
 
Figure 2.26: cumulative release of quercetin from QS ♦ ( ) and QGCS ▲ ( ). 
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2.3.3.6. Water permeability of QS and QGCS 
 
The presence of gelatin coating allowed us to perform the water permeability test. This coating was 
responsible of a less water permeability in comparison with PCL:PGS (1:1, v/v). QGCS showed a 0 % 
water permeability at a pressure of 0.2 bar (correpsonding to 150 mmHg), a value closer to the systolic 
blood pressure in a healthy person (120 mmHg). The first water drops appeared on the surface of QGCS 
when the applied pressure was 0.3 bar (225 mmHg). The permeability of the graft was 0.34 mL/cm2/min, 
a value extremely low in comparison with those reported in literature (e.g. Madhavan et al., 2013). Under 
a microscopic point of view, the capability of coated samples to be impermeable at water at 0.2 bar could 
be found an explanation in their 3D microstrucutre. As previously reported (Section 2.3.2.2), the porosity 
of GCS was lower (43.49 ± 10.85 %) in respect with PCL:PGS (1:1, v/v) (68.19 ± 0.02 %). This property 
justified the decrease of water permeability, working with GCS and QGCS. The water permeability test 
confirmed that gelatin was a cheap and necessary coating agent for PCL:PGS (1:1, v/v) scaffold. Data are 
summerized in Table 2.14. 
 
Table 2.14: water permeability of QS, QGCS, and PCL:PGS (1:1) at 0.2 bar. 
Sample 
Pressure  
(bar)  
Water permeability 
(%) 
QS 0.2 100 
QGCS 0.2 0 
PCL:PGS (1:1) 0.2 100 
 
2.3.3.7. Mechanical characterization of QS and QGCS 
 
In order to compare the mechanical properties of QS and QGCS with those of PCL:PGS (1:1, v/v), we 
focused our attention on Young’s modulus, tensile strength and elongation percentage of the scaffold (Table 
2.15). QS and PCL:PGS (1:1, v/v) showed a comparable Young’s modulus, tensile strength and elongation 
percentage. The addition of quercetin to the polymer did not change its mechanical properties. Conversely, 
QGCS exhibited, under a mechanical point of view, a different behaviour in comparison with QS and 
PCL:PGS (1:1): the Young’s modulus and the tensile strength were higher while the elongation percentage 
was lower. Figure 2.27 (A) shows representative stress-strain curves of dry PCL:PGS (1:1, v/v), QS, and 
QGCS. In general, QGCS samples presented a more brittle and harder behaviour, possessing a Young’s 
modulus from 12 to 20 times bigger and a lower elongation percentage (from 5 to 10 times lower). This 
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hardening properties, due to the presence of a layer of gelatin on the surface of the scaffold, was overcome 
by immersing QGCS in a NaCl solution (0.9 %, w/v) for at least 5 minutes, following a common vascular 
surgery procedure before implanting grafts. Surprisingly, the wet state restored the ductile properties of 
QGCS in terms of Young’s modulus and tensile strength, deleting the hardening behaviour of dry gelatin. 
Figure 2.27 (B) reported the stress-strain curve for wet GCQS. The condition of rehydration facilitated the 
sliding of polymer chains under mechanical deformation (Kharaziha et al., 2013). Samples in wet condition 
were considered to correspond better than samples in dry condition to the final application of the vascular 
prostheses, and therefore, all these data suggested that the coating with gelatin did not modify the 
mechanical properties of the scaffold when they were wet. There were no differences among dry and wet 
samples made of PCL:PGS (1:1, v/v) and QS (data not shown). 
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Figure 2.27: representative stress-strain curves for (A) dry samples of PCL:PGS (1:1), dry samples of QS, and 
dry samples of QGCS and (B) dry samples of PCL:PGS (1:1), dry samples of QS, and wet samples of QGCS. 
PCL:PGS (1:1) ( ), QS ( ) and QGCS ( ). 
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Table 2.15: mechanical properties of QS, QGCS, and PCL:PGS (1:1). 
 
Sample 
Young’s 
modulus (MPa) 
Tensile strength 
(MPa) 
Elongation 
(%) 
QSdry 6.65 ± 2.34a 2.68 ± 0.62a 450.94 ± 86.19a 
QGCSdry 221.09 ± 5.61b 7.26 ±0.97c 32.45 ± 7.60c 
QGCSwet 9.82 ± 2.09a 3.25 ± 0.16a,b 199.56 ± 28.98b 
PCL:PGS (1:1)dry 7.92 ± 0.25a 4.57 ± 0.56b 505.76 ± 35.12a 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each 
column (p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
Furthermore, it was investigated the mechanical properties of QS after one month of degradation (Figure 
2.28). The process of degradation of the polymers did not interfere with the mechanical behaviour but the 
breaking point in the degraded samples was lower. Probably, this fact was due to fibers weakening during 
degradation time.  
 
Figure 2.28: representative stress-strain curves for native QS ( ) and after one month ( ) of soaking in 
PBS. 
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2.3.3.8. Biocompatibility of QS and QGCS 
 
Biocompatibility of QS and QGCS were assessed using both human endothelial and mesenchymal stem 
cells. Before testing the cell cytotoxicity of QS and QGCS, the cell viability in presence of free quercetin 
solubilized in ethanol was assessed. The cellular growth was monitored even in presence of ethanol alone, 
using the same volume of solvent that was necessary to prepare the solution with the different 
concentrations of quercetin. These preliminary experiments were performed to be sure that an eventual 
cytotoxicity was exclusively due to the tested quercetin and not due to the ethanol. Figure 2.29 shows the 
curve of human endothelial growth over a period of 8 days in presence of different concentrations of 
quercetin. Treating the cells with 5 and 10 μM of quercetin, there was no cell cytotoxicity. At the highest 
concentration of quercetin (50 μM), endothelial cells showed the same growth rate in comparison with the 
control and the lowest concentration of the drug but they stopped to grow, reaching a plateau phase after 6 
days of culture. The presence of ethanol interfered with the cellular growth only in the presence of the huge 
amount of the solvent, not in the other cases. Thus, the partial cytotoxicity highlighted working with the 
highest concentration of quercetin (50 μM), probably, was due to an excessive amount of ethanol instead 
of the presence of the quercetin itself. 
 
Figure 2.29: Cell viability quantified by MTS assay. Cells were treated with: 5 μM Q ( ), 10 μM Q ( ), 
50 μM Q ( ), the volume of ethanol present in 5 μM Q ( ), the volume of ethanol present in 10 μM Q        
( ), the volume of ethanol present in 50 μM Q ( ), and no treatment ( ). 
 
The second step was represented by putting in contact endothelial cells and hMSC with QS and QGCS to 
prove their non-toxicity. As reported in Figure 2.30, the presence of the biomaterials in the cellular medium 
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didn’t interfere with cellular proliferation after 1 and after 4 days, working with endothelial cells. The same 
trend was found working with hMSC. Taking into account the previous studies regarding the quercetin 
release from QS and QGCS, these data confirmed that the released amount was no cytotoxic both for 
endothelial and hMSC cells. 
 
 
 
 
Figure 2.30: cell viability of PCL:PGS (1:1), QS, and QGCS on (A) endothelial cells  and on (B) hMSC.  
control,  PCL:PGS (1:1),  QS, and   QGCS. 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
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2.3.3.9. In vitro anti-inflammatory activity of QS 
 
The anti-inflammatory activity of QS was verified studying the relative expression of one of the most 
significant inflammatory marker expressed by endothelial cells. Matrix Metallo-Protenaise 9 (MMP-9), 
also known as gelatinase B, is one member of the zinc-metalloproteinases family and it is involved in the 
degradation of the extracellular matrix. In particular, one of its substrates is represented by gelatin. This is 
the reason why, during the research activity, described in this thesis, it was decided to evaluate its 
expression. In fact, MMP-9 could have a crucial role in degrading the coating made of gelatin of QGCS 
after the implantation. Endothelial cells where treated with Tumor Necrosis Factor α (TNF-α) to reproduce 
in vitro the inflammatory response that occurs after the implantation of the graft. TNF-α is a cell signalling 
protein involved in the inflammation process. It is able to induce the expression of many mediators of 
inflammation, including MMP-9. The level of MMP-9 activity was detected by zimography in the 
conditionated media of TNF-α-stimulated endothelial cells put in contact with PCL:PGS (1:1, v/v) and QS. 
The presence of TNF-α induced a clear expression of MMP-9 in endothelial cells as shown in Figure 2.31. 
 
 
Figure 2.31: relative expression of MMP-9. Data are normalized on the expression obtained with the treatment 
with TNF-α. Results are mean of three measurements ± SD.  
Among all the reported data there are statistically significant differences (p < 0.05). 
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The presence of the PCL:PGS (1:1, v/v) is slightly able alone to down-modulate the expression of MMP-9 
(p < 0.05). When cells were treated with TNF-α and put in contact with QS, a higher down-modulation of 
MMP-9 was obtained. The released quercetin from the scaffold was able to decrease the expression of 
MMP-9 induced by TNF-α. This data are in completely agreement with those reported by Chakraborty et 
al. (2012), Scoditti et al. (2012), Pan et al. (2015) who demonstrated that one of the cellular response 
induced by the treatment with quercetin of different kind of cells was the decrease of the expression of 
MMP-9. 
2.3.3.10. Conclusions 
 
This part of the research was addressed to obtain functionalized scaffold incorporating a well-known 
antioxidant, quercetin. The presence of quercetin did not modify the physicochemical properties of the pure 
PCL:PGS (1:1, v/v) scaffold and in order to obtain an usable scaffold, it was coated with gelatin. The 
presence of gelatin ameliorated the release of quercetin during time. The presence of both quercetin and 
gelatin did not remarkably changes the physicochemical, mechanical, and biological properties of the 
scaffold. In addition, QS was able to reduce the expression of one of the most important inflammatory 
markers, MMP-9. For all these reasons, QGCS could be regarded as a promising substitute in vascular 
tissue engineering. 
 
This work will be partially published as: “Fabrication and functionalization with quercetin of biodegradable 
vascular prostheses through electrospinning” by Ferrari P.F., Aliakbarian B., Garibaldi S., Arab-Tehrany 
E., Kahn C., Palombo D., Perego P. 2017 (submitted), partially presented as: “Engineered small diameter 
vascular grafts with anti-inflammatory properties” at the 66th international Congress of the European 
Society of Cardiovascular and Endovascular Surgery (ESCVS) 2017, Thessaloniki, Greece, by Aliakbarian 
B., Ferrari P.F., Palombo D., Perego P., and published in The Journal of Cardiovascular Surgery, abstract 
book, Vol. 58 – Suppl. 2 to n° 3, 14. 
2.3.4. Nanoparticles-functionalized Scaffolds (NS) 
 
The CaCO3 particles used to functionalize the scaffolds described in this section were prepared as described 
in the Section 3.2.3 using a concentration of PAANa of 1900 μg/mL. They were directly added to the 
spinning solution before the electrospinning process at the concentration of 0.10 % (w/v). 
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2.3.4.1. Scanning Electron Microscopy (SEM) analysis of NS 
 
Figure 2.32: representative SEM micrographs of (A) internal and (B) external surfaces of NS and of (C) internal 
and (D) external surfaces of PCL:PGS (1:1) (images at different magnification). 
 
In Figure 2.32 representative SEM images of internal and external scaffold surface for NS and PCL:PGS 
(1:1, v/v) are presented. These images were used to confirm the presence of CaCO3 particles in the 
microarchitecture of the functionalized scaffold. Even in this case, scaffolds presented a random orientation 
of microfibers. It was noticed a significant difference (p < 0.05) in the diameter distribution of the fibers. 
NS showed fibers that were half of those possessed by PCL:PGS (1:1, v/v). Probably, during the 
electrospinning process, the presence of nanoparticles served as guide for the formation of the fibers that 
resulted to be smaller in comparison with the control (Table 2.16). In both the internal and the external 
surface of NS is possible to put in evidence the presence of the nanoparticles among the electrospun fibers.  
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Table 2.16: fiber diameter of NS and PCL:PGS (1:1). 
Sample 
Internal diameter 
(μm)  
External diameter 
(μm) 
NS 2.46±1.75b 2.41±1.04b 
PCL:PGS (1:1) 5.11±1.11a 5.57±1.55a 
Results are mean of at least one hundred measurements ± SD. Different letters do refer to statistically significant differences among results 
for each column (p < 0.05), ANOVA with Tukey’s multiple comparison test. 
2.3.4.2. Thickness and porosity of NS 
 
Table 2.17 reports the thickness and the porosity of NS and PCL:PGS (1:1, v/v), respectively. No changes 
were observed measuring the thickness between these two kinds of samples. With respect to porosity, a 
very subtle difference between the NS and the control was highlighted. 
 
Table 2.17: thickness and porosity of NS and PCL:PGS (1:1). 
Sample Thickness (mm)  Porosity (%) 
NS 0.51 ±0.14a 71.39±0.16b 
PCL:PGS (1:1) 0.46 ± 0.11a 68.19 ± 0.02a 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each 
column (p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
2.3.4.3. In vitro degradation and fluid uptake of NS 
 
The mass loss and the fluid uptake of NS was compared with PCL:PGS (1:1, v/v) as a function of time in 
Figure 2.33 (A and B), respectively. A remarkable mass loss after the first day was noticed, both for 
PCL:PGS (1:1, v/v) and NS. In NS, the presence of nanoparticles provoked a higher specific surface area 
between the polymeric matrix and nanoparticles themselves. Therefore, a more conspicuous degradation 
during time were expected. At first, mass loss was more evident in the case of NS (13.03 ± 1.07 %) in 
comparison with PCL:PGS (1:1, v/v) (10.82 ± 0.37 %). In the two subsequent measurements (after 7 and 
14 days), the degradation remained more marked for NS with respect to the control. In the last measurement 
(after 28 days) the mass loss of NS seemed to be stabilized while there was an increase in the mass loss 
percentage of the control.  
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The fluid uptake of PCL:PGS (1:1, v/v) samples resulted to be almost constant just after 2 hours. NS, after 
4 hours of incubation absorbed 23 % more water than the control; after 24 hours of soaking time NS 
absorbed 50 % more water in comparison with the control. Taking into account all these experimental 
results, it could be speculated that a higher rate of degradation and fluid uptake for NS were due to different 
reasons. First, the degree of crystallinity of the polymeric blend in NS was reduced by the presence of the 
CaCO3 nanoparticles. This fact could led to an acceleration in the biodegradation rate of NS due to a 
possible mobility of the backbone chains and the amorphous region of the polymeric matrix (Lee et al., 
2005). Another factor influencing the degradation of NS was its higher porosity. As reported by Cui et al., 
(2006), the porous structure of electrospun fibers results in a faster matrix breakdown. The higher porosity 
of NS could be one of the reasons for its faster degradation during the initial phase of the experiments. In 
fact, the difference between the breaking speed of a chemical bond of polymeric materials and the 
distribution of water into the polymer matrix is directly linked with the degradation mechanism of 
biodegradable polymers. The last factor influencing the degradation rate and the fluid upatke could be the 
difference in the fibers diameter. The thickness of the fiber is related to their stability in aqueous solutions, 
thickener are the fibers, more unstable they are. 
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Figure 2.33: (A) mass loss and (B) fluid uptake of PCL:PGS (1:1) and NS. Mass loss:  PCL:PGS (1:1) and  
NS. Fluid uptake: PCL:PGS (1:1) ● ( ), NS ▲ ( ). 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each day 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
2.3.4.4. Release of BSA from the scaffold 
 
In Figure 2.34 the profile of the cumulative amount of released BSA from the scaffold over a period of 21 
days is reported. The initial inner structure and the dispersion of the nanoparticles within the fibers of the 
scaffold has to be considered as a critical factor governing the release kinetic of the entrapped drug. In the 
initial phase, a pronounced burst release was observed. Later the release of BSA became gradual. Reporting 
a linear release of the protein, it has to be considered that the molecules at first dispersed throughout the 
polymeric matrix. Then, the presence of an extremely porous matrix allowed the diffusion of the drug out 
of the scaffold making it possible a constant release of the protein from the inner part. During the entire 
studied interval, the 86 % of the total encapsulated protein was released. Considering that the aim of this 
part of the research was to fabricate a general model of scaffold releasing chemoattractant agents, growing 
factor or differentiation molecules, this could be considered a promising result. In fact, for example, cells 
need continuously the molecular stimulation to keep their phenotype and to proliferate on the surface of the 
scaffold.  
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Figure 2.34: cumulative release of BSA from NS. 
 
2.3.4.5. Mechanical characterization of NS 
 
Mechanical integrity is a fundamental property requiring of biomaterials. A well-built scaffold is not only 
be able of promoting cell attachment and proliferation, supporting cellular growth, but it is also able of 
maintaining its mechanical stability for all the surgical period required to repair the injured tissue. Table 
2.18 shows Young’s modulus, tensile strength and elongation for both PCL:PGS (1:1, v/v) and NS. As 
shown in Figure 2.35, PCL:PGS (1:1, v/v) and NS initially presented a linear stress increase. All the scaffold 
were largely stretched with increasing strain and the stress drop was seen with visible scaffold breakage. 
Clearly, all the value for the NS were significantly higher (p < 0.05). The incorporation of CaCO3 
nanoparticles within the fibrous scaffold was responsible of the observed improving in the tensile strength, 
Young’s moduls, and elongation when it was compared with the control. 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14 16 18 20 22
C
u
m
u
la
ti
v
e 
re
le
a
se
 o
f 
B
S
A
 (
%
)
Time (days)
FUNCTIONALIZATION OF ELECTROSPUN SCAFFOLDS                                                  RESULTS AND DISCUSSION 100 
 
  
Table 2.18: Young’s modulus, tensile strength, and elongation percentage of NS and PCL:PGS (1:1). 
Sample 
Young’s modulus 
(MPa) 
Tensile strength 
(MPa) 
Elongation 
(%) 
NS 4.91 ± 1.37b 2.01 ± 0.26a 576.99 ± 132.5b 
PCL: PGS (1:1) 7.61 ± 0.92a 3.14 ± 1.47a 218.48 ± 27.72a 
 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each 
column (p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
 
Figure 2.35: representative stress-strain curves for PCL:PGS (1:1) ( ) and NS ( ). 
2.3.4.6. Biocompatibility of NS 
 
Biocompatibility is a fundamental precondition of any material that is meant to be implanted in an organism. 
These materials indeed should be highly tolerable by cells that will be in contact with them. For this reason, 
it was decided to test the cellular viability of our scaffolds on a human endothelial cell line. To perform this 
analysis, cell viability was evaluated through the mitochondrial metabolic activity. Three different 
conditions were compared: control cells (cells without any kind of biomaterials), cells in contact with 
PCL:PGS (1:1, v/v) and cells in contact with NS. The results are reported in Figure 2.36. No significant 
differences were found comparing the growth of the cell in presence of the electrospun scaffolds and the 
control. The increasing values of absorbance during the entire period of cell culturing demonstrated that 
proliferation occurred in presence of both scaffolds without any cytotoxic event. 
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Figure 2.36: cell viability of PCL:PGS (1:1) and NS.   control,   PCL:PGS (1:1), and  NS. 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
 
2.3.4.7. Hemocompatibility of NS 
 
In this part of the research, the hemocompatibility was evaluated focusing the attention on the blood clotting 
time and hemolysis. The scope of the in vitro clotting time test is to measure the influence of the material 
on the clotting time. The absorbance of hemoglobin in the solution varied during time, and the higher is the 
absorbance, better are the anti-thrombotic properties of the scaffold. As indicated in Figure 2.37, after 5 
minute PCL:PGS (1:1, v/v) and poly (ethylene terephthalate), with an absorbance equal to 0.533 and 0.575, 
respectively, howed an absorbance value similar to the glass coverslip, used as a reference thrombogenic 
material, while the other tested material showed lower values. NS, after 30 minutes, present a lower value 
of absorbance in comparison with the PCL:PGS (1:1, v/v) and poly (ethylene terephthalate). This value was 
still comparable to that of expanded poly (tetrafluoroethylene). The last point of the kinetic indicated that 
all the tested materials, after 60 minutes, had higher absorbance with respect to the glass, indicating a lower 
thrombogenic activity. PCL:PGS (1:1, v/v), after 5 and after 30 minute of incubation with blood, showed 
the best anticoagulant properties. Poly (ethylene terephthalate) and expanded poly (tetrafluoroethylene) 
were chosen as reference materials because nowadays they are currently used in vascular surgery. 
Hemolysis percentage is a parameter that expresses quantitatively the breakage of red cells after the contac 
with a material. Materials are classified by the percentage of induced hemolysis as: hemolytic if the this 
parameter is over 5 %, slightly hemolytic if this value is between 2 and 5 %, and not-hemolytic if this 
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parameter is low than 2 % (Sterner et al., 2015). Figure 2.37 (B) shows the hemolysis percentage of 
PCL:PGS (1:1, v/v), NS, poly (ethylene terephthalate) and expanded poly (tetrafluoroethylene). Analysis 
of the obtained data highlighted that the presence of the nanoparticles in the scaffold significantly reduced 
the number of disrupted red cells, both with respect to PCL:PGS (1:1, v/v) and expanded poly 
(tetrafluoroethylene). There was no statistically differences between the percentage of hemolysis in the case 
of NS and poly (ethylene terephthalate). All these data suggested that both electrospun scaffolds, PCL:PGS 
(1:1, v/v) and NS were highly compatible with human blood. 
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Figure 2.37: hemocompatibility of PCL:PGS (1:1) and NS. (A) Kinetics of clotting time and (B) hemolysis 
percentage. Clotting time: PCL:PGS (1:1) ● ( ), NS ▲ ( ), poly (ethylene terephthalate) ♦ ( ), 
expanded poly (tetrafluoroethylene)  ( ), and glass + ( ). Result are mean of three measurements ± SD. 
2.3.4.8. Conclusions 
 
The scope of this part of the research was to functionalize PCL:PGS (1:1. v/v) with calcium carbonate 
(CaCO3) nanoparticles encapsulating bovine serum albumin (BSA). Nowadays tissue engineering is 
promoting the concept of “active” scaffold. Historically, scaffolds were born to replace temporarily a 
damaged organ until its new development. These scaffolds are generally considered as “passive” scaffold 
since they offer only the 3D structure to host the cells that are the responsible of the rebuilding of a new 
working organ. Today, next to this concept of “scaffold as a framework for cells”, scaffolds play a 
fundamental role in each step of the replacement of the damaged organ. It has to counteract the post-
implantation inflammatory response, to recruit the correct cell population from the blood releasing 
chemoattractants, to induce differentiation or trans- differentiation of the attached cells. For all these 
reasons, this part of the research was dedicated to create a model of scaffold incorporating nanoparticles 
loaded with a model protein, BSA. In the future, for example, BSA could be replaced with growing factors 
and chemoattractant agents. 
 
This work was partially presented as: “Functionalization of PCL:PGS electrospun scaffold with protein 
loaded nanoparticles” at Summer school on Biomaterials and Regenerative Medicine, Riva del Garda, Italy, 
2016 by Ferrari P.F., Aliakbarian B., Pastorino L., Palombo D., Perego P. and it will be partially presented 
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as. “Biodegradable small diameter vascular prostheses functionalized with protein-loaded nanoparticles” at 
the 67th international Congress of the European Society of Cardiovascular and Endovascular Surgery 
(ESCVS) 2018, Strasbourg, France, by Ferrari P.F., Aliakbarian B., Palombo D., Perego P.   
 
2.3.5. Lecithin-functionalized polymeric scaffolds (RLS and SLS) 
 
In the last part regarding the functionalization of PCL:PGS (1:1, v/v) scaffold, rapeseed and salmon lecithin 
were added to the spinning solution at different concentration (0.5, 1.0, and 5.0 mg/mL). Lecithin is a 
naturally occurring mixture of the diglycerides of stearic, palmitic, and oleic acid, linked to the choline 
ester of phosphoric acid. Because of its chemical composition, it shows amphiphilic properties. It is 
commonly found in different tissues of living plants and animals (Wenninger et al., 2000). This kind of 
functionalization was done in order to  have on the scaffolds a surface mimicking the endothelial and the 
erythrocyte membranes (Zhang et al., 2012). Furthermore, the presence of lecithin in scaffolds serve as 
building block of cellular plasmatic membranes (Wang et al., 2008). This part of the research was designed 
in collaboration with Professor Elmira Arab-Tehrany during the last period of the Ph.D., at University of 
Nancy. For this reason a lot of experiments are still ongoing. RLS and SLS were morphologically 
characterized using SEM, their chemical structure was studied using FTIR analysis and biocompatibility 
studies were performed. 
 
2.3.5.1. Scanning Electron Microscopy (SEM) analysis of RLS and SLS 
 
The morphology of electrospun fibers is strictly dependent on different processing parameters such as (1) 
viscosity of polymer solution that depends on the concentration of the polymers and on the temperature of 
the process, (2) working voltage, (3) flow rate of the spinning solution, (4) distance between needle tip and 
the rotating collector, and (5) inner diameter of the needle (Fujihara et al., 2005). As a consequence of this 
consideration and in order to obtain the same morphology of the scaffolds previously studied, all the 
parameters of the electrospinning process for both RLS and SLS were kept constant, as reported in Section 
2.2.3.3. For all the studied concentration of rapeseed lecithin, fibers appeared randomly distributed, as it 
was shown in the case of PCL:PGS (1:1, v/v) without the occurrence of bead defects (Figure 2.38 and 
Figure 2.39). There were no significant differences between the fiber diameters for all the tested 
concentration of lecithin (Table 2.19). No differences were noticed between RLS, SLS and PCL:PGS (1:1, 
v/v) in terms of morphology as well as there were no differences among RLS and SLS despite of their 
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different origin (plant or animal). In general, the presence of both rapeseed and salmon lecithin did not 
interfere with the microarchitecture of the electropsun scaffold.  
Figure 2.38: representative SEM micrographs of internal (left) and external (right) surface of RLS made with (A 
and B) 0.5, (C and D) 1.0, and (E and F) 5.0 mg/mL of rapeseed lecithin. 
A 
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Figure 2.39: representative SEM micrographs of internal (left) and external (right) surface of SLS made with (A 
and B) 0.5, (C and D) 1.0, and (E and F) 5.0 mg/mL of salmon lecithin. 
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Table 2.19: fiber diameter of RLS and SLS. 
 
Sample Diameter (μm)  
RLS (0.5 mg/mL) 3.45 ± 0.97b 
RLS (1.0 mg/mL) 3.51 ± 0.90b 
RLS (5.0 mg/mL) 3.55 ± 0.84b 
SLS (0.5 mg/mL) 3.53 ± 0.73b 
SLS (1.0 mg/mL)  3.57 ± 1.03b 
SLS (5.0 mg/mL) 3.35 ± 0.88b 
PCL:PGS (1:1) 4.01 ± 0.92a 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each 
column (p < 0.05), ANOVA with Tukey’s multiple comparison test. 
2.3.5.2. FTIR spectroscopy of RLS and SLS 
 
Figure 2.40 shows FTIR spectra in the wavenumber ranging from 4000 to 400 cm-1 for RLS (Figure 2.40 
A), SLS (Figure 2.40 B), and PCL:PGS (1:1, v/v). FTIR data were collected to evaluate potential changes 
in polymeric materials due to the addition of free rapeseed and salmon lecithin, respectively. For all the 
samples, the low concentration of lecithin and the most intense bands related to the two polymers (PCL and 
PGS) prevented the detection of the characteristic bands of the components of lecithin. FTIR spectra of 
RLS, SLS, and PCL:PGS (1:1, v/v) did not show any difference in their absorbance pattern. As a result, it 
was possible to notice that the chemical composition of the scaffold was not compromised adding free 
rapeseed or salmon lecithin during the fabrication process of the scaffolds. 
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Figure 2.40: FTIR spectra of (A) PCL:PGS (1:1) ( ) and of RLS with: 0.5 ( ), 1.0 ( ), and 5.0 mg/mL 
( ) of rapeseed lecithin; (B) FTIR spectra of PCL:PGS (1:1) ( ) and of SLS with: 0.5 ( ), 1.0 ( ), 
and 5.0 mg/mL ( ) of salmon lecithin. 
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2.3.5.3. Biocompatibility of RLS and SLS 
 
Figure 2.41 (A and B) refers to the biocompatibility data obtained working with scaffolds functionalized 
with RL or SL. These preliminary data suggest that there was not difference between the scaffolds 
functionalized with RL and SL in terms of biocompatibility, but their biocompatibility was different from 
that presented by the control. In fact, for both the materials, cell viability was comparable to the control 
only after 5 days of incubation. After 3 days, the cell viability was lower than that of the cells seeded without 
the scaffold. In the majority of cases, a decrease in cell viability is common working with scaffold in the 
first hours. It depends on the surface of the material and on the number of cells that are able to attach to 
them. Only the attached cells will survive and proliferate in the days after. The same trend was observed 
after 7 days. In general, these data have to be confirmed performing other test with cells such ad lactate 
dehydrogenase assay (LDH) and DNA quantification. 
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Figure 2.41: cell viability of (A) RLS and (B) SLS at different concentration of lecithin. RLS:  control,  
PCL:PGS (1:1),   0.5,  1.0, and  5.0 mg/mL. SLS:  control,  PCL:PGS (1:1),  0.5,  1.0, and  5.0 
mg/mL. 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
 
 
 
2.3.5.4. Conclusions 
 
The functionalization of PCL:PGS (1:1) scaffolds with rapeseed and salmon lecithin was done in 
collaboration with University of Nancy and this research activity is still ongoing. Morphological analysis 
of fibers demonstrated that the presence of rapeseed or salmon lecithin at different concentration did not 
tamper the microstructure of the electropsun scaffolds. FTIR analysis showed that the fuctionalization with 
rapeseed and salmon lecithin did not create strong chemical interaction of lecithin with the two polymers 
used to prepare the scaffolds. Finally, as a result of the first set of experiments, it seemed that hMSC did 
not appreciate the presence of lecithin in the biomaterial, presenting a reduced cell viability in comparison 
with the control after 3 and 7 days of contact with the scaffolds. 
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         CHAPTER III 
 
3. DEVELOPMENT OF NANODELIVERY SYSTEMS: CALCIUM 
CARBONATE NANOPARTICLES 
3.1. INTRODUCTION 
Over the last years, several systems to nano-encapsulate bioactive molecules, such as polymeric particles 
(Soppimath et al., 2001; (Mora-Huertas et al., 2010), nanoliposomes (Mozafari et al., 2008) , 
nanoemulsion (Lovelyn & Attama, 2011), and mineralized nanoparticles (Boyjoo et al., 2014), have 
been proposed in the literature. Among them, calcium carbonate-based nanoparticles are considered a 
good tool for drug delivery nanosystems because of their cost-effectiveness (He et al., 2008), good 
biocompatibility (Kurapati & Raichur, 2013), the possibility to modulate the particle size acting on the 
chemical composition (Lauth et al., 2014), and the capability to load a wide range of molecules (Wang 
et al., 2010). One of the most common approaches to confine biological compounds in calcium 
carbonate (CaCO3) particles is complex coacervation. In general, coacervation is defined as 
liquid/liquid phase separation of colloids into a two-phase system. Simple coacervation consists of a 
partial desolvation of biomolecules (Nicolas et al., 2013) while complex coacervation presumes that at 
least one component is a charged colloid (e.g. poly (acrylic) acid), PAANa, that interacts with 
oppositely charged ions (e.g. Ca2+) (Kaempfe et al., 2013). Nowadays, another goal of innovative drug 
therapy protocols is to control the release of drugs at the therapeutically optimal dose regimen directly 
into the tissue/organ where they are needed. For this purpose, CaCO3 nanoparticles have been 
considered a good template for the electrostatic self-assembling layer-by-layer (LbL) technique. This 
method exploits the alternate deposition of positively charged (e.g. chitosan, poly-L-arginine) and 
negatively charged polymers (e.g. dextran sulphate, poly-γ-glutammate) in order to fabricate 
nanostructured films enveloping nanoparticles (Ariga et al., 2011). Concerning the drug delivery 
systems, the LbL-based particles confine active agents increasing both their stability and that of the 
nanoparticles on which they are deposited and inducing a more sustained release of the encapsulated 
drugs (Johnston et al., 2006). Additionally, the LbL technique introduces the possibility to immobilize 
guidance molecules, such as receptors and antibodies, at the outer surface of the shell architecture. In 
immunotherapy, antibodies are able to recognize and to drive drug-loaded nanoparticles to the 
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pathological site. In fact, they are an important class of targeting molecules, as they exhibit high 
specificity and selectivity for cellular antigens. The presence of targeting molecules on polyelectrolyte 
layers can be achieved both by noncovalent and covalent attachment to the surface. Working with 
charged polymers makes it possible to functionalize the particles with antibodies operating with 
electrostatic interactions (Kamphuis et al., 2010). Thus, multilayered immune-nanoparticles are perfect 
candidates for the construction of site-selective drug delivery/release systems. Although cancer therapy 
is the main target of drug delivery carriers, recently they have been evaluated for the treatment of 
different degenerative diseases, such as cardiovascular diseases. In fact, from a pharmacological point 
of view, this nano-sized system gets into the hematic flow and it is guided by the antibodies to the 
pathological site, such as an atherosclerotic plaque. 
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3.2. MATERIALS AND METHODS 
In this section, materials and methods used during the research activity concerning the encapsulation of 
bioactive compounds (proteins and polyphenols) in calcium carbonate (CaCO3) nanoparticles are presented. 
In details, after a short section on chemicals, the materials and the methods used to synthetize and to 
characterize this nanosystem are reported.  
3.2.1. Chemicals 
 
Poly (acrylic acid) sodium salt (PAANa, Mw = 8000 g/mol, 45 % in water), poly-L-arginine hydrochloride 
(Mw =  15000-70000 g/mol), chitosan (medium Mw), dextran sulfate sodium salt (average Mw = 9000-
20000 g/mol), bovine serum albumin (BSA), standard polyphenols (tyrosol, caffeic, vanillic and p-
coumaric acid), calcium chloride (CaCl2, purity = 97 %), sodium carbonate (Na2CO3, purity ≥ 99.5 %), 
sodium chloride (NaCl), ethylenediaminetetraacetic acid (EDTA), Folin-Ciocalteu reagent, absolute 
ethanol, methanol, acetic acid, and Dulbecco’s phosphate-buffered saline (DPBS, pH = 7.4) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). 
Water used for the preparation of solutions and washing operations was purified by Milli-Q® system 
(Millipore, Molsheim, France). 
3.2.2. Cell mediums and reagents 
 
Human endothelial cell line EA. hy 926 were used for the experimentation. They were cultivated in 
Dulbecco’s Modified Eagle Medium (DMEM) high glucose with L-glutamine (Euroclone, Milan, Italy) 
with the addition of 10 % of fetal bovine serum (v/v) (Carlo Erba, Milan, Italy) and penicillin/streptomicin 
1 % (v/v) (Ge Healthcare, Pasching, Austria). Cells were collected and grown in an incubator at 37°C and 
5 % CO2 and culture medium was changed every 3 days of cultivation. Trypsin-EDTA was purchased from 
Carlo Erba (Milan, Italy), 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenil)-
2H-tetrazolium) (MTS) from Promega (Madison, WI, USA) and TNFα from Biovision Inc. (Milpitas, CA, 
USA) and Instant ELISA immunoassay for the detection of IL-6 from Bender MedSystems (Vienna, 
Austria).  
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ENCAPSULATION OF BOVINE SERUM ALBUMIN IN CALCIUM CARBONATE 
PARTICLES 
 
3.2.3. Synthesis of calcium carbonate nanoparticles incorporating bovine serum 
albumin 
 
Calcium carbonate (CaCO3) nanoparticles were synthesized via a combination of complex coacervation 
and mineralization method, as described by Lauth et al., (2014). Briefly, 4 mL of PAANa aqueous solution 
with two different final concentrations (700 and 1900 mg/mL) were each mixed with an equal volume of 
24 mmol/L of CaCl2 solution and maintained under agitation at 900 rpm for 1 min using a magnetic stirrer 
(Falc Instruments, Treviglio, Italy). After the complexation time between Ca2+ ions and PAANa, 4 mL of 
a 12 mmol/L Na2CO3 solution was added with 4 mL of the previous one. Na2CO3 was added to the mix in 
order to stabilize the droplets by forming fully mineralized CaCO3 nanoparticles. The samples were then 
centrifuged at 16 500 × g for 5 min (centrifuge Hettich Rotina 35 R, Tuttlingen, Germany). The obtained 
nanoparticles were then washed three times with water with the aim of removing the uncapsulated BSA 
and the excess of PAANa and freeze dried (freeze dryer Christ Alpha 1–2 LDplus, Osterode am Harz, 
Germany) for 24 hours. The lyophilized nanoparticles were stored at room temperature until analyses were 
performed. To prepare protein-loaded nanoparticles, BSA, at a final concentration of 550 mg/mL, was 
directly dispersed in the aqueous solution prior to the addition of PAANa and CaCl2. These nanoparticles 
were used even to functionalize the scaffold (nanoparticles-functionalized polymeric scaffold, NS), Section 
2.3.4. 
 
 
Figure 3.1: schematic representation of CaCO3 nanoparticles synthesis. 
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3.2.4. Scanning Electron Microscopy (SEM) analysis 
 
To obtain a morphological analysis of the particles, the samples were prepared by putting a small drop onto 
a glass slide at room temperature for 12 hours allowing the complete evaporation of the water. These glass 
slides were then metallized with gold by using a Polaron SEM coating system and CaCO3 particle 
morphology was observed with a scanning electron microscope (SEM Hitachi 2500, Tokyo, Japan). Particle 
diameters were measured on SEM images using GNU Image Manipulation Program (GIMP) v. 2.8 software 
in at least three images of each sample. In order to obtain a meaningful statistical value for every image, at 
least 20 particle diameters were taken into account. 
3.2.5. Transmission Electron Microscopy (TEM) analysis 
 
TEM was used to investigate the nanostructure of CaCO3 particles with a negative staining method. 
Samples were diluted 10-fold with ultrapure water in order to decrease the concentration of the particles. 
An equal volume of ammonium molybdate solution (2 %, w/v) and of the samples were put together for 3 
minutes at room temperature. Then, this solution was dropped on a Formvar-carbon coated copper grid 
(8200 mesh, 3 mm diameter HF 36) for 5 minutes. Filters papers was used to drawn off the excess of liquid. 
The grid was dried at room temperature and micrographs were collected using a Philips CM Transimission 
Electrone Microscope operating at 200 kV (Colas et al., 2007). 
3.2.6. Entrapment efficiency of bovine serum albumin in CaCO3 nanoparticles 
 
The amount of BSA entrapped in the CaCO3 nanoparticles was evaluated separating unentrapped BSA from 
nanoparticles by centrifuging them at 16 060 × g for 5 minutes for three times. All the supernatants were 
collected and the concentration of BSA was determined through spectrophotometric analysis using BCA 
assay. When the sample were too diluted, it was necessary to freeze dried them to concentrate the protein 
before registering absorbance. At the end of the three centrifugation, the pellet was treated with EDTA that 
induced a total breakage of the CaCO3 nanoparticles. As a consequence of that, it was possible to detect 
with BCA assay the concentration of encapsulated BSA.  
BSA entrapment and loading efficiency were calculated as reported by Papadimitriou & Bikiaris (2009) 
 
BSA entrapment efficiency (%) =  
(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐵𝑆𝐴 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠)
(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐵𝑆𝐴 𝑓𝑒𝑑 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦)
× 100   (Equation 3.1) 
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BSA loading (%) = 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐵𝑆𝐴 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
× 100    (Equation 3.2) 
 
3.2.7. Synthesis of multilayered CaCO3 nanoparticles, immobilization and detection 
of anti-rabbit IgG 
 
In order to obtain ultrathin films covering CaCO3 nanoparticles the Layer-by-Layer (LbL) electrostatic self-
assembly technique was adopted, as reported by Paini et al., (2015 A) in which the LbL assembly of 
chitosan/dextran was confirmed by Quartz Crystal Microbalance with dissipation monitoring (QCM-D) 
analysis (see Section 3.3.14). 20 mg of nanoparticles was dispersed in 1 mL of each polyelectrolyte solution 
(0.5 mg/mL in pure acidified water at pH = 5) and shaken for 15 minutes on a laboratory shaker (Falc 
Instruments, Treviglio, Italy). The shell assembly started with the deposition of positively charged chitosan. 
Then the samples were centrifuged at 16060 × g for 5 minutes (centrifuge Heraeus Instruments, Osterode 
am Harz, Germany) and the supernatant was separated from the precipitated nanoparticles. The particles 
were washed centrifuging them three times in acidified water at the same conditions reported above. This 
procedure was repeated until the multilayered structure was completed. The obtained multilayered 
nanoparticles were then rinsed by pure water. In the second part of the research chitosan was replaced by 
poly-L-arginine. This second polycation was chosen for its better solubility in NaCl 0.15 M (0.5 mg/mL), 
avoiding to use acetic acid and continuous stirring overnight necessary in the case of chitosan. The entire 
shell architecture was (poly-L-arginine/dextran)2/poly-L-arginine. 
At the end of the multilayers deposition procedure, 1.95 mg of horseradish peroxidase-linked anti-rabbit 
IgG (HRP-linked IgG) (Cell Signaling Technology, Danvers, MA, USA) was added to the CaCO3 
nanoparticles, shaken for 1 h at room temperature, centrifuged as described earlier, and washed four times 
(Habibi et al., 2011). The resulting shell architecture was (chitosan/dextran)2/chitosan/anti-IgG. After that, 
5 mL of nanoparticles with immobilized antibody was spotted onto a nitrocellulose membrane (Ge 
Healthcare, Piscataway, NJ, USA). On the same membrane an equal volume of multilayered nanoparticles 
without antibody immobilization was spotted as negative control. The samples were dried for few minutes 
at room temperature, washed with approximately 20 mL of phosphate-buffered saline (PBS) and visualized 
by ECL chemiluminescence assay (Merck Millipore, Darmstadt, Germany) using a UVItec system 
(Cambridge, UK). 
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Figure 3.2: schematic representation of LbL deposition on CaCO3 nanoparticles. 
 
3.2.8. BSA release from nanoparticles 
 
To investigate the release behaviour of BSA, 20 mg of both multilayered and non-multilayered CaCO3 
nanoparticles were resuspended in 550 mL of PBS at pH = 7.4 and maintained at 37 °C (incubator Heraeus, 
Hanau, Germany) until 72 hours were reached. At different time-points (2, 3, 4, 8, 24, 48, and 72 h), the 
samples were centrifuged with the same centrifuge described earlier and 350 mL of the supernatant was 
collected and replaced with an equal amount of fresh PBS. Released BSA was quantified by the 
bicinchoninic acid assay (Novagen, EMD Chemicals Inc., CA, USA) at 562 nm using a Biophotometer 
(Eppendorf, Hamburg, Germany). 
3.2.9. Mathematical models for BSA release from particles 
 
In order to evaluate if the release of BSA from multilayered and non-multilayered nanoparticles showed a 
different kinetic, different mathematical models were applied to the experimental data: 
1) first order model: when the release of the drug from the particles follows a first order kinetic, it can be 
expressed by the equation: 
𝑑𝐶𝐴𝑉
𝑑𝑡
= 𝑘𝐴 (𝐶𝐴𝑒 − 𝐶𝐴)   (Equation 3.3) 
 
where 𝐶𝐴𝑒 is the concentration at 𝑡 → ∞ and 𝐶𝐴 is the concentration at time 𝑡. 
Considering that:  𝑎 =  
𝐴
𝑉
, where 𝐴 is the surface of solid/liquid interface and 𝑉 is the volume of the medium 
used during the release studies, the equation will be: 
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𝑑𝐶𝐴
𝑑𝑡
= 𝑘 ∙ 𝑎 (𝐶𝐴𝑒 − 𝐶𝐴) 
 
𝑑𝐶𝐴
(𝐶𝐴𝑒 − 𝐶𝐴)
= 𝑘 ∙ 𝑎 𝑑𝑡 
 
−𝑑 (𝐶𝐴𝑒 − 𝐶𝐴)
(𝐶𝐴𝑒 − 𝐶𝐴)
= 𝑘 ∙ 𝑎 𝑑𝑡 
 
that has to be integrated considering the initial conditions: 
𝑡 = 0, 𝐶𝐴 = 0, 𝐶𝐴𝑒 − 𝐶𝐴 = 𝐶𝐴𝑒 
 
 
− ∫
𝑑 (𝐶𝐴𝑒 − 𝐶𝐴)
(𝐶𝐴𝑒 − 𝐶𝐴)
𝐶𝐴𝑒−𝐶𝐴
𝐶𝐴𝑒
= ∫ 𝑘 ∙ 𝑎 𝑑𝑡
𝑡
0
 
 
− ln (
𝐶𝐴𝑒 − 𝐶𝐴
𝐶𝐴𝑒
) = 𝑘 ∙ 𝑎 ∙ 𝑡 
 
𝐶𝐴𝑒 − 𝐶𝐴
𝐶𝐴𝑒
= exp(−𝑘 ∙ 𝑎 ∙ 𝑡) 
1 −
𝐶𝐴
𝐶𝐴𝑒
= exp(−𝑘 ∙ 𝑎 ∙ 𝑡) 
𝐶𝐴
𝐶𝐴𝑒
= (1 − exp( −𝑘 ∙ 𝑎 ∙ 𝑡)) 
 
𝐶𝐴 = 𝐶𝐴𝑒(1 − exp( −𝑘 ∙ 𝑎 ∙ 𝑡))   (Equation 3.4) 
 
As reported by (Dash et al., 2010), this model can be used to describe the water-soluble drug release in 
porous matrices. 
2) second order model: 
 
𝑑𝐶𝐴
𝑑𝑡
= 𝑘𝐼𝐼 (𝐶𝐴𝑒 − 𝐶𝐴)
2 
𝑑𝐶𝐴
𝑑𝑡
= 𝑘𝐼𝐼 (𝐶𝐴𝑒 − 𝐶𝐴)
2   
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𝑑𝐶𝐴
(𝐶𝐴𝑒 − 𝐶𝐴)2
= 𝑘𝐼𝐼 𝑑𝑡 
 
−𝑑(𝐶𝐴𝑒 − 𝐶𝐴)
(𝐶𝐴𝑒 − 𝐶𝐴)2
= 𝑘𝐼𝐼 𝑑𝑡 
 
∫ −(𝐶𝐴𝑒 − 𝐶𝐴)
−2 𝑑 (𝐶𝐴𝑒 − 𝐶𝐴) =  ∫ 𝑘𝐼𝐼 𝑑𝑡
𝑡
0
𝐶𝐴𝑒−𝐶𝐴
𝐶𝐴𝑒
 
 
[
1
(𝐶𝐴𝑒 − 𝐶𝐴)
−
1
𝐶𝐴𝑒
] = 𝑘𝐼𝐼 𝑡 
 
 
𝐶𝐴𝑒
𝐶𝐴𝑒
2−𝐶𝐴𝑒𝐶𝐴
= 𝑘𝐼𝐼 ∙ 𝑡    (Equation 3.5) 
 
 
 
3) Power law: a very simple, but comprehensive, semi-empirical equation to describe drug release from 
particles is the so-called power law: 
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛    (Equation 3.6) 
where 𝑀𝑡 and 𝑀∞ are the absolute cumulative amount of released drug at time 𝑡 and at infinite time, 
respectively, 𝑘 is a constant that takes into account structural and geometric properties of the studied system, 
and 𝑛 is a model parameter, indicative of the mechanism of drug release (Siepmann and Peppas, 2001). 
 
3.2.10. In vitro cytotoxicity assay 
 
To assess the maximum non-cytotoxic concentrations of multilayered and non-multilayered nanoparticles, 
the MTS assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega, USA) was performe 
(Biradar et al., 2011). Briefly, human endothelial EA. hy 926 cells were seeded into a flat-bottom 96 well-
plate with a density of 6 × 103 cells/well with complete medium and incubated at 37 °C with 5 % CO2. 
Nanoparticles were sterilized by exposing them to UV light for few hours. After 24 hours of cell incubation, 
multilayered and non-multilayered nanoparticles were added to the medium at different concentrations (40, 
80, 160, and 320 μg/mL). After appropriate time intervals (1, 2, 3, and 7 days), 20 mL of 3-(4,5-
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dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) was added 
directly to the culture wells and it was bioreduced by cells into formazan. After 1 hour of incubation, the 
amount of formazan was measured at 492 nm by a plate reader (Microplate Reader Tecan, Männedorf, 
Switzerland). All experiments were assessed in triplicate and results are expressed as a percentage of the 
control (100 %). 
3.2.11. Cell treatment, zimography for MMP-9 and ELISA for IL-6 
 
To demonstrate the absence of an inflammatory response due to the treatment with multilayered 
nanoparticles two inflammation-related markers were taken into consideration. One of them was Matrix 
MetalloProteinase 9 (MMP-9) and interleukin 6 (IL-6). EA. hy 926 endothelial cells (80 % confluence) 
were set in serum-free medium, pre-treated or not with multilayered nanoparticles at different 
concentrations (20, 40, 80, 160 μg/mL) for 1 hour and incubated. The cells considered as positive control 
were treated only with TNF-α (100 ng/mL) and the cells considered as negative control were not-treated. 
After 24 hours, conditionated media were collected, centrifuged at 13000 rpm for 5 minutes to remove cells 
and cellular debris and immediately frozen. To detect MMP-9, an equivalent protein amount (estimated by 
BCA method) from conditionated media were loaded on SDS-acrylamide gel cast with 0.28 % (w/v) 
gelatine (type A), run at 6/8°C in an ice bath, rinsed twice for 30 minutes in 2.5 % Triton-X-100, incubated 
for 12 hours at 37°C in 40 mM Tris-HCl, 0.2 M NaCl, 10 mM CaCl2, stained with 0.2 % Coomassie blue 
in 50 % methanol, 10 % acetic acid and destained in methanol:acetic acid. MMP-9 expression was evaluated 
by optical densitometry of gelatinolytic bands. IL-6 levels in the conditionated media were measured using 
an ELISA immunoassay kit according to the manufacturer's instructions (Bender MedSystems, Vienna, 
Austria). 
3.2.12. Hemocompatibility of CaCO3 nanoparticles 
 
The majority of protocols in the targeted therapy involves a direct contact between the vectors and the blood 
cells. An ideal drug delivery system has to be safe, not inducing the disruption of red cells and the activation 
of the immune system. For this reason, it is essential to study the hemocompatibility of drug incorporating 
vectors. In this research hemocompatibility of CaCO3 nanoparticles was studied in terms of hemolysis and 
blood coagulation. To verify if multilayered nanoparticles were able to induce a damage in the erythrocytes 
membranes, the whole blood collected from a healthy volunteer by venipuncture was transferred into 
ethylenediaminetetraacetic acid (EDTA) anticoagulant vacutainer tubes and immediately used for the 
analysis. The first step consisted in centrifuging 1.0 mL of whole blood at 200 × g for 5 minutes, with the 
aim of separating red blood cells from the serum. Then, erythrocytes were washed three times with NaCl 
NANODELIVERY SYSTEMS: CaCO3 nanoparticles                                                                MATERIALS AND METHODS 121 
 
  
0.9 % and diluted ten times. Freeze dried nanoparticles were resuspended in an isotonic solution obtaining 
different concentrations (20, 40, 80,160 μg/mL). One part of the diluted solution was mixed to four parts 
of the nanoparticles and they were incubated for 2 hours at 37°C. After that, samples were centrifuged and 
the supernatant was read at 540 nm with the same plate reader described above. To perform the coagulation 
assay, freeze dried nanoparticles were suspended in PBS at the different concentration mentioned above. 
One part of the nanoparticles suspension was mixed with ten parts of blood and they were incubated for 1 
hour. After the incubation time, they were centrifuged at 2500 × g for 10 minutes to induce the 
sedimentation of blood cells. 100 μL of the supernatant (plasma) was transferred in a water bath at 37°C 
and the same volume of CaCl2 (0.025 M) was added. Starting from this moment, the coagulation time was 
registered for each sample. 
3.2.13. Confocal microscopy analysis 
 
To study if the endothelial cells were able to internalize the multilayered nanoparticles, confocal 
microscopy analysis were performed. Briefly, EA. hy 926 were seeded onto glass microscopy slides and 
after 24 hours nanoparticles were added to the cell culture. After 18 hours of incubation, the cells were 
washed three times with PBS, fixed with paraformaldehyde (3 % in PBS) for 10 minutes, and washed twice 
in PBS. To prevent the autofluorescent signal from paraformaldehyde, the slides were treated with  NH4Cl 
(30 mM) for 10 minutes and then fetal bovine serum (10 % in PBS) to saturate all the aspecific sites. After 
that, cells were mounted with Mowiol medium on coverslips, and imaged using an Axiovert 200 m SP LSM 
500 META confocal laser-scanning microscope (Zeiss, Jena, Germany). 
 
ENCAPSULATION OF ANTIOXIDANTS IN CALCIUM CARBONATE PARTICLES 
 
This part of the research was partially done in collaboration with Doctor Marco Paini during his Ph.D.  
 
3.2.14. Preparation and engineering of calcium carbonate particles by Layer-by-
Layer self-assembling technique and release of polyphenols 
 
Calcium carbonate particles were prepared by mixing together calcium chloride (CaCl2) and sodium 
carbonate (Na2CO3). The chemical reaction was the following: 
CaCl2 + Na2CO3 → CaCO3 + 2NaCl 
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108 CaCO3 particles were coated using dextran and chitosan as layers. For each layer, particles were put in 
contact with the polysaccharide under continuous agitation for 20 minutes. After the deposition of the first 
layer, the suspension was centrifuged at 800 × g for 5 minutes to separate the excess of polysaccharide. The 
particles were then washed three times with Milli-Q water. The final shell architecture was 
(chitosan/dextran)4 or (chitosan/dextran)8. Then the core of the nanoparticles was dissolved using an EDTA 
solution at a concentration of 0.5 M at pH 7 followed by three washing steps in pure water. As a standard 
phenolic compounds, a mixture of tyrosol, caffeic, vanillic and p-coumaric acid was used. To prepare the 
loading solution, 2.5 mg were weighted per mL of pure water and of solutions with ethanol:water at 
different ratios (80:20, 65:35 and 50:50, v/v). Folin-Ciocalteu assay was performed to determine the 
concentration of these antioxidant in the loading solutions and it was expressed as mg of caffeic acid 
equivalent (CAE) per mL. Particles with four bilayers were incubated with 35 mL of the loading solution 
for 24 hours with continuous stirring at 300 rpm in dark conditions. Then, particles were centrifuged (800 
× g for 5), and the supernatant was collected and used to calculate the encapsulation efficiency according 
to the following equation: 
 
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑒𝑛𝑐𝑦 (%) =
𝑇𝑃𝐶−𝐶𝑠𝑢𝑝
𝑇𝑃𝐶
× 100     (Equation 3.7) 
 
where 𝑇𝑃𝐶 is total phenolic concentration of the initial solution  
𝐶𝑠𝑢𝑝 is the phenolic concentration after the loading step, both evaluated using Folin-Ciocalteu assay. 
Briefly, 0.5 mL of Folin-Ciocalteu reagent and 1.0 mL of Na2CO3 saturated solution were added to 4.8 mL 
of deionized water and 0.2 mL of diluted sample. The final volume was adjusted with deionized water and 
samples were incubated for 60 minutes in dark conditions. Then the absorbances of the samples were read 
using a UV-Vis spectrophotometer (Lambda 25, Perkin Elmer, Wellesley, USA) at 725 nm. A calibration 
curve using methanolic solutions of caffeic acid (10-1000 μg/mL) were performed and it is reported in the 
Figure 3.3. 
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Figure 3.3: calibration curve for the quantification of total polyphenol concentration. 
 
𝐴𝑏𝑠725 = 0.0023 × 𝑇𝑃    (R
2= 0.993)      (Equation 3.8) 
where 𝑇𝑃 is total polyphenol yield expressed as milligrams of CAE. 
With the aim of characterizing particles for pharmaceutical purposes, the release of encapsulated 
polyphenols was monitored during 240 minutes in total. Briefly, loaded particles were centrifuged at 2500 
rpm for 5 minutes and then resuspended in acidified deionized water. At 0, 15, 30, 45, 60, 120, 180, and 
240 minutes, 20 % of the solution was collected and it was analysed by Folin-Ciocalteu assay with the aim 
of quantifying the total phenolic compounds released. The concentration of polyphenols was calculated 
through spectrophotometric analysis and it was expressed as mgCAE per mL of acidified water. 
 
After loading of polyphenols, SEM images, using a Zeiss Supra microscope, were collected. 
3.2.15. Quartz crystals microbalance (QCM) with dissipation monitoring 
 
QCM-Z500 (KSV Instruments, Helsinki, Finland) with dissipation monitoring was used to study the build-
up of chitosan/dextran multilayers. This technique is widely described in literature (Kannisto et al., 2011) 
and is usefull to evaluate simultaneously the normalized resonant frequency (Δf) and energy dissipation 
shifts (ΔD). The quartz crystal with gold plateled polished electrodes is exited at its fundamental frequency 
(5 MHz) and at the 3rd, 5th, 7th, 9th and 11th overtones (12, 25, 35, 45 and 55 MHz). When a mass is deposited 
onto the surface of the crystal, there is a decrease of the oscillation frequency. If the deposited mass is 
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rigidly attached to the crystal, the decrease of the frequency is proportional to the mass and can be calculated 
using the Sauerbrey’s equation (Sauerbrey, 1959) (Equation 3.9 ) 
∆𝑓 = −
2𝑓0
2
𝐴√𝜌𝑞𝜇𝑞
 ∆𝑚         (Equation 3.9) 
in which Δf is the frequency change (Hz), f0 is the frequency of resonance, A is the crystal area, ρq and µq 
represent density and shear modulus of quartz, respectively, and Δm is the mass change. Working with 
viscoelastic materials, the deposited mass introduces a dissipative energy damping. The QCM-D response 
of a viscoelastic material can be modeled using a Voigt-based model (Voinova et al., 1998) and the 
thickness of added layers can be calculated. Before the experiments, the quartz crystal was washed with 
H2SO4 at 150 °C for 20 minutes followed by washing in pure water. A liquid chamber with a volume of 2.0 
mL was used during the experiments. Chitosan and dextran solutions were alternatively introduced into the 
chamber and left in contact with the quartz crystal. Unabsorbed polysaccharides were washed with pure 
water. Data analysis was done using the QCM Impedance Analysis software (KSV Instruments, version 
3.11). 
3.2.16. Statistical analysis 
 
All the experiments were performed at least in triplicate and the results were expressed as mean values and 
standard deviations. The influence of multilayered and non-multilayered CaCO3 nanoparticle concentration 
on endothelial cells growth was assessed by the analysis of variance (ANOVA) and the Tukey’s post hoc 
test. Multiple comparison of the mean values was performed by the least significant difference test at p < 
0.05. For data analysis, the Statistica v 8.0 software (StatSoft, Tulsa, OK, USA) was used. 
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3.3. RESULTS AND DISCUSSION 
3.3.1. Influence of PAANa concentration on CaCO3 particle size 
 
Drug carrier morphology is an important factor for the interaction of the nanoparticles with the target cells 
and therefore this aspect was investigated through SEM and TEM images analysis (Figure 3.4, 3.5, and 
3.6). With the aim of investigating the influence of PAANa concentration on the size of the native (without 
protein) and BSA-loaded CaCO3 nanoparticles, two different concentrations of the polymer (700 and 1900 
mg/mL) were studied. It was revealed that synthesized nanoparticles showed a homogeneous spherical 
geometry using PAANa at both concentrations. In the case of native particles, the final size was highly 
dependent on the PAANa concentration. Indeed, those obtained with a PAANa concentration of 700 mg/mL 
(Figure 3.4 A) were evidently larger (diameter of 802.93 ± 103.01 nm) than those produced with a 
concentration of 1900 mg/mL (diameter of 212.17 ± 60.56 nm) (Figure 3.4 B). In complete accordance 
with results reported by Lauth et al., (2014), an increase in the polymer concentration caused a reduction in 
the size of the resulting particles. The electrostatic interaction between carboxylic groups of PAANa and 
calcium cations in aqueous solution leads to the self-assembly of small complexes, known as complex 
coacervate droplets, that sequester from the aqueous polymer solution. The coacervate droplets are 
transformed into stable particle through the addition of carbonate ions in the solution. The size of native 
coacervates is strictly influenced by the polymer concentration. A higher concentration of PAANa causes 
an increase in the number of nucleation sites and inhibits the particle growth with a reduction of particle 
size. In fact, the electrostatic stabilization of coacervate droplets due to high net charge on the droplets 
surface makes them less prone to aggregation and growth keeping their nanosize (Lauth et al., 2014). BSA-
loaded nanoparticles were prepared with a final concentration of the protein equal to 550 mg/mL. The 
encapsulation of bovine serum albumin (BSA) did not significantly (p < 0.05) affect the circular shape at 
both concentrations of PAANa. In particular, the BSA-loaded particles made with 700 mg/mL (Figure 3.4 
C) and 1900 mg/mL of PAANa (Figure 3.4 D) showed the same trend reported for native nanoparticles. An 
increase in the polymer concentration caused a decrease in the particle diameter. Furthermore, BSA-loaded 
nanoparticles were smaller for the two studied polymer concentrations, 283.98 ± 78.65 and 151.90 ± 31.66 
nm for PAANa at 700 and 1900 mg/mL, respectively. Table 3.1 summarizes average diameters of native 
and BSA-loaded particles calculated by GNU Image Manipulation Program (GIMP). 
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Figure 3.4: representative SEM images of the nanoparticles obtained with different concentrations of 
PAANa: (A) native nanoparticles with 700 mg/mL, (B) native nanoparticles with 1900 mg/mL, (C) 
BSA-loaded nanoparticles with 700 mg/mL, and (D) BSA-loaded nanoparticles with 1900 mg/mL. 
 
A B 
D C 
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Table 3.1: average diameters of native and BSA-loaded nanoparticles obtained with 700 and 1900 μg/mL of PAANa. 
 
 
 
 
 
 
 
 
 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
In the case of multilayered nanoparticles, the mean diameter resulted to be higher. This fact was probably 
due to the presence of chitosan. In fact, it was a sticky polysaccharides and induce the fusion between single 
nanoparticles (Figure 3.5 B). 
 
 
Figure 3.5: representative SEM images of the nanoparticles: (A) native nanoparticles loaded with BSA (B) 
mutilayered nanoparticles with shell architecture (chitosan/ dextran)2/chitosan. White arrows indicate the fusion 
between the nanoparticles. 
Sample Native nanoparticles 
diameter 
(nm) 
BSA-loaded nanoparticles 
diameter 
(nm) 
PAANa  
(700 μg/mL) 
802.93 ± 103.01a 212.17 ± 60.56c 
PAANa  
(1900 μg/mL) 
283.98 ± 78.65b 151.90 ± 31.66d 
B A 
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Table 3.2: average diameters of native and nanoparticles with layers of chitosan/dextran. 
 
Samples Mean diameter (nm) 
BSA-loaded nanoparticles (native) 151.90 ± 31.66a 
Immuno-nanoparticles with chitosan/dextran 317.63 ± 50.94b 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
 
3.3.2. TEM observations of CaCO3 nanoparticles with layers of chitosan/dextran 
 
The TEM images (Figure 3.6) confirmed that both native nanoparticles (Figures 3.6 A and B) and BSA-
loaded nanoparticles (Figures 3.6 C and D) had a well-defined circular shape. Furthermore, it was 
confirmated the mean dimeter of the studied nanosystem. Both SEM and TEM images showed the low 
polydispersity of the samples. 
 
Figure 3.6: representative TEM images of (A and B) native nanoparticles and of (C and D) BSA-loaded 
nanoparticles obtained with different magnification. 
A 
D C 
B 
200 nm 
200 nm 
200 nm 
200 nm 
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3.3.3. BSA entrapment efficiency and BSA loading 
 
The entrapment efficiency and loading of a protein into a nanosized system are two important parameters 
to consider when working in the field of drug delivery. To evaluate the amount of BSA encapsulated into 
CaCO3 nanoparticles, BSA entrapment efficiency and loading were calculated. In accordance with Lauth 
et al., (2014) a low entrapment efficiency of BSA (9.61 ± 0.75 %) was probably due to the electrostatic 
repulsion between PAANa and BSA, since both of them are negatively charged at the neutral pH used 
during the synthesis process. For all the experiments, 2.24 mg of BSA were encapsulated per 20 mg of 
CaCO3 nanoparticles, resulting in a BSA loading of 11.20 ± 0.87 %. 
3.3.4. Detection of chemiluminescent signal from anti-rabbit IgG attached to the 
particles 
 
Chemiluminescence is the light produced by a chemical reaction. The enzyme horseradish peroxidase 
(HRP) catalyzes luminol oxidation by hydrogen peroxide and produces a high and durable 
chemiluminescence (Díaz et al., 1998) Driving molecules, such as antibodies, are an essential component 
of targeted therapy, since they are able to address the functionalized particles exactly where the bioactive 
compounds should be released. In our work, we attached HRP linked IgG at the outer layer of the capsules. 
Figure 3.7 shows the presence or absence of a chemiluminescent signal after the spotting of the particles 
onto a nitrocellulose membrane. The chemiluminescent signal was noticed only for nanoparticles 
functionalized with HRP-linked IgG (Figure 3.7 a). Indeed, the clear signal confirmed the immobilization 
of antibodies on the surface of the particles. No signal was detected in the case of nanoparticles where no 
antibodies were added during the sample preparation (Figure 3.7 b). This sample has to be considered as a 
good control of the experiment. 
 
Figure 3.7: chemiluminescent signal from (a) nanoparticles functionalized with HRP-linked IgG and (b) 
nanoparticles without HRP-linked IgG (control). 
 
a) b)
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3.3.5. Release profile of BSA from particles 
 
Close to the pathological tissue/organ, two different types of therapeutic agents release in the disease site 
have been described: instant release (burst release) and slow release over a protracted period (sustained 
release). The former is needed when the capsules are addressed to intracellular uptake (e.g. gene 
transfection and inhibition of intracellular pathways), whereas the latter is preferred when they should 
remain extracellular and/or should have constant levels of drug release during time. A sustained release can 
be achieved by slow diffusion of the molecules through an intact capsule wall, by gradual release of 
therapeutic molecules through a slowly degrading capsule wall, or through covered nanoparticles with 
polymeric films (Park et al., 2005; Wood et al., 2005). The cumulative amount of BSA released from 
multilayered and non-multilayered nanoparticles over a time span of 72 hours is shown in Figure 3.8. Non-
multilayered nanoparticles exhibited a faster release compared to the multilayered ones. Indeed, with non-
multilayered particles 99.33 ± 4.97 % of the total protein (2241.06 ± 175.86 mg) was released in 2 hours 
and it remained stable until 72 hours, showing a burst release. It could be assumed that, in this case, BSA 
is encapsulated close to the surface of the particles and this fact avoids a full dissociation of the carrier. 
Burst release of the protein could be expected working with inorganic porous carriers such as CaCO3. In 
the case of multilayered constructs, the cumulative curve was considerably slower and at the end of the 
experiment the BSA released was 77.34 ± 1.21 % of the entire encapsulated protein (20.17 ± 0.90 mg). The 
more sustained protein release profile over time from LbL-based nanoparticles could be explained by the 
fact that the presence of different thin films delayed BSA release. In conclusion, the existence of different 
layers of chitosan/dextran was essential to avoid BSA burst release. 
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Figure 3.8: release profile of BSA from non-multilayered (♦) and multilayered (▲) nanoparticles. Dashed lines 
refer to second order model applied to experimental data. ( ) non-multilayered nanoparticles, ( ) 
multilayered nanoparticles. 
 
Table 3.3: kinetic parameters of first, second order, and power law model for BSA release from native and 
multilayered nanoparticles. 𝑘𝐼 refers to first order model, 𝑘𝐼𝐼 to the second order model, and 𝑘 to power law. 
 
 
Model Sample Model parameters R2 
First order 
model 
native particles 𝑘𝐼 = 0.3957 0.8508 
multilayered particles 𝑘𝐼 = 0.1176 0.9551 
Second order 
model 
native particles 𝑘𝐼𝐼 = 3.92 × 10
-5 0.9998 
multilayered particles 𝑘𝐼𝐼 = 1.65 × 10
-4 0.9941 
Power law 
model 
native particles 
𝑘 = 26796 
𝑛 = 0.072 
0.7883 
multilayered particles 
𝑘 = 419 
𝑛 = 0.310 
0.9593 
  
 
  
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
C
u
m
u
la
ti
v
e 
re
le
a
se
 o
f 
B
S
A
 (
%
)
Time (hours)
NANODELIVERY SYSTEMS: CaCO3 nanoparticles                                                                 RESULTS AND DISCUSSION 132 
 
  
Different mathematical models, as described in Section 3.2.9, were applied to experimental data to confirm 
a different behavior in delivery BSA comparing native and multilayered nanoparticles. Among the studied 
models, the best fitting was described applying the second order model. It presented a R2 equal to 0.9941 
and 0.9998 for multilayered and native particles, respectively (Table 3.3). Indeed, its k values, (𝒌𝑰𝑰), 
highlighted that there was a different trend in releasing BSA. The 𝒌𝑰𝑰 value calculated for the native 
particles showed a more accelerated release of the drug in comparison with the multilayered counterpart. 
Experimentally, it was obtained a burst release working with native nanoparticles and a more sustained 
release working with multilayered particles. In particular, the presence of an architecture of (chitosan/ 
dextran)2/chitosan delayed significantly the release of the encapsulated protein from the multilayered 
nanoparticles. Figure 3.8 shows the experimental data and the second order models fitting. The different 
behavior in releasing BSA from the two nanosystems was found even applying a first order model. Power 
law model has to be considered the worst applied mathematical model due to its R2 values. 
 
3.3.6. Cell toxicity using CaCO3 nanoparticles with layers of chitosan/dextran 
 
A possible cytotoxicity of multilayered and non-multilayered CaCO3 nanoparticles was evaluated under in 
vitro conditions, taking into account the effect of nanoparticles on the proliferation of EA. hy926 
endothelial cells, through the MTS assay. Untreated cells, as well as cells treated with different 
concentrations of CaCO3 nanoparticles (40, 80, 160, and 320 μg/mL) for 1, 2, 3 and 7 days, were subjected 
to the MTS assay for cell viability determination. Figure 4 shows the results obtained, expressed as a 
percentage value with respect to the control. No statistically significant differences (p < 0.05) were noticed 
between the control and the cells incubated with 40, 80, and 160 μg/mL of non-multilayered nanoparticles. 
It was possible to highlight that the higher concentration (320 μg/mL) induced a partial cytotoxicity already 
after 2 days of incubation and cell viability remained constant until 7 days (Figure 3.9 A). Consequently, 
these results indicated that the maximum non-cytotoxic concentration of non-multilayered nanoparticles 
amounted to 160 μg/mL. Taking into account data from multilayered nanoparticle experiments, we found 
that no relevant differences (p < 0.05) with the lower concentrations (40 and 80 μg/mL) with respect to the 
control were noticed. Even in the case of cells treated with multilayered nanoparticles, there was a decrease 
of cell viability after 2 days, after which it remained stable until the end of the experiment. Furthermore, 
considering cells treated with the higher concentrations (320 μg/mL), it was noticed that cell viability 
started to reduce, as in the case of treatment with 160 μg/mL, after 2 days of incubation and drastically 
decreased in a time-dependent manner (Figure 3.9 B). This cell toxicity can be understood referring to 
external factor, such as the higher molecular weight of multilayered capsules in comparison to the non-
multilayered ones. As a consequence, sedimentation of capsules on the bottom of Petri dishes during cell 
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culture could determine a competition for space between cells and nanoparticles. This factor could be the 
one responsible for nanoparticle toxicity, as reported in previous studies (An et al., 2009; Habibi et al., 
2011;  Liu et al., 2005). 
 
 
 
 
 
 
Figure 3.9: cell viability of CaCO3 (A) non-multilayered and (B) multilayered with chitosan/dextran 
nanoparticles by MTS assay.  control,  40 μg/mL,  80 μg/mL,  160 μg/mL,  320 μg/mL. 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison tes). 
 
 
0
20
40
60
80
100
120
140
160
1 2 3 7
C
e
ll
 v
ia
b
il
it
y
 (
%
)
Time (days)
aa
a a
b
a, b
a
b
a, b
a, b
A)
a
a
a
a
a, c
a
a
a
b, c
b
0
20
40
60
80
100
120
140
160
1 2 3 7
C
el
l 
v
ia
b
il
it
y
 (
%
)
Time (days)
a
a
a
a
a
a
a
b
b
b
b
b
c
c
B)
a
a, b
a, b
a, b a, c
b, c
NANODELIVERY SYSTEMS: CaCO3 nanoparticles                                                                 RESULTS AND DISCUSSION 134 
 
  
 
3.3.7. SEM analysis of CaCO3 nanoparticles with layers of poly-L-arginine/dextran 
 
SEM images revealed the presence of fully mineralized CaCO3 nanoparticles with a well-defined round 
shape. No differences were observed comparing immuno-nanoparticles and native nanoparticles. The 
presence of multi-layers did not interfere with the entire 3D structure of the nanoparticles. Table shows the 
mean diameter of native nanoparticles, particles with a shell architecture (chitosan/ dextran)2/chitosan, and 
particles with a shell architecture (poly-L-arginine/ dextran)2/poly-L-arginine. 
 
Figure 3.10: representative SEM micrographs of the nanoparticles: (A) native nanoparticles, (B) nanoparticles 
with shell architecture (poly-L-arginine /dextran)2/ poly-L-arginine. 
 
Table 3.4: average diameters of native and nanoparticles with layers of poly-L-arginine/dextran. 
Samples Mean diameter (nm) 
BSA-loaded nanoparticles (native) 151.90 ± 31.66a 
Immuno-nanoparticles with poly-L-arginine/dextran 194.24 ± 41.99a 
 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
A B 
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3.3.8. Cell viability using CaCO3 nanoparticles with layers of poly-L-
arginine/dextran 
 
One of the most important parameter to take into account when working with biomaterials and 
nanomaterials is to demonstrate if they are biocompatible when are in contact with the targeted cells. In this 
case, endothelial cells will be addressed by nanoparticles (Ferrari et al., 2017). As a consequence, the 
biocompatibility was assessed until three days and for any time no differences were noticed between the 
control (cells without nanoparticles) and the four different concentration tested (Figure 3.11). 
 
 
Figure 3.11: cell viability of CaCO3 nanoparticles with layers of poly-L-arginine/dextran by MTS assay.  
control,  40 μg/mL,  80 μg/mL,  160 μg/mL. 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
 
3.3.9. Expression of MMP-9 and IL-6 after nanoparticles treatment 
 
Exogenous materials could be provoke a possible inflammation response when injected in the body. To 
verify if synthetized CaCO3 nanoparticles could be able to induce an inflammatory response, MMP-9 and 
IL-6 expression was evaluated after 24 hours of incubation with endothelial cells. Figure 3.12 shows an 
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induction of MMP-9 by TNF α and no expression was registered treating cells with different nanoparticles 
concentration (20, 40, 80 and 160 μg/mL). No differences regarding MMP-2 expression were noticed. 
 
 
Figure 3.12: gel zymography of MMP-2 and MMP-9 of endothelial cells treated with different concentrations 
of immunonanoparticles (20, 40, 80 and 160 μg/mL). NT: not-treated; TNF-α: treated with tumor necrosis factor-
α. 
 
 
 
 
Figure 3.13: relative expression of IL-6 in endothelial cells treated with different concentrations of 
immunonanoparticles (20, 40, 80 and 160 μg/mL). NT: not-treated; TNF-α: treated with tumor necrosis factor-
α. Results are mean of three measurements ± SD. 
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During inflammation different mediators are released by cells to induce recruitment of leukocytes from 
blood, their rolling and, finally, their diapedesis in the inflamed tissue. Interleukins are a very large group 
of molecules involved in the immune system and in the inflammation response. Among them, interleukin 
6 (IL-6) is one of the molecule responsible in inducing the expression of acute phase proteins (Gabay, 
2006). TNF-α, acting as a pro-inflammatory cytokine, causes a high expression of IL-6 in endothelial cells. 
The treatment of these cells with the multilayered nanoparticles di not provoke the expression of IL-6 in 
the culture. In any case, even testing the highest concentration of particles (160 μg/mL), there was not a 
higher expression of IL-6 in comparison with the control (NT) (Figure 3.13).  
 
3.3.10. Hemocompatibility of nanoparticles 
 
Being an injectable product, a possible hemolysis of the nanoparticles should be considered as an essential 
factor to validate them biologically. When blood contacts solid material surface, such as inorganic 
nanocarriers, many physiological reactions such as thrombus formation and red blood cells disruption, can 
happen. Therefore, hemocompatibility represents one of the most influent parameters to take into 
consideration working with drug delivery systems (Mayer et al., 2009; Thasneem et al., 2011; Bender et 
al., 2012; Angelova &Yordanov, 2017). In this work, the hemocompatibility of electrospun CaCO3 
nanoparticles was evaluated by hemolysis. In general, materials are classified in non highly 
hemocompatible (< 5 % hemolysis), hemocompatible (within 10 % hemolysis) and non-hemocompatible 
(> 20 % hemolysis) (Pal & Pal, 2006). For all the tested concentrations, a hemolysis < 1 was reported 
(Figure 3.14). The maximum value was reached treating blood with 80 μg/mL but no dose-dependent 
behaviour was reported.  
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Figure 3.14: (A) hemolysis percentage and (B) clotting time of fresh blood after incubation with different 
concentration of nanoparticles. Results are mean of three measurements ± SD. PBS: phosphate-buffered saline. 
 
3.3.11. Confocal microscopy analysis 
 
To qualitatively evaluate the up-take of the nanoparticles by endothelial cells, fluorescence microscopy 
analysis were performed. The fluorescence images of endothelial cells after culture in the media containing 
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the CaCO3 nanoparticles modified with an IgG linked to a fluorophore are shown in Figure 3.15. Confocal 
microscopy of the cells exposed to the multilayered nanoparticles demonstrated their presence in the 
cytoplasm of the cells. The capability of endothelial cells to internalize CaCO3 multilayered nanoparticles, 
could be useful in drug delivery protocol. In particular, it represents an advantage when the drug 
encapsulated is represented by a molecule acting on an intracellular molecule. In this case the potential 
inhibitor of a cytosolic or nuclear molecule could be protect into the nanoparticles before be internalized 
from the cells. Once into the cell, it could play its therapeutic role. In Figure 3.15, are reported confocal 
microscopy images before and after washing. The washing step was necessary to remove the particles that 
were non-specifically in contact with the endothelial cells. 
 
Figure 3.15: fluorescence photographs of phagocytized CaCO3 nanoparticles (A) before and (B) after washing. 
White arrows indicate phagocytized nanoparticles. 
 
3.3.12. Conclusions 
 
The aim of this part of the work was to define a simple protocol for the synthesis of a delivery nanosystem 
loaded with BSA, as a model protein to be employed directly where the an ideal therapeutic proteins is 
needed. In this study, CaCO3 protein-loaded nanoparticles were synthesized via combination of complex 
coacervation and mineralization. The synthesis process started with the complexation between Ca2+ ions, 
PAANa, and BSA within coacervates droplets, whose size can be tuned by the polymer concentration. In 
particular, we found that the higher the PAANa concentration, the smaller the diameter of the obtained 
nanoparticles, allowing us to fabricate particles of 151.9 nm in diameter with 1900 mg/mL of PAANa. 
10 μm 
A B 
10 μm 
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CaCO3 particles proved to be a good template for LbL electrostatic self-assembling technique and 
multilayered nanoparticles with shell architecture (chitosan/ dextran)2/chitosan were fabricated. BSA 
release from multilayered and non-multilayered nanoparticles was studied. For the former we described a 
typical burst release behavior while for the latter we noticed a sustained release during time. The 
biocompatibility data suggest that non-multilayered particles were well tolerated in comparison to the 
multilayered ones. In more details, the maximum concentration of non-multilayered nanoparticles that 
could be employed is twice the concentration of multilayered particles. Based on these results, we can 
conclude that the present work can be considered a very simple, cost effective, and easy scale up method 
to synthesize and to functionalize CaCO3 nanoparticles with natural polymeric multilayers and antibodies. 
In order to increase the biocompatibility of multilayered nanoparticles and with the aim of preventing the 
fusion phenomenon between nanoparticles, chitosan was replaced with poly-L-arginine. The fully 
mineralized CaCO3 nanoparticles, even in this case, exhibited spherical morphology and were successfully 
loaded with BSA. Antibodies were successfully immobilized on the surface of multi-layered nanoparticles 
These nanocarriers resulted to be biocompatible and hemocompatible at all the tested concentrations (20, 
40, 80 and 160 μg/mL). No inflammatory response, in terms of MMP-9 and IL-6 was noticed.  
 
This work was partially published as: “Engineered CaCO3 nanoparticles with targeting activity: a simple 
approach for a vascular intended drug delivery system”. The Canadian Journal of Chemical Engineering 
95: 1683-1689, 2017 by Ferrari P.F., Aliakbarian B., Zattera E., Pastorino L., Palombo D., Perego P., 
partially presented as: “Engineered CaCO3 nanoparticles with targeting activity” at Convegno GRICU 
2016, Anacapri, Italy by Ferrari P.F., Aliakbarian B., Zattera E., Pastorino L., Palombo D., Perego P., and 
partially presented as: “An innovative drug delivery system for atherosclerosis” at the 66th international 
Congress of the European Society of Cardiovascular and Endovascular Surgery (ESCVS) 2017, 
Thessaloniki, Greece, by Ferrari P.F., Aliakbarian B., Palombo D., Perego P. It has been awarded the 
“Young Vascular Award Session” as best oral presentation.   
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ENCAPSULATION OF POLYPHENOLS IN CaCO3 PARTICLES 
This work was the main topic of the Ph.D. thesis of Doctor Marco Paini and it was done in collaboration 
with him. 
 
Following the same protocol reported for CaCO3 nanoparticles encapsulating albumin, particles with 
chitosan/dextran layers were synthetized with the aim of entrapping polyphenols. In details, nanostructured 
capsules were loaded with a mixture of tyrosol, caffeic, vanillic and p-coumaric acid. To optimize the 
loading of these four compounds different ethanol:water ratios for the loading solution were studied. 
(dextran/chitosan)4 particles were loaded with different loading solutions in which were dissolved the four 
polyphenols above mentioned, increasing the ethanolic fraction. In fact, it is well known that the solubility 
of the majority of polyphenols is higher in ethanol in respect with water. (Paini et al., 2016).  The total 
polyphenol concentration of the different loading solution was calculate as reported in Section 3.2.14 and 
the quantity of the polyphenols entrapped into the particles was evaluated after 120 minutes of incubation. 
 
Table 3.5: total polyphenol concentrations (TPCs, expressed as mgCAE/mL) and amount of polyphenols (in mgCAE) 
released from nanocapsules (11.3 µL) prepared in solutions with different ethanol:water ratio after 120 min of 
incubation in water. 
 
Ethanol:water ratio 
(v/v) 
TPC 
(mgCAE/mL) 
Polyphenols released 
(mgCAE) 
0:100 5.2 ± 0.9 a 8.2 ± 0.1 a 
20:80 6.6 ± 0.2 a,b 8.6 ± 0.1 b 
35:65 7.9 ± 0.5 b 11.5 ± 0.7 b 
50:50 10.4 ± 0.2 c 7.8 ± 1.4 c 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
As it is shown in Table 3.5, a complete dissolution of the polyphenols mixture was obtain working with 
ethanol:water (50:50, v/v) with 10.4 ± 0.2 mgCAE/mL (approximately equal to initial theoretical TPC). It 
was noticed that an increase in the solubility of polyphenols induced a larger amount of loaded compounds 
in the particles. A further increase higher than 50 % of ethanol resulted in a decrease in the quantity of 
released polyphenols. Probably, the presence of a high volume of ethanol induced the formation of large 
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defect in the shell of the particles. The ethanol:water (35:65, v/v) was selected for all the subsequent analysis 
because of it maximized the solubility of polyphenols without affecting the structural stability of the 
particles. Figure 3.16 shows a representative image of one polyphenol particles with shell architecture 
(dextran/chitosan)4. 
 
Figure 3.16: representative SEM micrographs of a (dextran/chitosan)4 particle loaded with a polyphenolic 
solution made of ethanol:water (35:65, v/v). 
 
3.3.13. Entrapment efficiency 
 
The encapsulation efficiency of the nanoparticles loaded in pure water or in ethanol:water (35:65, v/v) was 
calculated referring to the equation 3.7. In the case of incubation with polyphenols in water, entrapment 
efficiency was 29.6 ± 2.0 %, whereas in the case of incubation with polyphenols in ethanol:water (35:65. 
v/v), it increased significantly (p < 0.05) to 42.0 ± 0.6 %.  This augmented entrapment efficiency could be 
explained considering the higher solubility of polyphenols in ethanol and the stability of the polysaccharide 
shell working at this percentage of ethanol. 
 
 
 
 
 
NANODELIVERY SYSTEMS: CaCO3 nanoparticles                                                                 RESULTS AND DISCUSSION 143 
 
  
3.3.14. Release of polyphenols from CaCO3 particles 
 
 
Figure 3.17: release profile of polyphenols from CaCO3 particles prepared with ethanol:water (35:65) 
(♦) and water (▲) loading solution. 
 
Figure 3.17 shows the release of polyphenols from CaCO3 particles prepared using two different 
loading solutions, water and ethanol: water (35:65, v/v). Initially, at t0 the release of polyphenols 
was not zero. Probably, it was due to the presence of polyphenols on the surface of the particles. 
After 15 minutes, the release was more evident in the case of polyphenols loaded with 
ethanol:water (35:65, v/v) in comparison with particles prepared in water. This behavior is to 
address to a higher solubility of polyphenols in ethanol instead of in water. The synthesis of CaCO3 
particles starting from a loading solution of ethanol:water (35:65, v/v), in fact, ensured a better 
dissolution of polyphenols in the mixture.  
3.3.15. Quartz crystal microbalance with dissipation monitoring 
 
The alternated deposition of chitosan and dextran layers was studied using QCM-D. The constitution of 
(chitosan/dextran)4 is reported in Figure 3.18. 
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Figure 3.18: (a) plot of surface coverage as a function of layers during the alternated adsorption of chitosan and 
dextran; (b) dissipation changes measured by QCM-D during the build-up of a (chitosan/dextran)4 multilayer. 
The data for the 3rd, 5th and 7th overtones are presented. 
 
An increase in surface coverage (Figure 3.18 a) with each adsorption step indicated that a mass of the 
polysaccharide is deposed. ΔD was almost constant and it showed the strong interaction among the different 
layers. The harmonics of chitosan were well separated, while in the case of dextran they were superimpose. 
This behavior showed that chitosan had more viscoelastic properties than dextran. It was possible to 
calculate approximately the thickness of chitosan/dextran bilayer and it was 9 nm. 
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3.3.16. Conclusions 
 
Nanostructured particles were successfully synthetized using CaCO3 as template. The self-assembly Layer-
by-Layer technique, using chitosan and dextran sulfate as polycation and polyanion, respectively allow us 
to obtain nanostructured particles. These particles were loaded with four different polyphenols with a good 
entrapment efficiency. QCM-D was carried out to characterize step-by-step the deposition of the polymers 
onto the surface of the particles. Considering all these data together, the polysaccharides capsules could be 
used to entrap a mixture of low water-soluble molecules, like polyphenols, in order to have an innovative 
drug delivery system. 
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         CHAPTER IV 
 
4. DEVELOPMENT OF NANODELIVERY SYSTEMS: RAPESEED 
LECITHIN NANOLIPOSOMES 
4.1. INTRODUCTION 
Bioactive compounds, like proteins and polyphenols, show a high susceptibility to environmental 
conditions (e.g. temperature, light, oxidation etc.). To protect these molecules to such adverse 
conditions and to increase, at the same time, their bioavailability, different encapsulation techniques 
are described in literature. Nowadays the most widespread encapsulation techniques are those 
addressed to liposome synthesis. Liposomes are self-organizing colloidal particles made of one or more 
lipid bilayer membranes that are able to entrap molecules in a confined core (Paini et al., 2015 B). The 
presence of amphiphilic membranes makes it possible to encapsulate both hydrophilic and hydrophobic 
compounds inside liposomes. One of the well-known group of molecules involved in the synthesis of 
liposome membranes is lecithin. It is extracted and purified from various natural sources, both from 
animal and vegetal kingdom. As reported by Arab Tehrany et al. (2012), lecithin from rapeseed is 
extremely rich in polyunsaturated fatty acids (PUFAs) which are considered as essential for healthy 
(Coonrod et al., 2008). This is the reason why lecithin was selected as source of phospholipids. Lecithin 
is able to self-organize in liposomes when it is sonicated in aqueous solutions. Liposomes are used as 
an excellent tool for increasing the bioavailability of extremely sensitive molecules, like proteins 
(Chang & Yeh, 2012) and of molecules poorly soluble in water (Kadri et al., 2016), as quercetin. 
Different techniques were described over the last years to synthetize small unilamellar vesicles: 
supercritical reverse phase evaporation (Otake et al., 2006), solvent injection (Schubert & Müller-
Goymann, 2003), detergent dialysis (Alpes et al., 1986), sonication (Kisel et al., 2001), French press 
(Barenholzt et al., 1979), homogenization and membrane extrusion (Pupo et al., 2005). Among these, 
due to its cost-effectiveness, high reproducibility, possibility to be scaled up and its easy to handle 
properties, sonication is one of the most prevalent technique for liposome synthesis. In this part of the 
thesis, data about encapsulation of bovine serum albumin (BSA) and quercetin (Q) in liposomes 
through sonication are presented 
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4.2. MATERIALS AND METHODS 
This section describes the materials and methods used to synthetize and to characterize the rapeseed lecithin 
nanoliposomes loaded with a model protein, bovine serum albumin (BSA), and a model antioxidant, 
quercetin (Q). This part of the research was done in collaboration with Professor Elmira Arab-Tehrany 
during the research period at University of Nancy, France. For this reason, a lot of experiments are still 
ongoing. 
4.2.1. Chemicals 
 
Q, BSA, absolute ethanol, methanol, formic acid (HPLC grade), and phosphate-buffered saline (PBS, pH 
= 7.4) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Lecithin was extracted from rapeseed 
as described by Linder et al. (2002). Water used for the preparation of solutions and washing operations 
was purified by ELGA system (High Wycombe, UK). 
 
4.2.2. Cell mediums and reagents 
 
Two different types of cells were used for the experimentation, human mesenchymal stem cells (hMSC), 
and human fibroblast. hMSC were collected from Wharton’s jelly (WJ) from connective tissue of human 
umbilical cord. In this case, umbilical cords were used after mother information and agreement, applying 
the guidelines ratified by the University Hospital Center of Nancy (agreement TCG/11/R11). Cells were 
collected after enzymatic digestion of the WJ using a collagenase solution at 1 mg/mL (Sigma-Aldrich, 
France) during 18 hours at 37°C. hMSC and human fibroblast were cultivated using DMEM (Gibco, 
France) after the addition of 10 % (v/v) of fetal bovine serum, 2 mM of L-glutamine, 2.5 g/L of fungizone®, 
100 IU/mL of penicillin and 100 μg/mL of streptomycin. Cells were collected and grown in an incubator 
at 37°C and 5 % CO2 and culture medium was changed every 3 days of cultivation. 
 
4.2.3. Synthesis of BSA-loaded liposomes 
 
At first, 50 mL of ultrapure water with two different concentrations of BSA, 0.5 and 2.0 mg/mL were 
prepared. 49 mL of this solution were added to 1.0 g of rapeseed lecithin in order to obtain a solution of 1 
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% (w/v). The suspension was mixed for at least 5 hours under magnetic stirring (600 rpm) in a nitrogen 
atmosphere and in dark conditions. Then, the mixture was subjected to sonication (Sonicator Vibra cell 
75115, 500 watt, Bioblock Scientific Co.) at room temperature (25 ± 2°C) at 40 kHz for 8 minutes (1 s on 
and 1 s off) to obtain a homogeneous solution. BSA-loaded nanoliposomes were stored at 4°C in the dark 
before the analysis. 
4.2.4. Measurement of liposome size, ζ-potential, and electrophoretic mobility 
 
The size distribution, the zeta potential, and the electrophoretic mobility of the liposome suspensions were 
measured by dynamic light scattering (DLS), using a Malvern Zetasizer Nano ZS (Malvern Instrument Ltd., 
UK). The apparatus consisted of a 4 mW He/Ne laser emitting at 633 nm, a measurement cell, a 
photomultiplier and a correlator. In order to prevent false results due to multiple light scattering in the small 
interparticle space between liposomes, dilution was necessary (Sood et al., 2014). As a result of that, before 
each analysis, samples were diluted in ultrapure water (1:400) and samples were put in a standard capillary 
electrophoresis cell. Size, zeta-potential, and electrophoretic mobility measurements were carried out at 
25°C with a fixed scattering angle of 173°, refractive index equal to 1.471 and absorbance equal to 0.01. 
4.2.5. Entrapment efficiency of BSA in liposomes 
 
To calculate the amount of BSA encapsulated in the nanoliposomes, an aliquot of the suspension was 
centrifuged at 10.000 rpm for 15 minutes at 4°C with an ultracentrifuge (Ultracentrifuge WX Ultra 80, 
Thermo Fisher Scientific, Waltham, MA, USA). Then, the supernatant was separated from the 
nanoliposomes and the concentration of untrapped BSA was measured through BCA assay, as reported 
previously. The entrapment efficiency was calculated as described in the case of CaCO3 nanoparticles 
(Section 3.2.6). 
 
4.2.6. Synthesis of quercetin-loaded liposomes 
 
At first, 10 mL of a methanolic solution of quercetin (1.0 mg/mL) was added to 1.0 g of rapeseed lecithin 
in a completely dried round bottomed flasks. After rotary evaporation of methanol, the obtained thin 
homogeneous lipid film on the wall of the round bottomed flasks was hydrated with 49 mL of ultrapure 
water to obtain a solution of 1 % (w/v). The suspension was before mixed and later sonicated, as described 
before for BSA-loaded nanoliposomes. 
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Figure 4.1: schematic representation of the synthesis of quercetin-loaded nanoliposomes. 
 
4.2.7. Nanoparticle tracking analysis 
 
Suspension made of liposomes were analysed by a NanoSight LM 10 instrument (NanoSight, Salisbury, 
UK). The instrument was equipped with a monochromatic laser beam at 405 nm and a sCMOS camera. 
Before the analysis, samples were diluted (1:4000) and for each sample, three videos of 60 s in duration 
were taken with a number of frames between 1516 and 1939, at 22°C. The liposomes movements were 
analysed by NTA software (version 2.1, Nanosight). The NTA software identified at first the particles and 
then track each particle on a frame-by-frame basis and its Brownian movement is tracked and measured 
from frame to frame. The two dimensional Stokes-Einstein equation is used by the software to calculate 
particle size, taking into account the speed of the particles themselves. NTA is able to analyze particles 
with a mean diameter between 10 and 2000 nm. NTA post-acquisition settings were optimized and kept 
constant among samples and each video was then analysed to give the mean vesicle size together with an 
estimation of the concentration . 
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4.2.8. Stability of quercetin-loaded liposomes 
 
The quercetin-loaded and control (empty) nanoliposomes were stored in drying rooms at 4, 20, and 37°C 
for 2 months. Mean particle size, polydispersity index (PDI) and zeta-potential of all formulations were 
examined with DLS after 2, 5, 7, 14, 28 and 60 days.  
4.2.9. Entrapment efficiency of quercetin in liposomes 
 
The amount of quercetin encapsulated in the nanoliposomes was determined by centrifuging the suspension 
at 10.000 rpm for 15 minutes at 4°C with the same ultracentrifuge described above. After centrifugation, 
the supernatant was collected and freeze dried. The freeze-dried supernatant was resuspended in pure 
methanol. The concentration of quercetin was determined by a reversed-phase HPLC system (Shimadzu, 
Kyoto, Japan) equipped with a quaternary pump (LC-20AD), an auto-injector (SIL-10AD), an UV-Vis 
photodiode array detector, an AlltimaTM C18 column (5μm, 150 × 2.1 mm) (GRACE, Deerfield, IL, USA) 
at 30°C and data were analyzed with Labsolution data software. Samples were analyzed using ultrapure 
water:formic acid (99.5:0.5, v/v) as mobile phase A and acetonitrile:formic acid (99.9:0.1, v/v) as mobile 
phase B. Solvent gradient changed during the analysis according to the following conditions: from 10 to 80 
%  B in 20 minutes, from 80 to 100 % B in 10 seconds, isocratic at 100 % B  for 4.50 minutes, from 100 to 
10 % B in 10 seconds and isocratic at 10 % B for 6.50 minutes. A flow rate of 0.2 mL/min, an injection 
volume of sample of 10 μL and a detection from 190 to 800 nm was used. 
 
 
Figure 4.2: gradient for solvent B (0.1 % of formic acid in acetonitrile) during HPLC-DAD analysis of quercetin. 
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The concentration of quercetin was calculated by integration of peaks at 380 nm after approximatively 
14.60 minutes (retention time) and using the calibration curve reported below: 
 
𝐴𝑟𝑒𝑎 = 16.51 × 107 × 𝐶  (R2= 0.997)     (Equation 4.1) 
 
  
Figure 4.3: calibration curve for the quantification of quercetin by HPLC. 
 
The entrapment efficiency was calculated by the equation: 
 
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =  
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔−𝑓𝑟𝑒𝑒 𝑑𝑟𝑢𝑔
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔
 × 100    (Equation 4.2) 
 
4.2.10. Release of quercetin from nanoliposomes 
 
To study the release of quercetin from nanoliposomes two different protocols were perfromed. The first 
step of both of them consisted of centrifuging the nanoliposome suspension three times at 1200 × g for 10 
minutes (centrifuge Sorvall ST 8R, Thermo Fisher Scientific, Waltham, MA, USA) to remove the excess 
of insoluble quercetin, and after with the same ultracentrifuge and under the same conditions reported 
above. After that, the pellet (nanoliposomes) was resuspended in PBS and divided in 1.5 mL different 
aliquots. For the first protocol, at each time point (60 minutes, 1, 2, 7 and 14 days) the solution containing 
nanoliposomes was centrifuged at 10.000 rpm × 15 minutes at 4°C to separate the released quercetin from 
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the nanocarriers. 1.0 mL of the supernatant was collected, replaced with fresh PBS and freeze dried. Then, 
the freeze dried samples were resuspended in 150 μL of ethanol:water (50:50, v/v). The second protocol 
was applied considering that the solubility of quercetin in aqueous solution is low. As a result, it is released 
in forms of crystals and at pre-determinated intervals (the same reported for the first protocol) the samples 
were centrifuged at 3000 rpm for 10 minutes (Aditya et al., 2012). During the centrifugation, the released 
crystals of quercetin precipitated as a pellet which was redissolved in 150 μL of ethanol:water (50:50, v/v). 
To determine the concentrations of the released quercetin, the absorbance of all the samples was read at 
352 nm, using a plate reader (MultiskanTM GO Microplate Spectrophotometer, Thermo Scientific, Finland) 
taking into account the calibration curve reported below: 
𝐴𝑏𝑠352 = 13.063 × 𝐶  (R
2 = 0.9999)     (Equation 4.3) 
where: 
• 𝐴𝑏𝑠352 is the absorbance of quercetin at 352 nm; 
• 𝐶 is quercetin concentration expressed in mg/mL. 
 
 
Figure 4.4: calibration curve for the quantification of quercetin by spectrophotometric analysis. 
 
The release of quercetin was studied at three different temperature (4, 20, and 37°C), keeping the samples 
in dark conditions. 
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4.2.11. Rheological characterization of nanoliposome suspensions 
 
Rheological studies of water-based solution containing nanoliposomes were performed using a Kinexus 
Pro rheometer (Malvern Instruments, Orsay, France). During all the rheological experiments, the system 
was covered with a hood to minimize water evaporation and to keep constant the temperature (25°C). Shear 
viscosimetry and oscillatory rheometry were studied. Steady-shear viscosity and shear stress measurements 
were determined using a cone-and-plate geometry (50 mm, 1°). For the steady-shear viscosity 
measurement, the shear rate was increased from 10-3 to 103 s-1. To determine the mechanical properties of 
the liposome dispersion, an amplitude sweep was first performed at a frequency of 1 Hz by changing the 
shear strain from 0.1 to 1000 % in order to determine the linear viscoelastic region. Based on this test, a 
value of strain within the linear region was then used in the subsequent frequency sweep analysis with the 
change of frequency between 0.01 and 10 Hz at 10 % of shear strain. 
4.2.12. In vitro cytotoxicity assay 
 
The adopted protocol to assess the biocompatibility of nanoliposomes was similar to that reported in section 
for CaCO3 nanoparticles. Briefly, hMSC and fibroblasts were seeded into a flat-bottom 96 well-plate with 
a density of 5 × 103 cells/cm2 with complete medium and incubated at 37 °C with 5 % CO2. Nanoliposome 
dispersions (empty and quercetin-loaded) were sterilized by filtering them with 0.22 μm filters. After 24 
hours of cell incubation, nanoliposome solutions were added to the medium at different concentrations 
(6.87-13.8 μg/mL and 0.33-0.67 mg/mL). In addition, free quercetin in ethanol at different concentrations 
(1, 10, 25 and 50 μM) and the same volume of ethanol used to dilute it were tested. After appropriate time 
intervals (1, 3, and 7 days), MTS assay was done. All experiments were assessed in triplicate and results 
are expressed as a percentage of the control (100 %). 
4.2.13. Statistical analysis 
 
All the experiments were performed at least in triplicate and the results were expressed as mean values and 
standard deviations. Multiple comparison of the mean values was performed by the least significant 
difference test at p < 0.05. For data analysis, the Statistica 8.0 software (StatSoft, Tulsa, OK, USA) was 
used. 
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4.3. RESULTS AND DISCUSSION 
ENCAPSULATION OF BSA IN NANOLIPOSOMES 
4.3.1. Measurement of size, ζ-potential and electrophoretic mobility of BSA-loaded 
nanoliposomes 
 
The nanoliposome size was registered immediately after their synthesis. The BSA-loaded nanoliposomes 
were found to be smaller than the unloaded particles (p < 0.05). In fact, the mean size of control (empty) 
liposomes was 149.87 ± 1.19 nm, while after encapsulation of BSA, it decreased to 143.13 ± 2.08 and 
138.18 ± 1.44 nm, working with 0.5 and 2.0 mg/mL of BSA, respectively (Table 4.1). This slightly decrease 
in size could be explained taking into account that there were no interaction between BSA (hydrophilic) 
and lipids, resulting in a well-defined separation between the core and the membranes of the liposomes. As 
a consequence, BSA remained in the core of the formed liposomes without affecting their mean size. The 
same trend was found working with CaCO3 nanoparticles and BSA (Section 3.3.1). Liposome charge is an 
important factor that participates to liposome stability and entrapment efficiency (Maherani et al., 2012). 
The mixture of lipids employed for the synthesis of liposomes were negatively charged and this charge was 
maintained even after the sonication process. The presence of BSA, at the two studied concentrations, did 
not affect the ζ-potential and the electrophoretic mobility of the BSA-loaded liposomes, as shown in Table 
4.1. 
 
Table 4.1: mean particle size, polydispersity index, zeta potential and electrophoretic mobility of empty and BSA-
loaded nanoliposomes. 
Sample 
Particle size 
(nm) 
Polydispersity 
index 
Zeta potential 
(mV) 
Electrophoretic 
mobility (µmcm/Vs) 
Empty liposome 149.87 ± 1.19a 0.27 ± 0.02 -41.13 ± 1.49a -3.23 ± 0.12a 
BSA-loaded 
liposome (0.5 mg/mL) 
 
143.13 ± 2.08b 0.27 ± 0.02 -41.85 ± 0.71a -3.28 ± 0.06a 
BSA-loaded 
liposome (2.0 mg/mL) 
138.18 ± 1.44c 0.26 ± 0.01 -40.33 ± 0.62a -3.20 ± 0.05a 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
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4.3.2. Entrapment efficiency 
 
The optimal encapsulation efficiency was reached when the lower amount of BSA was used. Working with 
the higher BSA concentration induced a decrease in the entrapment efficiency (p < 0.05) (Table 4.2). 
Probably, this fact was due to a difference in osmotic pressure between the internal and the external aqueous 
phase. The difference in osmotic pressure increased by increasing BSA loading, leading to a breakage of 
the lipophilic droplets. As a result, an exchange between the internal and the external aqueous phase 
occurred with a consequent loss of BSA (Lamprecht et al., 2000). These data are completely in agreement 
with a previous research published by Colletier et al. (2002). 
 
Table 4.2: entrapment efficiency of BSA-loaded nanoliposomes. 
Sample Entrapment efficiency (%) 
BSA-loaded liposomes 
(0.5 mg/mL) 
 
47.31 ± 2.37a 
BSA-loaded liposomes 
(2.0 mg/mL) 
37.27 ± 4.91b 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results (p < 0.05), 
ANOVA with Tukey’s multiple comparison test. 
 
This part of the work about encapsulation of a model protein (BSA) in nanoliposomes is still ongoig. It will 
be studied the morphology (TEM analysis), the stability of liposomes at different temperatures over a period 
of 60 days, the kinetic of BSA release from the particles, the biocompatibility, and the possibility to attach 
covalently different antibodies on their surface to create a liposomal-based drug delivery system. However, 
it was decided to show these preliminary results to compare them with those obtained working with CaCO3 
nanoparticles loaded with the same protein. 
4.3.3. Measurement of liposome size, ζ-potential and electrophoretic mobility of 
quercetin-loaded nanoliposomes 
 
Working with liposomes, mean size, size distribution, ζ-potential and electrophoretic mobility are important 
physicochemical parameters that could be modulated acting on fatty acid composition, lipid classes, 
surface-active properties of lecithins as well as on the synthesis parameters (e.g. during sonication and 
homogenization) (Benedet et al., 2007; Arab Tehrany et al., 2012; Hasan et al., 2016). The range of these 
physicochemical parameters has to be fixed depending on the final application that the nanosystem will 
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possess (Calvagno et al., 2007). For example, in food industry it is preferable to have microsized vesicles 
instead of the nanosized ones. On the contrary, in the pharmaceutical and medical sectors it is more 
desirable the opposite condition to allow, for example, a better interaction between cells and nanoparticles. 
Mean size, size distribution, ζ-potential and electrophoretic mobility of liposomes (both empy and loaded 
with quercetin) were measured immediately after the sonication process using DLS and they are shown in 
Table 4.3. 
 
Table 4.3: mean particle size, polydispersity index, zeta potential and electrophoretic mobility of empty and quercetin-
loaded nanoliposomes. 
Sample 
Particle size 
(nm) 
Polydispersity 
index 
Zeta potential 
(mV) 
Electrophoretic 
mobility (µmcm/Vs) 
Empty liposome 185.82 ± 20.99a 0.31 ± 0.05 -44.58 ± 2.58a -3.49 ± 0.20a 
Quercetin-loaded 
liposome 
204.04 ± 13.79b 0.32 ± 0.03 -46.09 ± 2.47b -3.61 ± 0.19b 
Results are mean of three measurements ± SD. Different letters do refer to statistically significant differences among results for each column 
(p < 0.05), ANOVA with Tukey’s multiple comparison test. 
 
The mean size of empty liposomes was 185.82 ± 20.99 nm, whereas after encapsulation of quercetin, it 
increased to 204.04 ± 13.79 nm (Table 4.3). This increase could be explained taking into account the 
interactions between lipids and quercetin. Hydrophobic interactions between lipid tails and quercetin may 
take place, allowing quercetin to come up to the bilayer. Since it has a planar configuration, quercetin 
showed a very high affinity for liposomes and it could easily intercalate into the well-organized structures 
of membrane phospholipids (Van Dijk et al., 2000). As a result, quercetin induced an enlargement of the 
phospholipid shell. 
In addition to the liposomal size, DLS is also able to measure the polydispersity index. This parameter is a 
dimensionless number of the breadth of the distribution of particle size (Zweers et al., 2003). As reported 
in Table 4.3, the PDIs were between 0.31 and 0.32. This fact indicated that liposome size was well-
controlled with a narrow dispersity. 
To better understand the electrical surface charge of the liposome, which is a fundamental property that 
affects liposome behaviour, ζ-potential measurements were performed. The values of the ζ-potential give 
an idea of the stability of colloidal systems: to have a more stable colloidal dispersion, it is required the 
repulsion between particles and high potential values. In fact, if all particles in the suspension present a 
same large charge (positive or negative), they repulse each other and there will be no aggregation of the 
particles in the suspension (Mady et al., 2009). The negatively electrophoretic mobility of both empty and 
quercetin-loaded liposomes is the result of the anionic fraction of phospholipids present in rapeseed lecithin 
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(Chansiri et al., 1999). In Table 4.3, it can be seen that there were only slight statistical differences (p < 
0.05) between the samples in terms of ζ-potential and electrophoretic mobility. All the presented results 
concerning mean size, size distribution, ζ-potential and electrophoretic mobility are consistent with ones 
reported by other authors working with rapeseed lecithin (Arab Tehrany et al., 2012; Hasan et al., 2014; 
Paini et al., 2015).  
4.3.4. Nanoparticle tracking analysis 
 
 
Figure 4.5: video frame for (A) empty and (B) quercetin-loaded nanoliposomes obtained with nanoparticles 
tracking analysis. 
 
A 
B 
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Figure 4.6: size distribution of (A) empty and (B) quercetin-loaded nanoliposomes obtained with nanoparticles 
tracking analysis.  
 
The nanoparticles tracking analysis confirmed all the data concerning the liposome size obtained by DLS. 
The presence of multilayers around each liposomes in the presented video frame (Figure 4.5) does not to 
be misled. In fact, these layers are not real ones but they are produced as a consequence of the light 
diffraction after the contact with the liposome surface during the analysis. Figure 4.6 shows the size 
A) 
B) 
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distribution for empty (A) and quercetin-loaded (B) liposomes. The majority of the particles is located 
around 200 nm. 
  
4.3.5. Stability of size and ζ-potential 
 
Long-term storage stability studies were carried out at three different temperatures over a period of 60 days 
measuring the particle size and the zeta potential. We choose three different temperatures: 4°C for potential 
food and pharmaceutical preparations that are, for example, thermosensitive, 20°C for the potential storage 
of food or pharmaceutical formulation at room temperature, and 37°C to reproduce physiological conditions 
of our body. No differences (p < 0.05) between the two samples (empty and quercetin-loaded) and among 
the studied temperatures in terms of size and zeta-potential were noticed as shown in Figure 4.7 (A, B. and 
C) and Figure 4.8 (A, B, and C). Liposomes were stable at each studied temperature, keeping constant their 
size and their surface charge.  
 
 
 
0
50
100
150
200
250
300
0 10 20 30 40 50 60
M
ea
n
 s
iz
e 
(n
m
)
Time (days)
A) 
NANODELIVERY SYSTEMS: rapeseed lecithin nanoliposomes                                               RESULTS AND DISCUSSION 160 
 
  
 
 
 
Figure 4.7: size stability of control (●) and quercetin-loaded (▲) nanoliposomes at (A) 4, (B) 20, and (C) 37°C. 
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Figure 4.8: zeta potential stability of control (●) and quercetin-loaded (▲) nanoliposomes at (A) 4, (B) 20, and 
(C) 37°C. 
 
4.3.6. Entrapment efficiency 
 
Quercetin is recognized as one of the most promising natural therapeutic agent in the vascular medicine 
due to its anti-inflammatory and antioxidant activities. Despite of its positive effects on human health, it 
suffers from some limitations such as light and oxygen sensitivity, low solubility in water and low 
bioavailability (Jangde & Singh, 2014). For this reasons, it was decided to encapsulate it in liposomes. With 
the aim of studying the effect of quercetin loading on its molecular integrity, HPLC analysis were done 
before and after the encapsulation step. The chromatogram of quercetin showed that the retention time of 
this molecule was 14.6 min. Quercetin after breakage of the nanoliposomes showed a very similar HPLC 
profile (data not shown). The entrapment efficiency of quercetin in nanoliposomes were calculated using 
the equation 4.2 and it was 28.84 ± 4.79 %. This value was not as high as we expected because of the low 
solubility of quercetin in water. In fact, during the sonication process, a huge amount of that compound 
precipitated in form of insoluble crystals before being encapsulated.  
4.3.7. In vitro release of quercetin from nanoliposomes 
 
The in vitro release behaviour of quercetin-loaded nanoliposomes was studied over a period of 14 days in 
PBS and the cumulative release curves are reported in Figure 4.9. By way of example, the release curves 
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reported below refer to one of the protocols described in Section 4.2.10. In details the same protocol 
described in Aditya et al. (2002) were applied with some modifications. As well as in the case of stability 
study, these experiments were performed at three different temperatures to cover all the range of the 
possible application of liposomes in food and pharmaceutical sectors. The release of drugs from 
nanosystems depends on different factors, like physicochemical properties of the entrapped drug and of the 
encapsulating agent, the chemical properties of the solvent used during the release studies, the size of the 
nanoparticles, the temperature kept constant during the experiments, the use of stabilizers during the 
synthesis of the nanoparticles, and the presence of nanostructured layers that cover the particles (e.g. 
chitosan, dextran sulfate, poly-L-arginine etc.) (Bala et al., 2006). The three different curves showed an 
exponential release of quercetin that didn’t reach a steady-state after 14 days at 20 and 37°C. At 4°C the 
exponential behaviour of the release of quercetin was less remarkable and the release was pretty poor at 
each interval. In 14 days, for all the studied temperature, it was not possible to obtain a complete release 
(100 %) of quercetin from nanoliposomes. This fact could be explained considering that the solubility of 
quercetin in aqueous solution (in this case PBS) is extremely low. The cumulative release curves showed 
significant differences at the three different studied temperature. Only after 60 minutes, the quantity of 
released quercetin was similar for the different temperatures. In details, working at 4°C, the final amount 
of quercetin was 66.86 and 69.33 % lower in comparison with released quercetin at 20 and 37°C, 
respectively. In general, at 4°C, for each point, the quantity of released quercetin was significantly slower 
in comparison with the values obtained at the same time, keeping the nanoliposomes at 20 and 37°C. In 
contrast to what is reported by Jangde & Singh (2014), in this case it was not registered a burst release that 
generally, in the case of liposome, is due to molecules adsorbed onto their surfaces. This step was overcome 
washing the nanoliposome suspension many times before starting the releasing experiments. In conclusion, 
the release of quercetin from nanoliposomes did not show a burst release, but rather a sustained release 
during time, indicating that these nanoparticles could potentially find application as a good drug delivery 
system. 
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Figure 4.9: cumulative release of quercetin from nanoliposomes at 4 ( ), 20 ( ), and 37°C ( ). 
 
4.3.8. Rheological studies 
 
Steady-state shear viscosity 
 
To evaluate if the loading of quercetin in nanoliposomes was able to induce changes in the properties of 
the liquid formulation, rheological studies were carried out. The possibility to control the rheological 
behaviour of liposome dispersions is considered of great importance under an industrial point of view. In 
fact, the rheological properties of such dispersion depend on the interaction between vesicles and vesicle 
deformability. Taking into account that the rheological behaviour of liposomal suspension is related to 
microstructural changes, a thorough knowledge of the changes in microstructure under shear could provide 
significant opportunities of enhancing the process of liposome dispersions (Hasan et al., 2016). Steady-
shear viscosity, shear stress and oscillatory rheometry to study mechanical stability of liposomal samples, 
were performed. The flow curves of empty and quercetin-loaded liposomes are reported in Figure 4.10.  
0
10
20
30
40
50
60
0 2 4 6 8 10 12 14 16
C
u
m
u
la
ti
v
e 
re
le
a
se
 o
f 
q
u
er
ce
ti
n
 (
%
)
Time (days)
NANODELIVERY SYSTEMS: rapeseed lecithin nanoliposomes                                               RESULTS AND DISCUSSION 165 
 
  
 
Figure 4.10: flow curves of empty ( ) and quercetin-loaded liposomes ( ). 
 
The solid lines of flow curves represent fits to the power law model: 
𝜕 = 𝑘𝛾𝑛          (Equation 4.4) 
where 𝜕 is the shear stress;  
𝑘 is the consistency index; 
𝛾 is the shear rate; 
𝑛 is the flow behaviour index. 
Representing a general measurement of viscosity, the 𝑘 index is useful in the case of comparative purposes 
and it is numerically equal to the viscosity at 1 s-1. The plastic viscosity and the yield stress of the two 
samples were determined plotting the flow curves of the square root of shear stress against the square root 
of shear rate (Figure 4.11).  
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Figure 4.11: Casson plots of the square root of the shear stress versus the square root of the shear rate for empty  
( ) and quercetin-loaded liposomes ( ). 
 
Table 4.4: rheological properties according to the power law model for empty and quercetin-loaded liposomes. 
Sample 𝒌 (Pa s) 𝒏 R2 
Empty liposomes 0.00010 ± 0.0005 1.016 ± 0.051 0.9986 
Quercetin-loaded 
liposomes 
0.0014 ± 0.0003 0.973 ± 0.036 0.9996 
 
The Casson model is a structure-based model: 
(𝜕)0.5 =  𝐾0𝑐 + 𝐾𝑐(𝛾)
0.5         (Equation 4.5) 
where the square of the intercept is the Casson yield stress, 𝜕0𝑐 = (𝐾0𝑐)
2, and the square of the slope is 
Casson plastic viscosity, 𝜂𝐶𝑎𝑠𝑠𝑜𝑛 =  (𝐾𝑐)
2       (Equation 4.6) 
The above mentioned equations were used to fit the experimental data of the two different samples. The 
rheological parameters are reported in Table 4.5.  
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Table 4.5: rheological properties according to the Casson model for empty and quercetin-loaded liposomes. 
 
Sample Plastic viscosity (mPa s) Yield stress (mPA) R2 
Empty liposome 1.07 ± 0.05 0.08 ± 0.01 0.9967 
Quercetin-loaded 
liposome 
1.05 ± 0.02 0.07 ± 0.01 0.9937 
Both liposome suspensions showed a nearly Newtonian flow behaviour (𝑛 approximately equal to 1). With 
the aim of studying the time-dependent flow behaviour of the liposomal dispersion, the shear stress was 
augmented from 10-3 to 0.5 Pa and then decreased in the same stress range. For the quercetin-loaded 
liposomes the plot (Figure 4.12) shows a thixotropic behaviour. 
 
Figure 4.12: curves obtained with quercetin-loaded nanoliposomes increasing and decreasing in the shear stress 
in the same shear stress range. 
  
Oscillatory rheometry 
 
Oscillatory rheology experiments were performed to evaluate the mechanical stability of the liposomal 
samples at a fixed strain within the linear viscoelastic region. The mechanical properties of the solutions 
are reported in Figure 4.13. The encapsulation of quercetin did not negatively influenced the general 
mechanical properties of liposome solution. Lipid vesicles interactions, such as electrostatic repulsion, long 
range entropic repulsion, and van der Waals attraction mediated the mechanical stability of liposomal 
suspension (Hasan et al., 2016; Jangde & Singh, 2016). 
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Figure 4.13: frequency sweep test of empty ( ) and quercetin-loaded liposomes ( ). 
 
4.3.9. In vitro cytotoxicity assay 
 
The effects of empty and quercetin-loaded nanoliposomes on hMSC and fibroblast were evaluated through 
MTS assay. The viability of treated cells with different concentrations of free quercetin (Q) (1, 10, 25 and 
50 μM) or of liposomes (6.87 and 13.8 μg/mL and 0.33 and 0.67 mg/mL, both empty liposome, EL, and 
quercetin-loaded liposome, QL) as well as untreated cells (control, CTL) was studied for 1, 3, and 7 days. 
Figure 4.14 shows the results expressed as a percentage value with respect to the control. Working with 
hMSC (Figure 4.14, A), with the two lowest concentrations of quercetin-loaded liposomes there was no 
any significant differences with the control. However, the presence of quercetin-loaded liposomes at the 
concentration of 0.33 and 0.67 mg/mL induced a partial toxicity on hMSC. In the case of cells treated with 
free quercetin, it is noticeable that at the concentration of 25 and 50 μM there was cytotoxicity after 7 days 
of incubation. These results have not to be addressed to a cytotoxicity of quercetin, but rather to the presence 
of ethanol as solvent. In fact, treating the cells with the same volume of ethanol used for preparing the 
solution of quercetin at 25 and 50 μM, the same cytotoxic effect was reported.  
Human fibroblast resulted to be more sensitive to the liposomes, to quercetin itself, and to ethanol (Figure 
4.14 B). Fibroblasts showed cytotoxicity to quercetin in a dose-dependent manner. These results are in line 
with those published by Pawlikowska-Pawlega & Gawron (1995). In fact, these authors found that mouse 
fibroblasts showed a partial growth inhibition when they were cultivated with 10 μg/mL of quercetin. In 
our case, even the lowest concentration was higher. It was not possible to discern at the highest 
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concentration of quercetin used, if the cellular toxicity derived from the volume of ethanol employed or 
from quercetin itself. It was not important to define if the responsible of this cellular behaviour was 
quercetin or ethanol because quercetin was toxic even at lower concentration. Treating the fibroblasts with 
liposomes, it was noticed a partial cytotoxicity with empty liposomes at a concentration equal to 0.33 
mg/mL and a significant cytotoxicity working with 0.66 mg/mL. In the case of quercetin-loaded liposomes, 
the cytotoxicity at these two concentrations was more marked. In the case of QL, the presence of a high 
concentration of non-well tolerated liposomal particles and a contemporary release of quercetin from them, 
could induced an enhanced cellular alterations. Even working with fibroblast, it was confirmed that the 
highest volumes of ethanol used during the experiments were not biocompatible. 
 
 
 
Figure 4.14: cell viability of free quercetin, empty and quercetin-loaded nanoliposomes at different 
concentrations on (A) hMSC and (B) human fibroblast. CTL: control, EL: empty liposomes, QL: quercetin-
loaded liposomes, Q: quercetin, E: ethanol   day 1,  day 2,  day 3. EL1: 6.87 μg/mL, EL2: 13.8 μg/mL, EL3: 
0.33 mg/mL, EL4: 0.67 mg/mL, QL1: 6.87 μg/mL, QL2: 13.8 μg/mL, QL3: 0.33 mg/mL, QL4: 0.67 mg/mL, Q1: 
1 μM, Q2: 10 μM, Q3: 25 μM, Q4: 50 μM, E1, E2, E3, E4: same volume of ethanol of Q1, Q2, Q3, and Q4
NANODELIVERY SYSTEMS: rapeseed lecithin nanoliposomes                                               RESULTS AND DISCUSSION 170 
 
  
 
4.3.10. Conclusions 
 
In this part of the work, BSA-loaded and quercetin-loaded nanoliposomes (QL) were successfully 
synthetized starting from rapeseed lecithin, using a sonication process. Liposomes were characterized 
under a physicochemical point of view, showing a mean diameter of around two hundred nanometres 
and a negative surface charge. BSA-loaded liposomes had a good entrapment efficiency, 47.31 ± 2.37 
%, working with 0.5 mg/mL of BSA in the loading solution, whereas in the case of QL it was 28.84 ± 
4.79 %. Stability studies revealed that this kind of particles are very stable in a wide range of 
temperatures for 60 days, in term of size and ζ-potential. The release of quercetin was sustained during 
time, allowing a long-term release of this antioxidant. Rheological studies demonstrated that liposome 
suspension can be considered as a Newtonian fluid, showing a thixotropic behaviour. All the tested 
concentrations of QL were well-tolerated by hMSC. In the case of fibroblasts, the highest tested 
concentration (0.33 and 0.67 mg/mL of QL) revealed to be not biocompatible. Taking into account all 
these data, it will be necessary to characterize more BSA-loaded nanoliposomes to understand if their 
properties (stability over time, BSA release, rheological properties, and cell viability) will be as good 
as or better than those presented by QL. On the other hand, QL represent a good candidate system to 
be further studied and engineered with antibodies to obtain a valid antioxidant delivery system.  
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5. OVERALL CONCLUSIONS 
In the first part of this Ph.D. thesis, several free or encapsulated bioactive compounds were used to 
functionalize small diameter vascular prostheses (2 and 5 mm in diameter) with the aim of fabricating a 
new innovative tool to be employed in vascular tissue engineering. A coating of gelatin was necessary to 
reduce the excessive permeability of the scaffolds. Overall, the coating with gelatin, the presence of free 
quercetin, of CaCO3 nanoparticles encapsulating proteins and of free rapeseed and salmon lecithin did not 
negatively influenced the morphological, physico-chemical, mechanical, and biological properties of the 
scaffolds. All these data, taken together, will allow us in the next future to synthetize a multiscale model of 
scaffold, combining all the functionalizating agents all together, in which each component will play a 
particular role: 
- PCL:PGS: they are the two biodegradable polymers using during the electrospinning process. They 
will ensure the biodegradability of the electrospun scaffold; 
- gelatin: its role it to reduce the blood permeability of the prostheses and to increase their 
biocompatibility and hemocompatibility; 
- quercetin: it will be able to act as anti-inflammatory agent in the post-surgical period; 
- CaCO3 nanoparticles: if they will be loaded with chemoattractant proteins, growth or differentiation 
factors, they will be able to recruit cells from the blood, induce their growth and, in some cases, 
their trans-differentiation; 
- rapeseed and salmon lecithin: their role will consist of preventing oxidative processes at the level 
of the prostheses. 
Overall, it is possible to do a comparison of all the studied coating and functionalizating agents during the 
Ph.D. research activity, taking into consideration Table 5.1. 
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Table 5.1: main results of the studied coated/functionalized scaffolds. 
Type of sample Results 
PPS 
- morphological studies: promising; 
- physico-chemical studies: promising; 
- permeability: not promising; 
- mechanical studies: promising; 
- suturability: promising; 
- biocompatibility studies: promising; 
- hemocompatiblity studies: promising. 
GCSS 
- morphological studies: promising; 
- physico-chemical studies: promising; 
- permeability: promising; 
- mechanical studies on dry samples: not 
promising; 
- mechanical studies on wet samples: 
promising; 
- in vivo suturability: promising; 
- biocompatibility studies: promising; 
- hemocompatiblity studies: promising. 
QS and QGCS 
- morphological studies: promising; 
- physico-chemical studies: promising; 
- permeability: promising (only in the case of 
QGCS); 
- mechanical studies on dry samples: 
promising (only in the case of QS); 
- mechanical studies on wet samples: 
promising;  
- biocompatibility studies: promising; 
- in vivo anti-inflammatory activity: 
promising. 
NS 
- morphological studies: promising; 
- physico-chemical studies: promising; 
- mechanical studies: promising; 
- biocompatibility studies: promising; 
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- hemocompatibility studies: promising. 
 
RLS and SLS 
- morphological studies: promising; 
- physico-chemical studies: to be completed; 
- mechanical studies: to be done; 
- biocompatibility studies: promising; 
- hemocompatibility studies: to be done. 
 
Concerning the future perspectives of this first part, they include: 
- study of the mechanical properties of the fabricated scaffolds in more details performing other tests; 
- multi-functionalization of the PCL:PGS scaffolds with different bioactive molecules at the same 
time; 
- set up of a controlled-flow bioreactor; 
- in vivo experimentation. 
 
In the second part of this thesis, different techniques were investigated for the nanoencapsulation of proteins 
and polyphenols, in order to make possible the development of new drug delivery systems. These bioactive 
compounds were encapsulated with the aim of modulating their solubility, their stability, and their release. 
In conclusion, it is possible to compare the two encapsulation systems studied during the Ph.D. research 
activity, CaCO3 particles and rapeseed lecithin nanoliposomes, referring to Table 5.2. 
 
Table 5.2: main results and future perspectives of the studied encapsulation techniques. 
Nanodelivery 
system 
Main results Future perspectives 
CaCO3 particles 
- nanometric dimensions; 
- potential release control with LbL; 
- biocompatibility working with 160 μg/mL; 
- possibility to attach antibodies on their surface; 
- no inflammatory response; 
- hemocompatibility; 
- cellular up-take 
- increase of entrapment efficiency; 
- stability studies 
- studies of rheological properties 
Liposomes 
- nanometric dimensions; 
- good entrapment efficiency; 
- stability during storage; 
- immobilization of antibodies on 
the surface 
- improving of biocompatibility 
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- sustained release without LbL; 
- good rheological properties 
- biocompatibility working with 13.8 μg/mL 
- studies of inflammatory response 
- hemocompatibility 
- cellular-uptake 
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dioxide on polyphenol and lipid contents of Arthrospira (Spirulina) platensis. Algal Research 12: 308-315. 
 
3. B 
Barisione C, Garibaldi S, Furfaro AL, Nitti M, Palmieri D, Passalacqua M, Garuti A, Verzola D, Parodi A, 
Ameri P, Altieri P, Fabbi P, Ferrari PF, Brunelli C, Arsenescu V, Balbi M, Palombo D, Ghigliotti G, 2016. 
Moderate increase of indoxyl sulfate promotes monocytes transition into profibrotic macrophages. PLoS 
ONE 11: 1-17. 
 
3. C 
da Silva MF, Casazza AA, Ferrari PF, Perego P, Bezerra RP, Converti A, Figueiredo Porto AL, 2016. A 
new bioenergetic and thermodynamic approach to batch photoautotrophic growth of Arthrospira 
(Spirulina) platensis in different photobioreactors and under different light conditions. Bioresource 
Technology 207: 220-228. 
 
3. D 
Vergani L, Vecchione G, Baldini F, Voci A, Ferrari PF, Aliakbarian B, Casazza AA, Perego P, 2016. 
Antioxidant and hepatoprotective potentials of phenolic compounds from olive pomace. Chemical 
Engineering Transactions 49: 475-480. 
 
3. E 
Casazza AA, Ferrari PF, Aliakbarian B, Comotto M, Perego P, 2016. Microalgae growth using winery 
wastewater for energetic and environmental purposes. Chemical Engineering Transactions 49: 565-570. 
 
3. F 
da Silva MF, Casazza AA, Ferrari PF, Aliakbarian B, Converti A, Pedrosa Bezerra R, Figueiredo Porto 
AL, Perego P, 2017. Recovery of phenolic compounds of food concern from Arthrospira platensis by green 
extraction techniques. Algal Research 25: 391:401. 
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3. G 
Vergani L, Vecchione G, Baldini F, Grasselli E, Voci A, Portincasa P, Ferrari PF, Aliakbarian B, Casazza 
AA, Perego P, 2017. Polyphenolic extract attenuates fatty acid-induced steatosis and oxidative stress in 
hepatic and endothelial cells. European Journal of Nutrition (in press). 
 
4. Papers published in National Journal 
 
4. A 
Casazza AA, Ferrari PF, Aliakbarian B, Pettinato M, Novelli F, Converti A, Perego P, 2016. Recupero di 
antiossidanti da Arthrospira platensis: estrazione di polifenoli mediante alte pressioni e temperature e 
successiva purificazione. Atti di convegno GRICU 2016. 
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5. Oral communications in International Congress (the speaker is underlined): 
 
5. A  
Aliakbarian B, Ferrari PF, Perego P, Palombo D. Effect of electrospinning parameters on mechanical 
properties of engineered small diameter vascular grafts. The Journal of Cardiovascular Surgery, abstract 
book, Vol. 56 – Suppl. 1 to n° 2, 94. ESCVS 2015, Istanbul, Turkey.  
 
5. B  
Aliakbarian B, Ferrari PF, Perego P, Palombo D. Functionalizing small diameter vascular grafts with 
gelatin. The Journal of Cardiovascular Surgery, abstract book, Vol. 57 – Suppl. 2 to n° 2, 73. ESCVS 2016, 
Belgrade, Serbia. 
 
5. C 
Vergani L, Vecchione G, Baldini F, Voci A, Ferrari PF, Aliakbarian B, Casazza AA, Perego P. 
Antioxidant and hepatoprotective potentials of phenolic compounds from olive pomace, International 
Congress on Industrial Biotechnology (IBIC) 2016, Bologna, Italy. 
 
5. D 
Aliakbarian B, Ferrari PF, Bagnato P, Palombo D, Perego P. Engineered small diameter vascular grafts 
with anti-inflammatory properties. The Journal of Cardiovascular Surgery, abstract book, Vol. 58 – Suppl. 
2 to n° 3, 14. ESCVS 2017, Thessaloniki, Greece. 
 
5. E 
Ferrari PF, Aliakbarian B, Bagnato P, Palombo D, Perego P. An innovative drug delivery system for 
atherosclerosis. The Journal of Cardiovascular Surgery, abstract book, Vol. 58 - Suppl. 2 to n° 3, 6. ESCVS 
2017, Thessaloniki, Greece. This presentation was awarded a “Best Oral Presentation” in the “Young 
Vascular Award Session”. 
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6. Oral communications in National Congress (the speaker is underlined): 
 
6. A 
Ferrari PF, Aliakbarian B, Zattera E, Pastorino L, Palombo D, Perego P. Engineered CaCO3 nanoparticles 
with targeting activity, GRICU MEETING 2016, Anacapri, Italy. 
 
6. B 
Casazza AA, Ferrari PF, Converti A, Perego P. Crescita di Chlorella vulgaris in fotobioreattore elicoidale 
impiegando acque reflue da vinificazione. FITEMI 2017, Palermo, Italy. 
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7. Contribution to International Scientific Meeting concerning the Ph.D. thesis 
7. A Summer School on Biomaterials and Regenerative Medicine 2016, 04-09 July, 
Riva del Garda, Italy 
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7. B 13th International Conference on Chemical and Process Engineering, 28-31 May 2017, Milan, 
Italy 
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8. Contribution to International Scientific Meeting 
8. A  
Casazza AA, Ferrari PF, Aliakbarian B, Comotto M, Perego P. Microalgae growth using winery 
wastewater for energetic and environmental purposes. International Congress on Industrial Biotechnology 
(IBIC) 2016, Bologna, Italy. 
 
8. B 
Casazza AA, Ferrari PF, Aliakbarian B, Pettinato M, Novelli F, Converti A, Perego P. Recupero di 
antiossidanti da Arthrospira platensis: estrazione di polifenoli mediante alte pressioni e temperature e 
successiva purificazione. GRICU MEETING 2016, Anacapri, Italy. 
 
8. C 
Aliakbarian B, Ferrari PF, Perego P. An innovative methodology to fabricate antioxidant active 
packaging. Food Innova 2017, Cesena, Italy. 
 
8. D 
da Silva MF, Ferrari PF, Casazza AA, Aliakbarian B, Converti A, Bezerra RP, Figueiredo Porto AL, 
Perego P. Use of non-conventional extraction techniques for the recovery of polyphenols from Arthrospira 
(Spirulina) platensis. FITEMI 2017, Palermo, Italy. 
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9. Summer Schools: 
9. A 
Summer school on Biomaterials and Regenerative Medicine 2015, 06-08 July 2015, Riva del Garda, Italy; 
 
9. B 
GRICU PhD National School 2015: “Biological and bioprocess engineering”, 07-11 September 2015, 
Padova, Italy; 
 
9. C 
Summer school on Biomaterials and Regenerative Medicine 2016, 04-09 July 2016, Riva del Garda, Italy; 
 
9. D 
GRICU Meeting and PhD National School 2016, 12-16 September 2016, Anacapri, Italy. 
 
 
 
 
10. Research periods abroad 
 
10. A 
Laboratoire d’Ingénierie des Biomolécules (LIBio), École Nationale Supérieure d’Agronomie et des 
Industries Alimentaires (ENSAIA), University of Nancy, France 
Supervisor: Prof. Elmira Arab-Tehrany 
Topic: physicochemical and biological characterization of scaffolds functionalized with quercetin and 
encapsulation of quercetin and bovine serum albumin in nanoliposomes 
Period: from 30th May 2017 to 30th October 2017     
 
 
 
 
 
